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1.1 THE RETINA 
 
The retina is a membranous structure, ~0.4mm thick, that lines the posterior part of the 
eye, occupying 72% of the inside of the globe (Fig. 1.1). The retina is approximately 
32mm long from ora to ora along the horizontal meridian. Its functions include detail 
discrimination, colour perception, vision in dim illumination and peripheral vision. 
 
 
Figure 1.1 Three-dimensional illustration of the interior of the eye  
 
The retina can be divided into the neurosensory layer and the retinal pigment 
epithelium (RPE). The RPE is anchored to Bruch’s membrane, which forms the border 
of the choroid. 
 
Neurosensory retina 
The neurons of the retina are divided into three layers. The first is the photoreceptor cell 
layer, consisting of the outer and inner segments and cell bodies (outer nuclear layer) 
(Fig. 1.2). The second is the inner nuclear layer consisting of nuclei of interneurons 
(horizontal, bipolar and amacrine cells), which are required for the initial steps of 
information processing. Müller cell somata lie in the middle region of the inner nuclear 
layer, and its radial processes extend toward the inner and outer borders of the retina. 
The third layer consists of ganglion cells. The synapses are confined to two synaptic 
layers (the outer and inner plexiform layers). Light rays pass through the ganglion and 
inner layers to reach the photoreceptor cells, where the light is converted into nerve 
impulses that are transmitted by the bipolar cells to the ganglion cells. The axons of the 
ganglion cells converge to form the nerve fiber layer, and leave the eye at the optic disc 
to form the optic nerve. In the fovea, at the center of the retina, there is a one-to-one 
relationship between the photoreceptors, the ganglion cells and the nerve fibers, 
ensuring high spatial resolution. To ensure the detection of small amounts of light, the 
peripheral photoreceptors are not coupled individually to ganglion cells. The increased 
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packing density of photoreceptors and their associated bipolar and ganglion cells in the 
central retina results in a thicker region at the central retina than at the peripheral retina 
(Fig.1.2).      
 
 
Figure 1.2 Light micrographs of vertical sections through a central and peripheral human retina. RPE: 
retinal pigment epithelium, PR: photoreceptors, OLM: outer limiting membrane, ONL: outer nuclear layer, 
OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer, 
ILM: internal limiting membrane 
 
There are two types of photoreceptors, rods and cones, which are distinguishable by 
shape of inner and outer segments, position of nuclei and shape of synaptic terminals 
(Fig.1.3). Rods mediate dim-light vision, and cones function in bright light and are 
involved in the detection of colour and fine detail. Both rods and cones consist of two 
distinct subcellular compartments, termed inner and outer segments, which are 
connected by a thin stalk rich in cytoskeletal elements. The inner segments contain 
nuclei and several organelles required for protein synthesis. Light capture occurs in the 
outer segments, which contain the photopigments rhodopsin in rods and iso-opsins in 
cones. The photopigment-containing membranes are continually being formed and 
removed. Formation occurs from an initial evagination of the plasma membrane at the 
junction between the inner and outer segments (morphogenesis). Removal occurs at the 
apex of the outer segments (shedding). 
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In humans, 95% of the photoreceptors are rods and 5% are cones. The highest 
concentration of photoreceptors is found in the macula, which is the central part of the 
retina, ~6mm in diameter. The center of the macula is called the fovea, and is on the 
optical axis of the globe, 3.4mm temporal to the optic disk edge and approximately 
1.5mm in diameter. Cone density is maximal in the fovea, which contains about 10% of 
the cones. The center of the fovea, called the foveola, is approximately 0.1mm in 
diameter, and free of cells, except for cone outer segments. Rods are distributed 
unevenly across the retina. In the center of the fovea (0.25mm in diameter), there are no 
rod receptors. Beyond this zone, they peak at an eccentricity between 5mm temporal 
and 7mm nasal, after which they steadily decline (Fig. 1.4).  
The interphotoreceptor matrix (IPM) is a mixture of glycoproteins and 
glycosaminoglycans, and surrounds the apical processes of the photoreceptor cells. The 
function of the IPM is that of mediating the transport of nutrients and metabolites. 
Photoreceptor-specific domains in the IPM, containing different glycoconjugates, have 
been identified as cone and rod extracellular matrix sheaths.1 The functional role of 
these sheaths needs to be established.  
The inner retina is vascularized by the central retinal artery and its branches, which 
supply circulation to the inner portion of the inner nuclear layer. Tight junctions exist 
between the capillary endothelial cells, retaining the blood-retinal barrier. 
Figure 1.3 Scanning electron micrograph of
photoreceptor cells from a monkey retina 
CIS: cone inner segment, COS: cone outer
segment, RIS: rod inner segment, ROS: rod outer
segment  
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Retinal pigment epithelium (RPE) 
The RPE is a monolayer of low cuboidal cells of neuroectodermal origin, situated 
between the choroid and the photoreceptors. The lateral surfaces of adjacent cells are 
closely apposed and joined by tight junctions near the apices. This structure, together 
with the polarized distribution of cellular proteins, creates the outer blood-retinal 
barrier, providing molecular exchanges to occur predominantly across the RPE cells. 
The presence of apical microvilli and basal plasma membrane infoldings increases the 
surface area available for molecular exchange. Melanin granules, responsible for the 
brown colour of the RPE layer, are found in the apical region of the RPE cell. Melanin 
molecules absorb light throughout the visible spectrum, thereby protecting the neural 
retina from the absorption of excessive light. Lipofuscin, which accumulates with age, is 
located in the basal part of the cell. Besides forming the outer blood-retinal barrier, the 
RPE is responsible for phagocytosis of rod and cone outer segments.2,3 Every day the 
distal 10% of each outer segment is internalized and subsequently degraded. Finally, 
one of the most specialized functions of the RPE is the metabolism of retinol. The visual 
cycle involves several transport mechanisms, partly located in the RPE, mediated by 
various intercellular and extracellular retinoid binding proteins and enzymes that 
convert retinol into various intermediates and finally to the active 11-cis-retinaldehyde.  
 
Choroid 
The choroid is a densely pigmented and richly vascularized layer that nourishes the 
RPE and outer retina. Choroidal circulation is supplied by the short and long posterior 
ciliary arteries and the anterior ciliary arteries. The choriocapillaris is fenestrated, which 
allows diffusion of various substances (e.g. fluorescein in fluorescein angiography) 
between the capillaris and the interstitium of the choroid. The basement membrane of 
Figure 1.4 Diagram of spatial  
density of rods and cones as a  
function of retinal eccentricity.  
The blind spot is situated at the 
optic disc 
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choroid’s innermost layer, the choriocapillaris, forms the outer layer of Bruch’s 
membrane, which is 2-4µm thick and consists of 5 layers. The inner layer of Bruch’s 
membrane forms the basement membrane of the RPE. 
 
 
1.2 CLINICAL AND MOLECULAR METHODS OF EXAMINATION 
 
1.2.1 Clinical diagnosis  
History  
The genetic analysis of families with retinal dystrophies depends on accurate disease 
classification. Autosomal dominant (ad) retinal diseases usually show a high degree of 
variability both within and between families. Nevertheless, a complete history can be 
very helpful in establishing a diagnosis. Important aspects are, for example, the age of 
onset, the family history and the presence of consanguinity in the family (in case of 
autosomal recessive inheritance).  
 
Visual acuity 
Visual acuity needs to be measured under standardized conditions. The presence and 
progression of visual symptoms like metamorphopsia, night blindness and 
photophobia provides valuable diagnostic information.  
 
Fundus imaging 
Essential in the evaluation of the retina is stereoscopic examination through well-
dilated pupils. The aspect of the foveal reflex, pigment alterations, drusen, yellowish 
lesions, cystic changes, macular edema, atrophy, scarring and attenuation of arterioles 
are a few of the changes that can be seen by funduscopy. Fluorescein angiography 
(FAG) provides additional information about the presence of defects in the RPE, 
neovascularizations, cystoid macular edema or other abnormalities of the retina and 
choroids, like blockage by lipofuscin or hemorrhage.  
 
Retinal function tests 
Electrophysiology 
The neural and non-neural cells within the retina generate a diffuse electrical response 
to illumination that can be recorded by measuring the fluctuating potential between the 
cornea and a reference electrode. This signal, the electroretinogram (ERG), consists of 
the a-wave, originating in the photoreceptors, the b-wave, originating in the inner 
retina, and the c-wave, originating in the RPE. The clinical applications of c-wave 
measurements are limited. An ERG can be performed under photopic (light-adapted) 
conditions, facilitating the recording of a response exclusively from the cone system, or 
under scotopic (dark-adapted) conditions. Scotopic conditions measure the responses of 
both rods and cones (Fig. 1.5), but the rod component is dominant under these 
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conditions, because the number of rods (110-125 million) is much higher than the 
number of cones (6.4 million), and rods are intrinsically more sensitive to light. The 
greatest use of ERGs is in assessing diseases that primarily affect the photoreceptors, 
like retinitis pigmentosa (RP) or cone rod dystrophy (CORD). 
 
 
Figure 1.5 ISCEV standard rod ERG responses in a normal subject, a patient with an RDS splice site 
mutation, and 4 patients with autosomal dominant retinitis pigmentosa due to different rhodopsin 
mutations.4  
 
The electro-oculogram (EOG) measures a standing potential across the eye originating 
in the RPE (Fig. 1.6). An Arden ratio is calculated by dividing the highest EOG 
amplitude during light adaptation (light peak) by the lowest amplitude during dark 
adaptation (dark trough). The EOGs of individuals with no retina pathology will have 
an Arden ratio of at least 1.8. The greatest use of EOGs is in assessing diseases that 
primarily affect the RPE, in particular Best vitelliform macular dystrophy (VMD). 
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Dark adaptation 
Dark adaptation measures the absolute threshold of cone and rod sensitivity after 
exposure to light. The recovery of sensitivity is faster in cones than in rods, but the 
absolute level of sensitivity is greatest in rods. Dark adaptation is useful in the 
evaluation of night-blinding retinal disorders, like RP.  
 
Colour vision 
The perception of colour arises when electromagnetic energy at wavelengths between 
400 and 700 nm is absorbed in the visual pigments of the cone outer segments. Three 
types of cones of different but overlapping spectral sensitivities are involved, the long, 
middle and short wavelength-sensitive cones, which can be distinguished by their 
relative spectral positions. The photoreceptor signals are processed by the complex 
neural circuitry of the eye and brain, which can recognize contrasts between light and 
colours and can compare the intensity of red versus green and blue versus yellow. The 
classification of dysfunctional colour vision is based on this contrast-recognition 
physiology. Clinical tests of colour vision include screening tests for rapid identification 
of abnormalities, colour discrimination and colour matching.5 Acquired colour vision 
defects, which often accompany hereditary retinal disease, are more variable than 
congenital stationary colour vision defects, which makes their classification difficult. 
 
Visual fields 
Visual fields allow the precise definition of the spatial location of retinal disorders, 
facilitating a correlation between retinal structural defects and visual function. Visual 
field defects in RP start with mid-peripheral scotomas and usually progress 
peripherally, leaving a small central island of vision. Macular dystrophies are 
characterized by central visual field defects or distortion. 
 
 
 
Figure 1.6 Graphs of the 
EOG ratios in a normal 
subject (Arden ratio: 2.0) and 
in an abnormal eye of a 
patient with Best VMD 
(Arden ratio: 1.3) 
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1.2.2 Genetic analysis 
In families with a monogenic disease, the first step toward identification of the 
underlying gene defect is to determine its chromosomal location by linkage analysis. 
Subsequently, other techniques, such as candidate gene analysis, can lead to the 
identification of the actual gene involved.  
 
Linkage analysis 
Genetic linkage analysis is based upon the observation that alleles of genes or 
polymorphic DNA markers, located close to each other, tend to be inherited together, or 
cosegregate. The closer together a causative gene and a DNA marker are, the lower the 
probability that they will be separated by recombination during meiosis. If they 
cosegregate in a significant number of meioses, it is likely that the disease-causing gene 
is closely localized to this marker. As the distance between a gene and a marker 
increases, it becomes more likely that they will be separated by a crossover. The 
frequency of such crossover events is called the recombination fraction, and ranges in 
value from 0.0 to 0.5. Thus the recombination fraction is a measure of the genetic 
distance (in centiMorgans, cM) between two loci. Two loci that show 1% recombination 
are defined as 1 cM apart on the genetic map. The likelihood that the observed 
cosegregation of the markers and the gene is true linkage, rather than a distribution that 
has occurred randomly, is referred to as the LOD score (logarithm of the odds ratio).6 A 
LOD score can be calculated by adding all informative meioses minus 1 (needed to 
establish phase), and multiplying this number by roughly 0.3 in cases of dominant 
inheritance and no recombinations. A LOD score of 3 or higher, meaning an odds ratio 
higher than 1000:1, gives 95% confidence in the hypothesis of linkage. A LOD score 
lower than –2, indicating 100 to 1, or greater odds against linkage, is taken as evidence 
for the exclusion of linkage for a certain recombination value.  
In Fig.1.7A, assuming marker allele A1 to be linked to the gene defect, all affected 
individuals carry paternal allele A1 and all unaffected individuals carry paternal allele 
A2. In this example, the LOD score can be calculated using the information of 11 
meioses minus 1 (= 10), multiplied by 0.3 (= 3). In Fig. 1.7B, assuming allele A1 is linked 
to the genetic defect (phase established using individual II-1), one affected (II-5) and 
four unaffected individuals (II-2, II-6, II-9, II-11) show no recombination, whereas three 
affected (II-4, II-8, II-10) and two unaffected individuals (II-3, II-7) do show 
recombination, strongly suggesting that allele A1 is not linked to the genetic defect.  
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Figure 1.7 In diagram A, DNA marker A1 cosegregates with the autosomal dominant phenotype 
(linkage); in diagram B, neither DNA marker A1 nor marker A2 cosegregates with the disease phenotype 
(no linkage). +: segregation of marker allele as expected on basis of hypothesis that A1 is closely linked 
to gene defect, -: no segregation of marker allele on basis of hypothesis that A1 is closely linked to gene 
defect. 
 
Candidate gene approach 
The candidate gene approach consists of a detailed analysis of the gene map of the 
relevant chromosomal region. Ideally, the candidate gene should possess a known 
function likely to be related to the disease process. If good candidate genes are found, 
they need to be analysed for mutations by sequence analysis. In cases where no logical 
candidate genes can be identified, all genes from a critical disease interval need to be 
sequenced. If a mutation is found, patients with similar phenotypes should be analysed 
and a control group needs to be tested for the mutation, in order to exclude the 
possibility that the mutation is a polymorphism. If possible, a putative causal mutation 
should be tested by functional analysis of the mutant versus the normal protein.  
 
 
1.3 PERIPHERAL AUTOSOMAL DOMINANT RETINAL DYSTROPHIES  
 
Retinitis pigmentosa  
Retinitis pigmentosa is a significant cause of inherited progressive retinal disease 
worldwide. Its incidence is approximately 1:3500.7,8 RP is genetically extremely 
heterogeneous, and can be inherited in autosomal dominant (ad), autosomal recessive 
(ar), or X-linked modes. When no family history is evident, cases are classified as 
isolated. To date, linkage studies have revealed 40 RP loci: 12 for adRP, 23 for arRP and 
5 for X-linked RP. The autosomal dominant form of RP is responsible for approximately 
22% of all cases.9,10 ArRP may also occur as part of a systemic disorder such as Usher 
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syndrome, Bardet-Biedl syndrome, Cockayne syndrome, familial juvenile 
nephronophthisis, Alström syndrome, neurological disorders, metabolic disorder and 
skeletal dysplasias.11 
 
1.3.1 Clinical aspects of autosomal dominant retinitis pigmentosa  
RP is a term used for a group of progressive hereditary disorders that diffusely and 
primarily affect photoreceptors (rods and cones), leading to subsequent damage of 
photoreceptor cells and eventually to widespread atrophy of most layers of the 
retina.11,12 There is wide variety in its clinical expression, but the main characteristics 
include bilateral involvement, night blindness, loss of peripheral vision, rod 
dysfunction and progressive loss of photoreceptor function.12 The rod dysfunction is 
evidenced by elevated dark adaptation and/or rod responses, which are prolonged in 
implicit time or unable to be recorded by ERG. Fundus examination may reveal bone 
spicule-like pigmentations, attenuated arterioles, a variable waxy pallor of the optic disc 
and an atrophic appearance of the peripheral retina and RPE.13 These features need not 
be present to establish the diagnosis, but they are typical for advanced RP and 
instrumental in distinguishing RP from other retinal dystrophies. Other retinal changes 
include macular lesions varying from atrophy of the macular area to cystoid macular 
edema.14 Irregularity of the vitreoretinal interface, and posterior subcapsular cataracts 
may also be present.15,16 Subperipheral fields are generally lost, but central vision can be 
seriously affected early in RP while peripheral fields remain. This can be due to cystoid 
macular edema, vascular leakage, macular preretinal fibrosis or RPE defects in the 
macular region 14,17-19 
The clinical classification of adRP can be based on diffuse or sectorial involvement, 
fundus appearance, electroretinographic findings and age of onset. For example, in one 
classification four types are distinguished from diffuse to regional RP, on the basis of 
funduscopy, perimetry and ERG measurements.20 Type 1 is characterized by diffuse 
fundus pigmentary changes and cone and rod functions that cannot be detected by 
ERG. Types 2 and 3 are characterized by more perceptible pigmentary changes in the 
inferior retina. Type 2 patients show a marked loss of rod ERG function with prolonged 
cone implicit times, whereas type 3 patients show substantial rod function and normal 
cone implicit times. Type 4 patients have funduscopically and functionally 'delimited' 
disease. Another widely accepted classification system for adRP is based on 
psychophysical testing and age of onset.21-23 Type 1 adRP is characterized by a diffuse 
loss of rod sensitivity, later loss of cone sensitivity, and early onset of night blindness in 
childhood. Type 2 is characterized by a regional loss of both rod and cone sensitivity, 
with abnormal but preserved cone responses on ERG and the onset of night blindness 
in adulthood. The current increase in knowledge of the molecular defects leading to RP 
and its functional aspects allows these clinical subdivisions to be combined with the 
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molecular data to obtain an improved classification system. Moreover, genotyping 
might allow the identification of targets for therapeutic intervention. 
 
1.3.2 Genetic aspects of autosomal dominant retinitis pigmentosa 
Currently, 12 loci associated with adRP are known, and in all but one (RP17) the gene 
has been identified (Table 1.1). In 25-50% of adRP cases, the causative gene(s) have not 
been identified. Rhodopsin accounts for the highest proportion of the disease, followed 
by PRPF31. The estimated frequencies for these and the remaining adRP loci (Table 1.1) 
are based on mutation detection in large clinic-based patient series and on small 
samples from around the world.  
 
Table 1.1 Autosomal dominant RP: loci and genes and their estimated involvement 
Chrom. 
location 
Locus Identified 
gene 
Protein Number and 
percentage of 
cases 
Ref
1q21.1 RP18 HPRP3 Human homolog of yeast pre-
mRNA splicing factor 3 
3 families 
2/150  
1-5% 24-27
3q21-q24 RP4 RHO Rhodopsin 59/206 
10/20 
12/39 
~30% 28-32
6p21.1-
cen 
RP7 RDS Peripherin/retinal 
degeneration slow 
19/206 3-8% 33-36
7p14.3 RP9 PIM1K Pim-1 oncogene kinase 2 families 
1/20 
<1% 37-40
7q31.1 RP10 IMPDH1 Inosine monophosphate 
dehydrogenase 1 
6 families <6% 40-45
8q11-q13 RP1 RP1 RP1 protein 8/206 
17/344 
3-8% 45-51
14q11.2 RP27 NRL Neural retina leucine zipper 6 families 
4/189 
1-3% 52-55
17p13.3 RP13 PRPC8   Human homolog of yeast pre- 
mRNA splicing factor C8 
5 families <5% 56-59
17q22 RP17 - - 3 families <5% 60-62
17q25 - FSCN2 Retinal fascin 2 (208delG) 
 
14/120  
only 
Japanese 
~12%  63,64
19q13.3 - CRX Cone rod otx-like 
photoreceptor homeobox 
transcription factor 
1/164 <1% 65,66
19q13.4 RP11 PRPF31 Human homolog of yeast pre-
mRNA splicing factor 31 
4/20 ~20% 31,67
68 
 
AdRP genes have been found to be involved in different molecular processes of the 
retina: biosynthesis and structure, eye development, phototransduction, pre-mRNA 
splicing, and other less well-defined functions.69-72 These processes will be outlined in 
more detail below. 
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Biosynthesis and structure 
Disc morphogenesis is a crucial process. Disruption of the continuous renewal of outer 
segment discs results in malformation of the discs. Deficient degradation of the 
shedded disc material leads to the formation of retinal deposits, which obstruct the flow 
of metabolites passing through the RPE to the photoreceptors. Different genes with 
functions in normal disc morphogenesis have been found to be mutated in adRP. 
 
Rhodopsin 
The rhodopsin protein is the main photopigment in humans, residing mainly (90%) in 
the disc membranes of the rod outer segments. Approximately 30% of cases of adRP are 
caused by mutations in the rhodopsin gene, most of which result in single amino acid 
substitutions.29,32 Two classes of rhodopsin mutations can be distinguished on the basis 
of the different characteristics of mutant and wild-type rhodopsin in transfected 
cultured cells.73 Class I rhodopsin mutations (15%) cluster at the extreme carboxy-
terminus. The carboxy-terminus binds to the Tctex-1 protein, which is involved in the 
transport of rhodopsin-laden post-Golgi vesicles. Various class I rhodopsin mutants fail 
to bind to the Tctex-1 protein.74 Class II rhodopsin mutations (85%) are found mainly in 
the transmembrane and extracellular domains, and interfere with the folding and/or 
stability of the protein. The mutant rhodopsin tends to accumulate in the endoplasmic 
reticulum, and has a reduced or absent binding to 11-cis-retinal.73,75-81  
 
Peripherin/RDS 
Peripherin/RDS is an integral membrane glycoprotein located at the disc rim in rod and 
cone photoreceptors, and it plays a role in morphogenesis and the maintenance of the 
disc structure of the photoreceptor outer segments36,36,82 Oligomerization and 
dimerization of the peripherin/RDS protein are necessary for the maintenance of a 
flattened photoreceptor disc morphology.83 This is critical for the visual process, since 
disc flattening maximizes the area available for photoreception and allows efficient 
renewal of the rod outer segments. Peripherin/RDS mutations can cause adRP and a 
variety of macular pattern dystrophies.45,84-87 A few cases of digenic RP have been 
described, in which the disease is caused by the simultaneous presence of heterozygous 
mutations in the peripherin/RDS gene and in the ROM-1 gene. The ROM-1 gene encodes 
the rod outer segment membrane protein-1, and in rod discs peripherin/RDS and 
ROM1 interact and form functional homotetramers.88-90 
 
Retinal fascin (FSCN2) 
A FSCN2 gene mutation screening was performed in 120 adRP patients, 200 arRP 
patients and 100 isolated RP patients. Fourteen adRP patients were found to harbour a 
208delG mutation, which presents 3.3% of all RP patients and 11.7% of adRP cases.64 
Retinal fascin is a photoreceptor-specific paralog of the actin-bundling protein fascin. 
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Fascins crosslink f-actin into highly ordered bundles within dynamic cell extensions 
such as neuronal growth cone filopodia. The likely function of retinal fascin, in light of 
known roles of fascin in other cell types, is to assemble actin microfilaments important 
for photoreceptor disc morphogenesis.63  
 
Eye development 
Numerous transcriptional regulatory proteins are essential for ocular development, but 
few have been found to cause nonsyndromic retinal disease in humans.91 
  
Cone-rod otx-like photoreceptor homeobox transcription factor (CRX) 
The CRX gene, encoding a transcription factor, belongs to the orthodenticle homeobox 
family of homeobox genes, members of which are involved in the development of 
anterior head structures and other embryonic features.92 CRX is expressed principally in 
rod and cone photoreceptors.65,93,94 Murine Crx is first expressed in the outer part of the 
undifferentiated neuroblast layer, and its expression peaks when rod photoreceptors 
differentiate and begin to express photoreceptor-specific genes.95 CRX regulates the 
expression of rhodopsin and other outer segment proteins, including arrestin and rod 
transducin, and also activates the transcription of interphotoreceptor retinoid binding 
protein and β-phosphodiesterase.93,94 In humans, CRX mutations have been associated 
with several clinical phenotypes, including ad cone-rod dystrophy, late-onset adRP and 
Leber congenital amaurosis.66 
 
Neural retina leucine zipper (NRL) 
NRL is a basic motif-leucine zipper transcription factor that is preferentially expressed 
in rod photoreceptors.96,97 NRL transactivates photoreceptor promotors alone, or it acts 
synergistically with CRX to regulate rhodopsin transcription.93,98-100 A mutant NRL in 
mammalian cells synergizes with CRX more efficiently than wild-type NRL, leading to 
an increase in transcriptional activity.52 This may relate to the observation that over-
expression of rhodopsin in transgenic mice causes photoreceptor degeneration.101 The 
deletion of Nrl in mice results in the complete loss of rod function and super-normal 
cone function, mediated by S cones.102 It is postulated that NRL acts as a modulator of 
expression of rod-specific genes and an inhibitor of the S cone pathway. NRL mutations 
have been found to be associated with adRP and isolated RP.52,54  
 
The association of clinical phenotypes with mutations in CRX and NRL suggests that 
over- or underproduction of outer segment proteins may be deleterious.  
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Phototransduction 
Rhodopsin 
Genes encoding proteins of the phototransduction cascade are good candidate genes for 
retinal dystrophies. Indeed, many proteins have been found to be associated with 
different forms of retinal dystrophy (ad, ar or X-linked). In rod photoreceptors, 
rhodopsin is the light-absorbing, conjugated photopigment, composed of an apoprotein 
opsin molecule bound to the light-sensitive chromophore 11-cis-retinal. Light induces 
isomerization of the retinal, which results in conformational changes in the opsin 
molecule, exposing G-protein-binding sites. This leads to the activation of the G-protein 
transducin. The phototransduction cascade has started and eventually results in closing 
of the cGMP-dependent cation channels and transmembrane hyperpolarization. The 
recovery phase of phototransduction involves active turnoff and recycling of the 
transduction components by rhodopsin kinase, which phosphorylates photoactivated 
rhodopsin, and by arrestin, which binds to the phosphorylated opsin.103,104 This results 
in the binding of a new 11-cis-retinal molecule to opsin, and prevents further activation 
of transducin.105 Most rhodopsin mutations, resulting in adRP, affect folding, stability or 
intracellular trafficking, as described earlier. Exceptions are two mutant rhodopsins, 
which are unable to bind 11-cis-retinal due to 296lysine substitition.106,107 This causes a 
constitutive activation of transducin, but the activation is arrested by photoreceptor 
inactivation mechanisms consisting of phosphorylation and arrestin binding.108-110    
 
Pre-mRNA splicing 
PRPC8, PRP31 and HPRP3 
RNA splicing ensures the removal of intronic RNA sequences from the primary 
transcript, and the fusion of exonic RNA sequences. Three genes have recently been 
found to be involved in pre-mRNA splicing: human homolog of yeast pre-mRNA 
splicing factor C8 (PRPC8), human homolog of yeast pre-mRNA splicing factor 31 
(PRP31) and human homolog of yeast pre-mRNA splicing factor 3 (HPRP3).24,58,68 These 
genes are expressed in all tissues, but mutations cause pathology only in photoreceptor 
cells. The spliceosome is a complex macromolecular machinery catalysing pre-mRNA 
splicing.111 The spliceosomal proteins provide important catalytic and regulatory 
functions for pre-mRNA processing, through dynamic interactions as part of the 
spliceosome and through interactions with other splicing factors (see 7.2). Mutations in 
these proteins lead to defects in the splicing process and are associated with adRP.24,58,68    
 
Miscellaneous 
Inosine monophosphate dehydrogenase 1 (IMPDH1)  
IMPDH1 is a ubiquitously synthesized enzyme, functioning as a homotetramer, which 
catalyzes the rate-limiting step in de novo synthesis of guanine nucleotides. As such, it 
plays an important role in cyclic nucleoside metabolism within photoreceptors, but the 
                               GENERAL INTRODUCTION 
 
 27
exact mechanism by which mutations in IMPDH lead to RP is unknown.41,42 Guanine 
nucleotides play crucial roles in cellular growth, differentiation and apoptosis, and are 
important substrates for DNA and RNA synthesis and cell signaling.112 
 
Pim-1 oncogene kinase (PIM1K) 
The mechanism whereby mutations in the widely expressed PIM1K gene may lead to 
retinal degeneration remains unknown.39 The most likely explanation is that the high 
metabolic rate and presence of photoactivated molecules in the neural retina constitute 
physiological stresses not present in other tissues.113 However, it is also possible that 
specific domains of a multifunctional protein are required only in a specific 
physiological context. Other 'housekeeping' genes with no obvious involvement in 
visual system development or function may cause retinal disease, as seen above in the 
pre-mRNA splicing genes.24,58,68 
 
RP1 
The exact function of the RP1 protein is unknown. The expression of RP1 is regulated 
by oxygen levels in the retina.48 The mouse ortholog (Rp1) of the human RP1 gene has 
been cloned, and a targeted disruption of Rp1 in mice has been found to result in 
progressive degeneration of photoreceptors, disorganization of photoreceptor outer 
segments, mislocalization of rhodopsin and a reduced ERG signal.114 The phenotype of 
the mice concerned resembles the phenotype of RP1 patients. These findings 
demonstrate that RP1 is required for normal morphogenesis of photoreceptor outer 
segments, and may also play a role in the transport of rhodopsin to outer segments. The 
RP1 protein also contains a leucine zipper, a single putative transmembrane domain, 
and three putative nuclear localization signals, suggesting that RP1 may function as a 
transcription factor, possibly during photoreceptor differentation.48,49  
 
 
1.4 CENTRAL AUTOSOMAL DOMINANT RETINAL DYSTROPHIES  
 
1.4.1 Clinical aspects of autosomal dominant macular dystrophies 
Autosomal dominant central retinal dystrophies represent a heterogeneous group of 
disorders, which predominantly affect the central cone-rich area of the retina. In 
general, they are characterized by a bilateral appearance, slow progression, and gradual 
loss of visual acuity, colour vision and central visual fields, but they encompass a range 
of clinical and histopathological findings (Table 1.2).115 Attempts have been made to 
classify central dystrophies by mode of inheritance, age of onset, descriptive fundus 
signs and electrophysiological findings.115 The traditional clinical classification of 
central retinal dystrophies is based on the cellular location of the dystrophy, i.e. the 
photoreceptors, the RPE, Bruch’s membrane and the choroid. However, many 
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dystrophies show overlapping abnormalities, and the primary defect is often not easy 
to identify. Moreover, some causal genes involved in ad macular dystrophies are 
expressed in a cell type that is different from what was expected on the basis of clinical 
and histological observations. A functional classification of the genes involved will be 
outlined in section 1.4.2.   
 
Adult vitelliform macular dystrophy (AVMD/ RDS/ VMD2) 
Patients with AVMD usually present with mild loss of visual acuity or metamorphopsia 
in the fourth to fifth decade of life. AVMD is characterized by the bilaterally 
symmetrical appearance of a round or oval shaped yellowish foveal lesion. The lesions 
vary in size, but are mostly between one-third and one-half disc diameter in size. 
Fluorescein angiography reveals a characteristic ring of hyperfluorescence surrounding 
a hypofluorescent area, which corresponds to the foveal lesion. The EOG is usually 
normal or slightly reduced, and the ERG is normal.116,117 The visual fields are normal or 
show some decreased sensitivity. Colour vision is mildly affected. Families with AVMD 
may display an autosomal dominant pattern of inheritance.117,118 AVMD differs from 
Best disease (or vitelliform macular dystrophy, VMD) in that it has a later age of onset, 
smaller lesions and a normal to slightly reduced EOG, instead of an early age of onset, 
larger lesions and an abnormal EOG in Best disease. Evenso it lacks the typical course 
through different stages of macular disease seen in classical Best disease. AVMD is 
known to be associated with mutations in the peripherin/RDS gene and the VMD2 
gene.84,119,120  
 
Age related macular degeneration (ARMD1/HEMICENTIN-1) 
Age related macular degeneration (ARMD) is a heterogeneous collection of disorders 
that include a spectrum of disease processes that involve the RPE and the choroid and 
may lead to disruption of the macular area by subretinal choroidal neovascularization. 
Nearly 20% of the patients with ARMD have a positive family history.121,122 Genome-
wide association studies using families with at least two siblings affected by ARMD 
reveal susceptibility loci at 1q31 and 17q25.123,124 Only a single family with monogenic 
ARMD has been described so far. In the 10 affected family members, who have visual 
acuities ranging from 1.0 to CF and an age of onset from 52 to 75 years, large soft 
drusen accompanied by varying degrees of RPE degeneration and/or geographic 
atrophy were found.125 Electrophysiological or visual fields examinations were not 
performed. A genome scan mapped the underlying defect in this family to chromosome 
1q25-q31 (ARMD1) and recently it was suggested that HEMICENTIN-1 is the ARMD1 
gene.126 
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Table 1.2 Autosomal dominant macular dystrophies: clinical characteristics, prevalence 
and number of associated loci  
 
Disease Onset 
age (y)  
VA Fundus ERG EOG Color 
vision
Visual 
fields 
Fam. 
(#) 
Loci 
(#) 
ARMD  52-75 1.0-CF drusen, RPE 
degeneration, 
atrophy 
- - - - ≥ 1  1 
AVMD 30-50 1.0-0.6 foveal round / oval 
shaped yellow 
lesion 
N SN MD Normal /  
decreased 
central 
sensitivity 
≥ 20 2 
BCAMD  20-40 1.0-0.3 bull’s eye macula, 
peripheral bone 
spicules and 
atrophy 
pho: AN 
sco: AN
SN/ 
AN 
D normal / 
constricted 
visual fields 
≥ 2  
 
1  
BSMD / 
pattern 
dystrophy 
10-30 1.0-0.8 bilateral 
polymorphous 
pigmentations 
N SN/ 
AN 
N normal / 
decreased 
central 
sensitivity 
≥ 10 1 
CACD 30-60 1.0-CF well-demarcated 
macular atrophy 
N/SN N/SN N/D normal / 
central 
scotoma  
≥ 10 2 
COD  10-30  1.0-0.1 
or CF 
bull’s eye macula pho: AN
sco: N 
N/SN SD central 
scotoma 
≥ 7  3 
CORD  10-30 1.0-0.1 bull’s eye macula, 
peripheral bone 
spicules and 
atrophy 
pho: AN
sco: AN
N/SN D central 
scotoma & 
constricted 
visual fields 
≥ 20  6 
CYMD  0-20 1.0-HM CME, macular 
atrophy, peripheral 
hyperpigmentations
N/SN N/AN N/D normal / 
central 
scotoma 
≥ 2  1 
DD / 
DHRD 
20-30 1.0-0.5 brownish and later 
white round spots 
N N/SN MD normal / 
central 
scotoma  
≥ 20 2 
NCMD  10-20 1.0-0.1 drusen-like 
deposits, confluent 
macular lesions, 
maculopathy 
N N N decreased 
sensitivity  
(≈ lesions) 
≥ 14 1 
PBCRA 0-1 0.2-CF large atrophic 
macular and nasal 
retinal lesions 
pho: AN 
sco: AN
AN D - ≥ 1  1 
SFD  10-40 1.0-LP drusen or confluent 
yellow plaque along 
the arcades, 
atrophic macula, 
subretinal  
neovascularization 
N/SN N/SN D central 
scotoma 
≥ 7  1 
STGD  6-20 1.0-HM atrophic macula, 
with yellow flecks 
N/SN N/SN MD central 
scotoma 
≥ 5  2 
VMD 0-10 1.0-0.5 
or CF 
egg-yellow round 
central structure  
N SN/ 
AN 
MD normal / 
decreased 
central 
sensitivity 
≥ 100 
 
1 
 
Disease: see abbreviations, VA: visual acuity, CF: counting fingers, HM: hand movements, LP; 
light perception, CME: cystoid macular edema, ERG: electroretinogram, pho: photopic, sco: 
scotopic, N: normal, SN: subnormal, AN: abnormal, EOG: electro-oculogram, D: disturbed, MD: 
mildly disturbed, SD: severly disturbed, Fam.: families, #: number 
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Benign concentric annular macular dystrophy (BCAMD) 
BCAMD initially (at the age of 30 years) shows a ringlike depigmentation around the 
fovea, associated with good visual acuity and without signs or symptoms typical of 
cone dystrophy or a history of chloroquine ingestion.127 After the fourth to fifth decade, 
a more progressive macular dystrophy, and peripheral involvement with bone 
corpuscle-like pigmentations, is seen.128 Patients then complain of night blindness, and 
visual acuity ranges from 0.3 to 1.0. Electrophysiological testing reveals increased 
photoreceptor dysfunction, with a slight predominance of rod dysfunction. The EOG is 
definitely abnormal, and deteriorating with age. The patients suffer from an acquired 
type III blue-yellow defect, with pseudoprotanomaly. In conclusion, after the fifth 
decade, the dystrophy presents as a diffuse retinopathy with the functional 
characteristics of an atypical retinitis pigmentosa. Histological studies have not been 
performed, but the well-preserved visual acuity over a long period of disease suggests 
primary involvement of the RPE or rod photoreceptors. The gene defect underlying 
BCAMD is discussed in more detail in Chapter 3. 
 
Central areolar choroidal dystrophy (CACD/RDS) 
CACD is characterized by a well-demarcated circumscribed area of atrophy of the RPE 
and choriocapillaris in the macula. Age of onset of disease varies between 40 and 60 
years, and there is a central scotoma and visual impairment.129 The early stages of 
disease are characterized by fine parafoveal pigmentary changes, followed by evident 
hypopigmentation.130 Fluorescein angiography shows transmission hyperfluorescence 
in this stage. Parafoveal atrophy of the RPE and the choriocapillaris is evident from the 
age of 40 and the fluorescein angiography visualizes the absence of the choriocapillaris. 
Electrophysiological testing (including EOG, ERG and color vision testing) may be 
normal to subnormal in more advanced cases.129,131 Histopathological studies suggest a 
primary dystrophy of the choroidal vessels, but primary RPE dystrophy with secondary 
involvement of the choroid also remains a possibility.132 In seven CACD families an 
Arg142Trp founder mutation has been found in the peripherin/RDS gene.133 One of these 
families, and two other families, demonstrate the rare combination of CACD and 
drusen in association with the Arg142Trp mutation.134 The association of CACD with a 
mutation in the peripherin/RDS gene indicates the primary involvement of the 
photoreceptor cells. Finally, the defect in a CACD family from Northern Ireland has 
been linked to chromosome 17p13, but the gene has not yet been identified. 135,136 
 
Cone dystrophy (COD3/ GUCA1A, RCD1, RCD2) 
The age of onset of cone dystrophy (COD) is usually between the first and third decades 
of life. Complaints consist of photo-aversion, progressive loss of visual acuity and 
impaired color vision. Patients see better at dusk and prefer to wear sunglasses. Vision 
deteriorates gradually to 0.1, and in severe cases to hand movements (HM). The vision 
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loss typically precedes macular changes evident on ophthalmoscopic examination, 
which reveals a bull’s eye macular lesion, sometimes accompanied by mild bone spicule 
pigment clumping and geographic macular atrophy in a later stage. Optic atrophy and 
attenuated vessels are also commonly found at a later stage. The ERG demonstrates 
diffuse cone dysfunction and normal rod function. In more severe cases, mildly affected 
scotopic responses can be found. The EOG is normal in mild cases, but becomes affected 
in severe cases. There is severe color blindness, almost resembling congenital 
achromatopsia. Visual fields reveal central scotomas, often with a relative central 
sparing. Cone dystrophies show great variability in severity and rate of progression 
between families, and even within families. Histological studies reveal a primary defect 
of the photoreceptors, rapidly followed by involvement of the RPE.137 So far, adCOD 
has been found to be associated with mutations in the guanylate cyclase activator 1A 
(GUCA1A) gene on chromosome 6p21.1, and with as yet unidentified genes on 
chromosomes 6q25-26 and 17p13-p12.138-141 
 
Cone-rod dystrophy (CORD/RDS, CORD/AIPL1, CORD/UNC119, CORD2/CRX, 
CORD6/GUCY2D, CORD7/RIM1)  
CORD initially resembles cone dystrophy. Rod involvement becomes evident over time. 
Patients can complain of night blindness, along with poor color discrimination and poor 
visual acuity. In later stages, fundus examination reveals peripheral bone corpuscles 
and atrophy similar to RP. At this stage, CORD is hard to differentiate from RP. The 
ERG shows both cone and rod dysfunction, and visual fields become constricted or ring 
scotomas arise. So far, 6 non-syndromic loci have been found to be associated with 
cone-rod dystrophy. Five genes were identified: the peripherin/RDS gene at chromosome 
6p21, RIM1 at 6q, GUCY2D and AIPL1 at chromosome 17p, UNC119 at chromosome 
17q11.2 and the CRX gene at chromosome 19q.65,66,142-150 The corresponding proteins 
have different functions and will be described below.  
 
Dominant cystoid macular edema (CYMD) 
CYMD has so far been described only in a large Dutch family and a small Greek 
family.151-153 CYMD is characterized by an early onset cystoid macular edema resulting 
in macular atrophy. In late stages of disease, peripheral hyperpigmentations and 
attenuated arterioles can be found. Visual acuity ranges from 1.0 in early stages to HM 
in severe cases. There is hyperopia, a diminished EOG in most cases, an affected ERG in 
late stages, and deficient color vision, depending on the mode of fixation. The gene 
defect underlying CYMD maps to chromosome 7p15.3.154 The causative gene has not 
yet been identified. CYMD is described in more detail in Chapter 6. 
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Dominant drusen (DD)/Doyne honeycomb retinal dystrophy (DHRD/EFEMP1) 
Dominant drusen, Malattia Leventinese and Doyne honeycomb dystrophy are different 
names for the same disorder.155,156 Initially, there are no symptoms, but visual acuity 
loss (up to 0.5) and metamorphopsia develop at a certain stage. Around the third 
decade, several round brownish-yellow structures arise on the vitreal side of Bruch’s 
membrane. Around the fifth decade, there are many sharply defined round white spots 
scattered at the posterior pole. These spots may be arranged in mosaic or honeycomb 
patterns. Subsequently, the dots confluence especially in the macular area, the RPE and 
choriocapillaris become atrophic and pigmentations may develop. Fluorescein 
angiography reveals hyperfluorescent or hypofluorescent drusen. ERG test results and 
dark adaptation remain normal, except in very severe cases. EOG testing is initially 
normal, but becomes subnormal depending on the degree of retinal involvement. Color 
vision is mildly affected. Visual fields are normal, but in severe cases central scotomas 
occur. Histochemical and ultrastructural studies reveal degenerating RPE cells that are 
converted into amorphous material filling the inner collagenous zone of Bruch’s 
membrane (drusen formation) and later the inner choroid, through discontinuities in 
Bruch’s membrane.157 These RPE cells contain large amounts of lysosomes, so it is 
suggested that uncontrolled activity of lysosomal enzymes is causative for the 
degeneration of the RPE. In most families with dominant drusen, a single mutation 
Arg345Trp (R345W) has been found in the EFEMP1 gene at 2p16-p21.158-161 EFEMP1 
encodes the EGF-containing, fibulin-like extracellular matrix protein-1. In a few other 
dominant drusen families that map to 2p16-p21, no mutations were found in the 
EFEMP1 gene, suggesting an EFEMP1 promoter sequence mutation or a second 
dominant drusen gene at this locus.162 The defect underlying dominant drusen was also 
located in one family at 6q14,163,164 and a peripherin/RDS mutation is associated with 
CACD and dominant drusen in three families.134 
 
North Carolina macular dystrophy (MCDR1) 
North Carolina macular dystrophy (NCMD) has a highly variable expressivity, and an 
age of onset in the second decade. The phenotype is classified into three grades: I: good 
visual acuity (1.0-0.8) and yellowish drusen-like peripheral and macular deposits; II: 
visual acuity of 0.9-0.3 and confluent macular lesions; III: visual acuity of 0.5-0.1 and 
large colobomatous lesions in the central macula.165,166 ERG, EOG and color vision 
examinations show no abnormalities. NCMD is considered to be nonprogressive, except 
for the development of choroidal membranes in some patients. Histological studies 
reveal focal absence of photoreceptor cells and RPE with attenuation of Bruch’s 
membrane, and focal atrophy of the choriocapillaris. Some lipofuscin adjacent to the 
macular lesion is found in the RPE.167 The gene defect maps to chromosome 6q14-q16.2 
(the MCDR1 locus), but the gene has not yet been identified.168-170 NCMD has been 
described in various countries and no evidence of genetic heterogeneity has been 
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reported. An early-onset autosomal dominant macular dystrophy (MCDR3), resembling 
MCDR1 has recently been mapped to chromosome 5p.171 The affected family members 
show early onset retinal changes confined to the macular region. The macular 
abnormalities vary from mild retinal pigment epithelium (RPE) pigmentary changes to 
atrophy. Drusen-like deposits are present in various degrees. Subretinal neovascular 
membrane is an established complication. The only significant differences in the 
phenotypes of MCDR1 and MCDR3 are abnormal colour vision in MCDR3 patients and 
evidence of progression in a single MCDR3 case. NCMD is discussed in more detail in 
the Addendum.  
 
Macular dystrophy (RDS) 
Several families with autosomal dominant macular dystrophies, that do not resemble 
one of the macular dystrophies described in this chapter, have been identified. One 
example is a family of which affected members present with nightblindness from the 
third decade and visual acuity loss between the ages of 36 and 56 years. 
Ophthalmoscopic changes, identified at 35 years, consist of macular atrophy and a 
normal peripheral fundus.172 Other examples include two families of which affected 
members present with macular dystrophy accompanied by complaints of blurred 
central vision and photophobia, starting in the third decade. By 40 years of age, visual 
acuity is less than 0.1.172 These families, and several other families with aspecific central 
dystrophies, all carry mutations in the peripherin/RDS gene.87,172 Macular dystrophies 
associated with peripherin/RDS mutations are described in more detail in Chapter 4 and 
section 7.3. 
 
Pattern dystrophy (RDS) 
Several conditions, like butterfly-shaped macular dystrophy (BSMD), reticular 
dystrophy, macroreticular dystrophy, fundus pulverulentus and adult-onset 
foveomacular vitelliform dystrophy, belong to a variety of autosomal dominant 
dystrophies of the RPE that are grouped into a single clinical entity known as pattern 
dystrophies.173 116;173-177Patients often have no complaints, and funduscopic changes are 
found in the course of routine ophthalmoscopic examination. Fundamental to the 
diagnosis are a subnormal EOG, normal or only slightly diminished visual acuity and 
an autosomal dominant inheritance pattern.175 The lesions are often bilateral, and 
consist of accumulated yellowish or pigmented material at the level of the RPE. The 
lesions vary from butterfly-shaped macular lesions to knotted fishnet-shaped structures 
extending towards the periphery. Fluorescein angiography reveals that the structures 
are clearly outlined by the choroidal fluorescence. The ERG and color vision are normal, 
but visual fields can show some decreased central sensitivity. Variability in the 
expression of pattern dystrophy has been described both within familiesand in a single 
patient during various stages of the disease.178-181 Pattern dystrophy is frequently seen 
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in myotonic dystrophy (Curschmann-Steinert).182,183 Microscopic examination reveals 
an area of total loss of the RPE and photoreceptor cell layer, with intact choriocapillaris 
and lipofuscin-containing cells in the subretinal space. Outside the area of RPE atrophy, 
the RPE is greatly distended by lipofuscin.184 So far, pattern dystrophy has been 
associated only with mutations in the peripherin/RDS gene,185-188 but genetic 
heterogeneity is suggested as discussed in more detail in Chapter 5. 
 
Progressive bifocal chorioretinal dystrophy (PBCRA) 
PBCRA is a slowly progressive chorioretinal dystrophy characterized by reduced visual 
acuity (0.3-CF), nystagmus, myopia and large atrophic macular and nasal retinal 
lesions. Large macular lesions are evident a few weeks after birth, accompanied by 
white deposits nasal to the optic disc and in the peripheral retina. The macular lesion 
enlarges and the nasal lesions coalesce into a confluent white lesion of chorioretinal 
atrophy. Finally, the macular and nasal lesions expand towards the optic disc. 
Fluorescein angiography reveals an absence of choroidal perfusion in the atrophic 
macular and nasal lesions, as well as staining of peripheral deposits, suggesting 
chorioretinal abnormalities. The ERG shows diminished photopic and scotopic 
responses and EOG and color vision are disturbed. These results suggest a widespread 
abnormality in RPE and retina function. PBCRA probably affects the retina 
diffusely.189,190 No reports on the visual fields in PBCRA are available. The gene 
underlying PBCRA has not been identified, but maps to chromosome 6q16-q16.2.191 
This region overlaps with the MCDR1 locus. Since there are some phenotypical 
similarities between PBCRA and NCMD (at MCDR1), they may be the results of 
different mutations in the same gene or they are caused by mutations in two different 
adjacent genes.190  
 
Sorsby’s fundus dystrophy (SFD/TIMP3) 
SFD is characterized by atrophy of the choriocapillaris, RPE and retina, and 
complicated by subretinal neovascularization leading to loss of central vision. An early 
manifestation is the presence of numerous fine drusen or a confluent plaque of faintly 
yellow material beneath the RPE, located along the arcades and nasal to the disc. A 
sudden loss of visual acuity is often manifested during the second, third or fourth 
decade, and may result in almost complete blindness.192 Other symptoms may be 
metamorphopsia, nyctalopia and difficulty with adaption to light. Fluorescein 
angiography shows a delay in choroidal perfusion and early hypofluorescence.193 The 
ERG and EOG are initially normal, but become subnormal in advanced stages, when 
sizable parts of the retina are involved.194 Dark adaptation has a delayed or absent cone-
rod break.195 Color vision is affected and visual field examination reveals a central 
scotoma, which increases progressively in size and intensity.  Histopathology shows an 
abnormal accumulation of lipid-containing material in the inner portion of Bruch’s 
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membrane, which could ultimately lead to vascular penetration of Bruch’s 
membrane.196,197 Mutations in the TIMP3 gene, located on chromosome 22q12.1-q13.2 
are associated with SFD.196,198 TIMP3 encodes a tissue inhibitor of metalloproteinase, 
which is involved in extracellular matrix remodeling.196 
 
Autosomal dominant Stargardt disease (STGD3/ELOVL4, STGD4/PROML1) 
Classically Stargardt disease is inherited in an autosomal recessive manner (STGD1) in 
approximately 90–95% of the reported cases, and its estimated prevalence is between 1 
in 8000 and 1 in 10000.199 The affected gene in recessive Stargardt disease is the 
photoreceptor-specific ATP-binding cassette transporter gene (ABCA4 gene) on chromosome 
1p, which is expressed in rods and cones.200-202However, several pedigrees with features 
typical of Stargardt disease suggest autosomal dominant inheritance.203-205 These 
pedigrees have been mapped to chromosomes 4p (STGD4) and 6q14 (STGD3).206,207 At 
locus 4p, a missense mutation in PROML1, encoding human prominin (mouse)-like 1, 
has been found to cosegregate with disease (personal communication with Zhang K.). 
At locus 6q14, the causative gene is the elongation of very long chain fatty acids-4 gene 
(ELOVL4).208,209 Visual loss is the most common clinical symptom with which patients 
with ad Stargardt-like macular dystrophy present, and often occurs in the first or 
second decade of life. It may precede retinal changes and is often associated with subtle 
RPE abnormalities. These early findings are later followed by an atrophic macular 
degeneration with or without yellowish fundus flecks, which may become more 
prominent with time. There are minimal color vision defects, and no significant ERG or 
EOG changes.206,207,210 Finding a "dark choroid" on fluorescein angiography is thought 
to suggest blockage due to lipid accumulation in the RPE. This is common in the 
recessive form of the condition and present in the dominant form linked to 4p,206 but it 
is uncommon in the dominant form linked to 6q14.210 The autosomal recessive and 
dominant forms of the Stargardt disease phenotype may be difficult to differentiate on 
the basis of the fundus examination, but they may be distinguished on the basis of 
inheritance patterns and DNA sequence variations in the ABCA4, ELOVL4 and 
PROML1 genes respectively. Recently a British family was described with an autosomal 
dominant Bull’s eye macular dystrophy (MCDR2) also mapping to chromosome 4p211 
and carrying the same missense mutation in PROML1 as the STGD4 pedigree.212 The 
MCDR2 phenotype differs from that of STGD4 in that retinal flecks are absent and there 
is no evidence of a dark choroid on fluorescein angiography. 
Histological studies of the eyes of patients with STGD1 suggest primary defects in the 
photoreceptors and in the RPE.213,214 A suggested explanation for the pathophysiology 
of STGD1 is the accumulation of protonated N-retinylidine-phosphatidylethanolamine 
in the rod outer segments, caused by the defective ABCA4 gene and leading to the 
accumulation of A2-E, a byproduct of N-retinylidene-phosphatidylethanolamine, in the 
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RPE cells. The lipopigment is toxic to the RPE, and the loss of RPE support function 
eventually leads to photoreceptor death.215  
 
Vitelliform macular dystrophy (VMD2/VMD2) 
The penetrance and expressivity of VMD (also called Best disease) is variable, as in 
other dominantly inherited diseases. Lesions may present as unilateral or bilateral, 
single or multiple, macular or eccentric lesions. Visual acuity is initially normal or 
slightly subnormal, but it may diminish considerably, to as low as CF in late stages. 
VMD has been divided into five stages. Stage 1 (pre-vitelliform) is characterized by an 
abnormal EOG with a normal fundus appearance, and stage 2 (vitelliform) is 
characterized by the classic egg-yolk macular lesion in the first or second decade of life. 
Fluorescein angiography reveals a corresponding area of blocked choroidal 
fluorescence. Stage 3 (pseudohypopyon) represents absorption of part of the lesion. In 
stage 4 the egg yolk begins to break up, and assumes a scrambled egg appearance. 
Visual acuity usually decreases in this stage. Stage 5 is characterized by a moderate to 
severe visual impairment associated with a hypertrophic scar, a fibrovascular scar with 
choroidal neovascularization, or atrophic maculopathy. The EOG is subnormal or 
abnormal and the ERG is normal during all stages.216-218 Carriers with normal fundi on 
ophthalmoscopy also have a subnormal EOG.218 The visual fields are normal or show 
some decreased sensitivity. Color vision is mildly affected. Histopathological 
examination reveals that RPE cells across the entire fundus have accumulated an 
excessive amount of lipofuscin, as defined by ultrastructural appearance, 
autofluorescence, and staining properties. Such an accumulation of heterogeneous 
material located between Bruch’s membrane and the pigment epithelium in the fovea is 
interpreted as representing a pre-vitelliform lesion. The material itself appears to be 
derived from degenerating RPE cells, and contains few intact lipofuscin granules. 
Foveal photoreceptor loss occurs above the lesion.219 VMD maps to chromosome 
11q13,220-223 and the causative gene is VMD2, encoding bestrophin.119  
 
1.4.2 Genetic aspects of autosomal dominant macular dystrophies 
Molecular genetic studies of ad central macular dystrophies reveal a high degree of 
genetic heterogeneity (different genes causing the same disease) and allelic 
heterogeneity (different mutations in the same gene causing either the same disease or 
different diseases).224,225 To date, 21 disease loci implicated in autosomal dominant 
dystrophies of the retina and choroid, with primary involvement of the macular area, 
have been assigned to specific chromosomal regions (Table 1.3), and 13 genes have so 
far been identified and one gene (IMPG1) might be involved. The genes can be 
classified by their involvement in different molecular processes of the retina. Several 
genes have not yet been identified, and the precise function of the genes that have 
already been identified is often unknown. 
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Table 1.3 Loci and genes involved in autosomal dominant macular dystrophy 
Chrom. 
Location 
Locus Identified 
gene 
Protein References 
1q25-q31 ARMD1 HEMICEN
TIN-1 
Hemicentin-1 125,126,226 
2p16-p21 DHRD EFEMP1 EGF-containing fibrillin-like 
extracellular matrix protein 1 
158,159,161,227, 
228 
4p             STGD4  
MCDR2 
PROML1 Human prominin (mouse)-like 1 206,211,212  
5p MCDR3 - - 171 
6p21.1 COD3 GUCA1A Guanylate cyclase activating protein-1 
  
138,142 
6p21.2-
cen 
CORD 
BSMD 
MD 
CACD 
AVMD 
RDS Peripherin/RDS 84,133,186,229, 
230 
6q CORD7 RIM1 - 145,231 
6q14 STGD3 ELOVL4 Elongation of very long chain fatty 
acids protein 4 
207-209 
6p12.3-
q16 
BCAMD IMPG1(?)  232 
6q14 DD - - 163 
6q14-
q16.2 
MCDR1 
PBCRA 
- - 168-170,191 
6q25-q26 RCD1 - - 139 
7p21-p15 CYMD - - 154 
11q13 VMD2 VMD2 Bestrophin 119,220-223 
17p13 CACD - - 135,136 
17p13.1 CORD6 GUCY2D Retinal-specific guanylate cyclase 2D 144,233,234 
17p13.1 CORD AIPL1 Arylhydrocarbon-interacting receptor 
protein-like 1 
149 
17p13-  
p12 
RCD2 - - 140,141 
17q11.2 CORD UNC119 Unc119 protein 146 
19q13.3 CORD2 CRX Cone-rod otx-like photoreceptor 
homeobox transcription factor 
65,150,235,236 
22q12.1-
q13.2 
SFD TIMP3 Tissue inhibitor of metallo- 
proteinases-3 
196,198 
 
Biosynthesis and structure   
Peripherin/RDS 
Peripherin/RDS mutations can be causal for adRP as well as for a variety of ad macular  
dystrophies, like AVMD, BSMD, CORD, CACD, and some aspecific macular 
dystrophies. The function of this protein is described in section 1.3.2, Chapter 4 and in 
the discussion. 
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Prominin (mouse)-like 1 (PROML1) 
Mutations in the PROML1 gene have found to be associated with a family with 
autosomal dominant Stargardt disease and with a family with bull’s eye macula 
dystrophy (personal communication with Khang Zang). PROML1 belongs to the 
prominin family of five-transmembrane domain proteins. PROML1 is expressed in 
adult retina and retinoblastoma cell lines and the protein is concentrated in membrane 
evaginations at the base of the outer segments of rod photoreceptors.237 In an Indian 
family with autosomal recessive retinal dystrophy a homozygous mutation in PROML1 
resulted in a truncated protein. Functional studies in transfected CHO cells 
demonstrated that the truncated protein failed to reach the surface, indicating that loss 
of prominin causes retinal degeneration, possibly because of impaired generation of the 
evaginations and/or impaired conversion of the evaginations to disks.237  
 
Eye development 
Cone-rod otx-like photoreceptor homeobox transcription factor (CRX) 
CRX is involved in the expression of rhodopsin and other outer segment proteins, and 
has been found to be associated with adCORD, late-onset adRP and Leber congenital 
amaurosis. The function of this protein is described in section 1.3.2. 
 
Photoreceptor neurotransmission 
Rab3A-interacting molecule (RIM1) 
The RIM1 gene, which is implicated in autosomal dominant cone-rod dystrophy 
(CORD7), is expressed in brain and photoreceptors of the retina where it is localised to 
the pre-synaptic ribbons in ribbon synapses. RIM1 is thought to be involved in normal 
synaptic vesicle primimg and exocytosis.145 
 
Unc119 protein (UNC119) 
This protein is specifically expressed in the photoreceptors in the retina. The encoded 
product shares strong homology with the C. elegans unc119 protein. It is localized at the 
photoreceptor synapses in the outer plexiform layer of the retina, and thought possibly 
to play a role in the mechanism of photoreceptor neurotransmitter release through the 
synaptic vesicle cycle.238,239 A heterozygous premature termination codon mutation has 
been found in a 57-year-old woman with late onset cone-rod dystrophy.146 
 
Phototransduction 
Guanylate cyclase activating protein-1A (GUCA1A)   
GUCA1A is a Ca2+ binding protein that stimulates synthesis of cyclic guanosine 
monophosphate (cGMP) in photoreceptors and is inhibited by intracellular calcium, 
which rises in the dark-adapted state.240,241 Studies have been undertaken to examine 
the function of the mutant and wild-type protein by using a recombinant Tyr99Cys 
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GUCA1A mutant.242,243 It seems that the effect of this dominant negative mutation in 
GUCA1A is that the mutant protein loses its calcium sensitivity, and is effectively no 
longer a calcium switch. The mutant protein interferes with the remaining wild-type 
GUCA1A, and the ability of GUCA1A to be switched off is lost, rendering it 
permanently active. These experimental observations support the inference that the 
cone degeneration associated with the Tyr99Cys mutation in GUCA1A is a result of 
constitutive activation of cGMP synthesis. Evidence exists that continuous high levels of 
cGMP can cause photoreceptor cell death.244 In situ hybridization in primate retinas 
shows that GUCA1A is expressed exclusively in photoreceptor inner segments.245 
Immunohistochemical staining for GUCA1A in human retinas has demonstrated that 
there is intense staining of cone outer and inner segments, the cell body from axon to 
pedicle, but weaker immunoreactivity in rod inner segments, and very minimal 
immunostaining of rod outer segments.246 The GUCA1A gene is implicated in 
autosomal dominant cone-rod dystrophy (COD3). 
 
Guanylate cyclase 2D (GUCY2D) 
GUCY2D (also named RETGC) is involved in the phototransduction cascade and the 
synthesis of cGMP from 5'-GMP.247 cGMP levels are responsible for increasing the 
proportion of open cGMP-gated channels in the dark-adapted state. Mutations in 
GUCY2D could, therefore, give rise to retinal disease.248 All mutations described in ad 
cone-rod dystrophy are either in the same, or in adjacent, codons in a highly conserved 
region of the protein, and can result in variable severities of cone-rod dystrophy, 
especially with regard to the involvement of the scotopic system.234 The phenotype of a 
dystrophy predominantly of the cone variety, but with some involvement of rods, is 
consistent with the tissue localization studies of GUCY2D.249 Immunoimaging with 
confocal and electron microscopy in human and monkey retinas has demonstrated that 
RETGC is primarily located in the photoreceptor layer, and that outer segments of 
cones are more densely labeled with antibodies than those of rods.250,251 Mutations in 
GUCY2D can also result in Leber congenital amaurosis (LCA).252 
 
Protein trafficking 
The genes discussed below may be involved in the regulation of the directional 
intracellular transport of proteins in photoreceptors. 
 
Epidermal growth factor-containing fibrillin-like extracellular matrix protein 1 (EFEMP1) 
EFEMP1 is expressed in the RPE and the retina and encodes a protein homologous to a 
family of extracellular matrix glycoproteins known as fibulins.253 A single mutation 
(Arg345Trp) has been identified in the EFEMP1 gene in several families, and it has been 
suggested that this mutation originates from a common ancestor.161 The Arg345Trp 
mutation alters the last epidermal growth factor (EGF) domain of EFEMP1, and is 
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similar in this respect to a number of fibrillin mutations that cause Marfan syndrome.254 
Mutations in an EGF-like domain can have a predictable detrimental effect on the 
domain itself, and also perturb calcium binding even when the required consensus 
sequence is intact.255-257 Calcium stabilizes the conformation of the individual domain 
and influences the packing of tandemly arranged EGF-like domains within the same 
polypeptide chain, as well as the packing of neighboring molecules that are thought to 
be precisely aligned within the microfibril.255,257-259 One consequence could thus be that 
fibrillin structure is abnormal beyond the mutated domain, including neighboring 
domains as well. Another effect of certain mutations in the EGF domain of fibrillin in 
Marfan is a significant reduction in extracellular-matrix deposition. The disruption of a 
disulfide bond causes the fibrillin monomer to assume a protein conformation that 
delays intracellular processing and/or secretion from the cell.260 Two pedigrees with 
dominant drusen showing linkage to chromosome 2p16 have been found not to have an 
EFEMP1 mutation.162 This may be interpreted as evidence suggesting the presence of a 
second dominant drusen gene at this locus. Alternatively, these pedigrees may express 
mutations of the EFEMP1 promoter sequence (as described in 1.4.1). 
 
HEMICENTIN-1 
The HEMICENTIN-1 gene encodes a large extracellular member of the immunoglobulin 
superfamily. Like EFEMP1 (involved in Malattia Leventinesse and Doyne honeycomb 
retinal dystrophy), HEMICENTIN-1 has a serie of cbEGF domains followed by an 
unsual EGF-like domain. Analogous to EFEMP1, only one single HEMICENTIN-1 
(Gln5345Arg) mutation might be associated with ARMD.126 However in contrast to 
EFEMP1, additional environmental and genetic factors might play a role in the 
phenotypic variation of ARMD 
 
Arylhydrocarbon-interacting receptor protein-like 1 (AIPL1) 
The exact function of AIPL1 is unknown. The protein contains three tetratricopeptide 
motifs consistent with nuclear transport or chaperone activity, suggesting that AIPL1 
may be involved in protein trafficking or folding.261,262 AIPL1 is expressed specifically in 
the rod photoreceptor cells. The AIPL1 staining pattern extends within the rod 
photoreceptor cells, from the inner segments, through the rod nuclei, to the rod 
photoreceptor synaptic spherules in the outer plexiform layer. AIPL1 has not been 
detected in the cone photoreceptors of peripheral or central human retina.263 AIPL1 
mutations cause approximately 7% of LCA worldwide, and AIPL1 mutations have been 
described in two families with adCRD and juvenile RP respectively.149,261 
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Visual cycle and RPE 
Elongation of very long chain fatty acids protein (ELOVL4) 
ELOVL4 is involved in the biosynthesis of very long chain fatty acids.208,209 The 
pathogenesis triggered by ELOVL4 mutations that leads to dominant Stargardt disease 
(STGD3) is not yet understood. There is evidence that mammalian enzymes involved in 
very long chain fatty acid biosynthesis function as a membrane-bound complex. One 
mechanism of disease might be the disruption of the membrane-bound complex by an 
altered ELOVL4 protein, leading to insufficient synthesis of very long chain fatty acids 
and accumulation of toxic precursors or intermediates. Northern blot analysis using 
human retina mRNA shows specific and abundant expression of a 2.9-kb transcript. In 
situ hybridization of rhesus monkey and mouse retinal sections demonstrates that, in 
adult retina, ELOVL4 is expressed exclusively in photoreceptor cells.209  
 
Bestrophin 
Using heterologous expression, the human, the fruitfly D. melanogaster and C. elegans 
bestrophin homologs are found to form oligomeric chloride channels. Human 
bestrophin also shows sensitivity to intracellular calcium.264 Each of 15 missense 
mutations associated with vitelliform macular dystrophy (VMD) greatly reduces or 
abolishes the membrane current. Four of these mutant bestrophins have been 
coexpressed with the wild type and each dominantly inhibits the wild-type membrane 
current, in a manner consistent with the dominant nature of the disorder. These 
experiments establish the existence of a new chloride channel family, and                        
establish VMD as a channelopathy.264 The use of rabbit and mouse antibodies and the 
immunocytochemical staining of macaque and porcine eyes show bestrophin to be 
localized at the basolateral plasma membrane of the RPE cells, suggesting that mutated 
bestrophin generates the altered EOGs of individuals with VMD.265 
 
Tissue inhibitor of metalloproteinases-3 (TIMP3) 
The TIMP3 gene belongs to the TIMP gene family. The proteins encoded by this gene 
family are natural inhibitors of the matrix metalloproteinases, a group of peptidases 
involved in degradation of the extracellular matrix.196 The TIMP3 protein is most likely 
implicated in extracellular matrix remodeling. Normally, TIMP3 is synthesized by the 
RPE and deposited in Bruch’s membrane.266,267 The expression of this gene is induced in 
response to mitogenic stimulation and is subject to cell cycle regulation, creating a site-
specific excess rather than an absence or deficiency of functional TIMP3.268,269 Mutations 
in this gene cause SFD.196,270 In SFD, the disturbed balance between the dysfunctional 
TIMP3 and its metalloproteinase may cause reactive changes in Bruch’s membrane, 
represented by a thickening of the inner portion of Bruch’s membrane which can 
ultimately lead to vascular penetration of Bruch’s membrane.196,271 In addition, mutant 
TIMP3 can induce apoptosis of RPE cells suggesting apoptosis as the final pathway for 
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cell death in SFD.272 Furthermore, TIMP3 has been shown to be a potent inhibitor of 
angiogenesis, most probably by blockade of vascular endothelial growth factor (VEGF)-
2 receptors, which may account for the complication of choroidal neovascularization 
seen in SFD.273 A knock-in mouse carrying a disease-related Ser156Cys mutation in the 
orthologous murine Timp3 gene has been generated. This knock-in mouse displays the 
early features of age-related changes in Bruch's membrane and the RPE that may 
represent the primary clinical manifestations of SFD.268  
 
1.5 STRATEGIES FOR THERAPY OF AUTOSOMAL DOMINANT RETINOPATHIES 
 
Gene therapy 
Because many genes associated with inherited eye disorders are being identified, an 
increasing number of diseases are, in principle, candidates for gene therapy trials. The 
eye is also highly accessible, facilitating the easy delivery of viruses. Currently, the 
adenovirus, adeno-associated virus and lentivirus are commonly used to transfer 
genetic material to the RPE and photoreceptors. 
Autosomal recessive and X-linked mutations result in reduced or absent gene function, 
which can be corrected by delivering the absent gene to its target cell. Gene therapy has 
recently been used successfully in a large-animal model of human autosomal recessive 
disease. A recombinant adeno-associated virus carrying wild-type RPE65 was used in a 
naturally occurring animal model, the RPE65(-/-) dog, suffering from early and severe 
visual impairment similar to that seen in human early onset rod-cone dystrophy. Long-
term visual function was restored in this large animal model of childhood blindness.274  
 
Autosomal dominant mutations either result in the effective inactivation of one of two 
encoded proteins (haploinsufficiency), or in the gain of function. In the latter case, it is 
necessary to inactivate the defective gene completely or to correct the mutant nucleotide 
sequence. Another challenge encountered in dominant disease is that of developing 
therapeutics that can counteract a broad spectrum of different mutations in the same 
gene. An attractive approach to this suppression-replacement mutation-independent 
strategy is the use of ribozymes that cleave untranslated regions of mutant and wild 
type mRNA.275,276 A replacement gene encoding a wild-type protein is supplied in 
parallel, but this gene is subtly modified in the untranslated region so the ribozyme 
cannot cleave transcripts from the replacement gene.277 The modifications in the 
replacement genes protect only transcripts, and have no effect on the encoded protein. 
Suppression is entirely mutation-independent and, in essence, involves a gene-
exchange strategy. Ribozymes targeting the rhodopsin and peripherin/RDS genes have 
been developed and utilized.277 Two other suppression-replacement strategies being 
explored involve the use of intragenic polymorphisms and the degeneracy of the 
genetic code (i.e. a single amino acid may be encoded by more than one codon). 
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Suppression of the mutant allele is directed to a neutral polymorphism rather than to a 
rare mutation in the first option, or is directed to degenerate sites in mRNA in the 
second option. In both cases, mutant and normal alleles are suppressed and 
replacement genes, which are protected from suppression but encode the normal 
protein, are generated.277-279  
An alternative, or possibly complementary, approach for mutation independent 
therapeutic interventions, which overcomes mutational heterogeneity, could be 
targeted to secondary effects, such as apoptosis (programmed cell death), instead of to 
the primary gene defect.113 Inhibition of key players that orchestrate apoptosis may 
provide protection against photoreceptor cell apoptosis.280-284 In fact, rd mice receiving a 
subretinal bcl-2 gene in an adenovirus vector, which is an apoptotic factor under the 
regulation of the 2.5 kb human rhodopsin upstream fragment, exhibited rescue for as 
long as 6 weeks after birth.285  
A final possible approach for mutation-independent therapy is the delivery of 
neurotrophic and growth factors to photoreceptor cells in order to improve their 
survival rates286-288 Neurotrophic factors (nerve growth factor, brain-derived 
neurotrophic factor, ciliary neurotrophic factor, neurotrophin 3, neurotrophin 4-5) and 
growth factors (fibroblast growth factor, interleukin-1b, transforming growth factor) 
bind to their specific receptors and activate a specific cascade of events. Delivery of 
ciliary neurotrophic factor to rds/rds mice results in photoreceptor rescue, and brain-
derived neurotrophic factor prolongs the survival of retinal ganglion cells in an 
axotomized retinal ganglion cell rat model.287,289,290 Furthermore, viral delivery of basic 
fibroblast growth factors has been shown to retard photoreceptor cell death in a Royal 
College of Surgeons (RCS) rat as well as in a RHO Ser334ter transgenic rat.286,291 
 
Retinal transplantation 
The ultimate goal of transplantation is to replace lost photoreceptors with healthy ones, 
which will have the capacity to re-establish the appropriate cellular connections at the 
outer plexiform layer. Various tissues and cells, including cultured RPE cells, iris RPE, 
fetal neural retina and enzymatic or mechanically-dissociated adult photoreceptor cells, 
have been studied.292-296 RCS rats undergo progressive photoreceptor degeneration due 
to a primary defect in RPE cells. Immortalized human RPE cells have been transplanted 
into these rats at three to four weeks of age, prior to significant photoreceptor loss. At 
six months of age, sensitivity maps and multi-unit response properties were obtained 
across the visual field by recording at 76 equidistant sites encompassing the whole 
superior colliculus. A significant degree of functional protection, both in terms of area 
of responsive retina and in terms of response characteristics, is observed following RPE 
transplantation. Although partial, the degree of anatomical preservation (in terms of 
both outer nuclear layer thickness and area of rescue) correlates well with the levels of 
preserved visual sensitivities.297 
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Sheets of fetal neural retina and RPE have been transplanted into the subretinal space 
near the fovea in the eyes of 5 patients with RP. This was done unilaterally in these 
patients, who had only light perception in both eyes. No immunosuppressive 
medications were given, and the patients were followed for 6 months. The fetal retina, 
with its RPE, survived for 6 months without evidence of rejection. However, no 
improvements in vision were observed, possibly due to the severe retinal degeneration 
of the patients.298 In another study, mechanically dissociated fetal retinas of 14-18 
weeks’ gestation were grafted in 12 patients with advanced RP. Five of these patients 
reported subjective improvement of vision. However, a placebo effect or the influence 
of injury could not be excluded.299 Retinal transplantation thus seems promising, but its 
effectiveness in patients with retinal dystrophies still needs to be established. 
 
Vitamin A/Drugs 
A large study has suggested that 15.000 IU/day of vitamin A has a mild beneficial effect 
on the course of RP.300 In this study, a heterogeneous group of patients in whom there 
was no prior knowledge of their molecular defect was followed. In the case of 
rhodopsin, vitamin A treatment specifically addresses the class II RHO mutations.301 
Vitamin A suppletion can also hasten photoreceptor cell death in the case of ABCA4 
mutations, which are associated with arRP,302;303 because increased quantities of N-
retinylidine-phosphatidylethanolamine may accumulate in the retina when treated with 
vitamin A.304 In the cases of arRP12 and LCA patients, both with mutations in the 
Crumbs homologue 1 gene (CRB1), it is speculated that the depletion of rhodopsin 
through a vitamin A-deficient diet could prevent light-induced retinal degeneration, so 
vitamin A supplementation might be counterproductive rather than beneficial in 
slowing disease progression.305 Vitamin A has, however, been shown to have beneficial 
effects in SFD.306 
In Rpe65-deficient mice, models of early onset rod-cone dystrophy, oral administration 
of 9-cis-retinal, generated isorhodopsin, which is a rod photopigment, and it restored 
light sensitivity as measured by electroretinography.307 Early intervention by means of 
9-cis-retinal administration results in a significant reduction in retinal ester 
accumulation and an improved rod retinal function for more than 6 months after 
treatment.308 These studies show that pharmacological intervention produces long-
lasting preservation of visual function in dark-reared Rpe65(-/-) mice, and may be a 
useful therapeutic strategy in recovering vision in humans diagnosed with LCA or early 
onset retinal dystrophy caused by mutations in the RPE65 gene. 
Pharmacological manipulation of ABCA4 activity is also under investigation. For 
example, isotretinoin, an established treatment for acne, inhibits lipofuscin 
accumulation by blocking the formation of a major lipofuscin fluorophore, A2E (N-
retinylidene-N-retinylethanolamine).309 In this way it might delay the onset of visual 
loss in recessive Stargardt disease.  
                               GENERAL INTRODUCTION 
 
 45
Several classes of drugs, including nucleotide and NAD analogs, are known to affect 
IMPDH isoenzymes, suggesting that small-molecule therapy may one day be available 
for RP10 patients.112 
 
Reducing photopic exposure 
The theory that limiting ocular light exposure slows down the progression of retinal 
dystrophy has been tested by occluding one eye of an adRP patient and one eye of an 
arRP patient with an opaque shell for six to eight hours per day for 5 years. Comparable 
RP progression was found in both eyes of both patients.310 However, other studies 
indicate that limiting light exposure may be of benefit to some genetic subtypes of RP. 
In mice that express certain rhodopsin mutations (Pro23His, Val20Gly, Pro27Leu), 
histological and electrophysiological studies have shown that the rate of photoreceptor 
degeneration is significantly lower in transgenic mice that were reared in the dark than 
in those that were kept under cyclic light conditions.311,312 The Pro23His mutation is 
associated with the most frequent form of human adRP in the USA, so for this group of 
patients reducing exposure to light may be beneficial. Also, it has been suggested that 
there are at least two apoptotic pathways, which are initiated by light activation of 
rhodopsin and which lead to photoreceptor-cell death.313 This is of clinical relevance for 
patients with defective rhodopsin deactivation.314,315 Another study in D. melanogaster, 
which is mosaic for a CRB1 deficiency in the head region, suggests that daylight might 
have a deleterious effect on disease progression in arRP and LCA patients with 
mutations in CRB1.305 Furthermore it has been shown that A2E synthesis can be 
virtually blocked by raising ABCA4-/- mice in total darkness.316  
 
 
1.6 AIM AND OUTLINE OF THIS THESIS 
 
Extraordinary progress in retinal disease gene identification has been made in the past 
decade. In the case of autosomal dominant inherited diseases, linkage analysis allows 
the genomic mapping of the disease locus. At the present, 12 adRP loci and 21 ad 
macular dystrophy loci have been identified. This information needs to be integrated 
with clinical observations as well as with retinal biochemistry, physiology and animal 
models of retinal diseases. Currently, there are still many families with autosomal 
dominant peripheral and central dystrophies of the retina in which the gene has not 
been identified. Known genes can be causative for the phenotype, but new genes await 
discovery. Elucidation of these genes (known or unknown) and integrating the 
genotypes with the phenotypes will clarify the biochemical pathways involved. 
In Chapter 2, we describe an, adRP family in which the genetic defect 
cosegregates with 17p13.1-p13.3, harboring the RP13 locus (Chapter 2.1). Soon after the 
genetic mapping of the underlying defect to the 17p13 region, a missense mutation 
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(6970G>A; Arg2310Lys) has been identified in a patient of this family in exon 42 of the 
splicing factor gene PRPC8. The phenotype observed in this family is similar to that 
described for three other RP13 families with mutations in PRPC8 (Chapter 2.2). 
In Chapter 3, we describe the results of linkage analysis in a family with benign 
concentric annular macular dystrophy. The BCAMD phenotype is initially 
characterized by parafoveal hypopigmentation and good visual acuity, but progresses 
to a RP-like phenotype. Linkage analysis establishes complete segregation of the 
BCAMD phenotype to the chromosomal region 6p12.3-q16. Sequence analysis of the 
interphotoreceptor matrix proteoglycan 1 gene, IMPG1, reveals a single base pair 
change (T>C) of nucleotide 1866 in exon 13, resulting in a Leu579Pro amino acid 
substitution. This sequence variant is absent in 190 control individuals.  
In Chapter 4, we describe a large family with a peculiar autosomal dominant 
macular dystrophy, which is characterized by an age of onset in the third to fourth 
decade, and a typical history of periods of metamorphopsia and mild visual acuity loss. 
Clinical signs include subretinal yellowish macular deposits evolving into geographic 
atrophy and retinal hypo- and hyperpigmentations. ERGs demonstrate rod dysfunction 
and EOGs are mildly to severely disturbed. All affected members have been found to 
carry a 3-base pair deletion, which results in the deletion of Asn169 of peripherin/RDS.   
Chapter 5 describes the linkage analysis of a family with butterfly-shaped 
macular dystrophy, which has until now only been associated with mutations in the 
peripherin/RDS gene. A candidate loci approach has been used, investigating the 
peripherin/RDS gene, the ROM-1 gene, 4 genes expressed in cone photoreceptors, all 
known non-syndromic macular, retinal pigment epithelium and choroidal dystrophy 
loci, all known LCA loci and all known non-syndromic congenital and stationary retinal 
disease loci. No linkage could be established to the peripherin/RDS gene or to any other 
locus, providing evidence of genetic heterogeneity in BSMD.  
Finally In Chapter 6, a clinical classification of dominant cystoid macular edema 
into three stages is proposed. In addition, the CYMD gene defect is fine mapped to a 3.8 
cM/2.0 Mb interval at 7p15.3, and five positional candidate genes are excluded.  
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ABSTRACT 
 
A Dutch family with autosomal dominant retinitis pigmentosa displayed a 
phenotype characterized by an early age of onset, a diffuse loss of rod and cone sensitivity 
and constricted visual fields (type I). One male showed a mild progression of the disease. 
Linkage analysis showed cosegregation of the genetic defect with markers from 
chromosome 17p13.1-p13.3, a region overlapping the RP13 locus. The critical interval of 
the RP locus as defined in this family is flanked by markers D17S926 and D17S786, with a 
maximal lodscore of 4.2 (θ = 0.00) for marker D17S1529. Soon after the genetic mapping of 
the underlying defect to the 17p13 region, a missense mutation (6970G>A; R2310K) was 
identified in exon 42 of the splicing factor gene PRPC8 in a patient of this family. 
Diagnostic restriction enzyme digestion of exon 42 amplified from genomic DNA of all 
family members revealed that the R2310K mutation segregates fully with the disease. The 
phenotype observed in this family is similar to that described for three other RP13 families 
with mutations in PRPC8. 
 
INTRODUCTION 
 
Retinitis Pigmentosa is a significant cause of progressive retinal disease worldwide. The 
incidence is approximately 1:3700.1 Common clinical features are bilateral involvement, 
loss of peripheral vision, early night blindness and eventual loss of central visual acuity. 
During the course of the disease, the retina and the RPE show atrophy and pigmentary 
changes. Other typical features are arteriolar attenuation and waxy disc pallor. 
 RP is genetically extremely heterogeneous. It can be inherited in autosomal 
dominant (ad), autosomal recessive (ar), or X-linked modes. When no family history is 
evident, cases are classified as isolated. To date, linkage studies have revealed 33 RP loci, 
10 loci for adRP, 18 loci for arRP and 5 loci for X-linked RP. For 20 RP loci, the causal gene 
has been identified.2 ArRP can also be part of a syndrome as e.g. Bardet-Biedl syndrome, 
Cockayne syndrome, Refsum disease or Usher syndrome.3 The autosomal dominant form 
of RP is responsible for approximately 22% of RP.4,5 In addition to the genes rhodopsin 
(RP4), peripherin/RDS (RP7), RP1 and NRL (RP27), adRP has been linked to loci at 
chromosome 1q13-q23 (RP18), 7p13-p15 (RP9), 7q31.3 (RP10), 17p13.3 (RP13), 17q22 (RP17) 
and 19q13.4 (RP11).6-16 It is estimated that mutations in the rhodopsin gene account for 
30% of adRP cases.17 The RP11 locus accounts for 20% of the cases; 50% of the defects are 
situated in the remaining mapped loci and loci still to be found.18  
There is a large clinical variability in RP. Different adRP clinical classification 
systems have been proposed. For example, two subgroups were defined with full or 
reduced penetrance.19 In addition four types were distinguished from diffuse to regional 
RP based on funduscopy, perimetry and ERG measurements.20 Widely accepted is the 
classification system based on psychophysical testing and age of onset.21,22,23 Type 1 shows 
a diffuse loss of rod sensitivity, later loss of cone sensitivity, and early onset of night 
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blindness in childhood, while type 2 shows a regional loss of both rod and cone sensitivity 
with abnormal but preserved cone responses on ERG and an onset of night blindness in 
adulthood. In this study we describe a Dutch family with adRP in which the gene defect 
could be mapped to 17p13.1-p13.3 (RP13) using linkage analysis of the adRP candidate 
loci. The causal mutation was identified in the PRPC8 gene. Clinical manifestations of RP 
in this family are compared with those of other RP13 families. 
 
 
 
Figure 2.1 Pedigree and haplotype analysis of the RP13 family. Critical recombinations were observed in 
generation I between markers D17S1840 and D17S926, determining the telomeric boundary and in 
individual IV-2 between markers D17S1353 and D17S786 determining the centromeric boundary.  
  
 
PATIENTS AND METHODS 
 
Clinical examination  
RP in this family affects at least three generations and is consistent with autosomal 
dominant inheritance. Dominant X-linked inheritance can be excluded since there are two 
father-to-son transmissions (Fig. 2.1). We clinically evaluated the 9 affected sibs of this 
family. Patients had Snellen visual acuity determination with correction, slitlamp 
biomicroscopy and a dilated fundus examination. ERG and EOG values were obtained 
according to the International Society for Clinical Electrophysiology of Vision protocol.24 
Visual field examination was performed monocularly with a Goldmann perimeter. In 
addition colour vision testing25, dark adaptation with a Goldmann-Weekers dark 
adaptometer and fluorescein angiography were included. 
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Linkage studies 
Blood samples were obtained from 18 family members. Standard methods were used to 
extract DNA from the blood samples for molecular genetic analysis. Samples were 
subjected to polymerase chain reaction (PCR) amplification, using microsatellite markers 
as reported by Gyapay et al26, with a standard cycling profile of 30 cycles at 94ºC, 55ºC and 
72ºC with 30 seconds at each step. The following markers were employed: D3S1589 
(AFM290zf1), D3S1290 (AFM198yh6) (RP4), D7S493 (AFM162xa7), D7S673 (AFM290vg9), 
D7S526 (AFM248vc9) (RP9), D7S480 (AFM042xh10), D7S504 (AFM199xh12) (RP10), 
D19S572 (AFMa083wb5), RRAS, D19S180 (RP11), D17S926 (AFM207xa11), D17S945 
(AFM282yd1) (RP13), D17S1606 (AFM338xg5), D17S1604 (AFMa163tf9) (RP17), and 
D1S250 (AFM240yg1), D1S189 (AFM036xc5) (RP18). PCR products were labeled with the 
incorporation of α-[32P]-dCTP and size separated by electrophoresis in a 6.6% denaturing 
polyacrylamide gel. Haplotypes were constructed manually. Two-point lod scores were 
calculated using the subroutine Mlink of the Linkage package.27,28,29 A gene frequency of 
0.00001 and a penetrance of 100% were assumed for the disorder.  
 
AIPL1 and PRPC8 mutation analysis  
The six exons of the AIPL1 gene were amplified from genomic DNA of two affected sibs 
by the polymerase chain reaction with primers as described in a paper by Sohocki et al.30 
The amplification products were treated with shrimp alkaline phosphatase and 
exonuclease I (Amersham Pharmacia) and sequenced using a BigDye Terminator 
sequencing kit (Applied Biosystems) on an ABI Prism automated sequencer according to 
the manufacturer's protocols. Segregation of the PRPC8 6970G>A (R2310K) mutation in 
exon 42 was analysed using HaeIII restriction analysis of a PCR fragment of 264-bp 
generated using the forward primer 3’-CTGTCTGGAGGGGCTGAG-5’ and the reverse 
primer 5’-TGCATGAGGCAGGAGCCCTGTT-3’. The restriction fragments were separated 
using 2% agarose gels. The mutant allele is HaeIII digested to products of 25 and 239 bp; 
the normal allele is cut into three fragments: 25, 112, and 127 bp. 
 
 
RESULTS 
 
Clinical characteristics 
The structure of the Dutch adRP family is depicted in Figure 1; the clinical features are 
summarized in table 2.1. 
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Table 2.1 Clinical features of the affected family members. 
Pedigree 
number 
Age at  
Exam.  
(years)/ 
Gender 
Age at 
onset of 
symptoms 
Visual 
Acuity 
OD 
Visual 
Acuity 
OS 
Visual Field ERG
Scot.
ERG  
Phot.
EOG 
OD 
EOG 
OS 
Dark 
Adap.
Colour
Vision
III-1 69 / F 10 3/300 20/30 Tunnel Vision 10º 
(V4e  isopter) 
NR NR 1.17 1.3 3.5 BYD 
III-5 64 / M 40 20/25 20/60 General decline of 
sensitivity and 
temporal scotoma 
ODS 
NR AN 
(<1%) 
1.2 1.07 0.5 Mild 
RGD 
III-6 76 / F 6 20/400 20/25 Tunnel Vision 10º 
(V4e  isopter) 
NR NR 1.0 1.15 NP NP 
III-7 68 / M 40 20/60 20/30 Tunnel Vision 10º 
(V4e  isopter) 
NR NR 1.14 0.95 3 - 
III-10 65 / F  16 20/100 20/50 Tunnel Vision 10º 
(V4e  isopter) 
NR NR 0.93 1.19 - BYD 
    IV-1 36 / M 16 20/25 20/30 Tunnel Vision 10º 
(V4e  isopter) 
NR NR 1.3 1.1 3 - 
1V-4  36 / M 35 20/25 20/30 Concentric 
depression 
AN AN 1.15 1.15 0.4 - 
IV-6 36 / F 16 20/50 20/50 General decline of 
sensitivity and ring 
scotoma ODS 
NR NR 1.0 0.95 3 RGD 
IV-7 13 / M 20 20/16 20/16 General decline of 
sensitivity and ring 
scotoma ODS 
AN AN 1.21 1.14 - N 
* M indicates male; F female; Scot scotopic; Phot Photopic; NR non-recordable; AN abnormal; Adap 
adaptation; BYD blue-yellow defect; RGD red green defect; NP could not be tested; N normal 
 
 
The age of onset is 6-20 years for all female and two male patients and between 35-40 years 
for three other male patients. The initial symptom recalled by most patients was night 
blindness, which was followed by visual field loss a few years later. The visual acuity (VA) 
ranges from 3/300 to 20/16, which is the VA of patient IV-7 at 13 years (no recent accurate 
VA has been obtained). Funduscopy reveals attenuated arterioles, waxy pallor of the optic 
discs, bone-spicule pigmentation in the mid-periphery and atrophy of the RPE (Fig. 2.2). In 
most patients the ERG is photopically and scotopically non-recordable. Abnormal values 
are detected in individual IV-7 at the age of thirteen. No recent ERG is available. The ERG 
of his sister IV-6 also shows abnormal values at 15 years and currently her ERG is non-
recordable. Patient III-5 has cone responses less than 1% and patient IV-4 has abnormal 
scotopic and photopic values. The light peak/dark trough ratios are all below 1.65. The 
dark adaptation curves are elevated in all patients varying from 0.4 - 3.5 log units. The 
Goldmann visual fields demonstrate constricted visual fields up to 10º, except for 
individuals III-5, IV-6 and IV-7, who have temporal and ring scotoma’s and in addition a 
general and a central decline of sensitivity.  
 
                CLINICAL CHARACTERIZATION AND GENETIC ANALYSIS IN A RP13 FAMILY 
 
 63
 
 
Figure 2.2  Fundus images of patient number III-10 (photograph a) and IV-6 (photograph b) showing areas of 
atrophy, attenuated arterioles, a waxy optic disc and diffuse peripheral bone spicules.   
 
 
Linkage analysis 
Eighteen family members (9 affected, 6 unaffected and 3 informative spouses) have been 
genotyped. Using linkage analysis we could exclude the following candidate loci for adRP: 
RP4, RP9, RP10, RP11, RP17, and RP18. The RP1, RP7 and RP27 loci were not tested. We 
identified linkage at 17p13 (RP13) using markers D17S926 (AFM207xa11) and D17S945 
(AFM282yd1). Two-point linkage analysis revealed significant linkage with no 
recombinations using 3 markers located at 17p13.1-p13.3, i.e. D17S1840 (Z = 3.7), D17S1529 
(Z = 4.2, θ = 0.00), and D17S1876 (Z = 3.7). The genetic map depicted in figure 2.3 is based 
on the Genethon-map. The analysis of the recombination events suggests that the 
causative gene for RP in this family is located between markers D17S926 and D17S786, 
which flank a 16.7-cM genetic interval (Fig 2.1). The telomeric boundary of the critical 
interval is determined by a recombination occurring in generation I between markers 
D17S1840 and D17S926, resulting in different haplotypes for individuals II-2 and II-3. The 
haplotype resulting from the recombination was assigned arbitrarily to II-2. Assuming full 
penetrance of the gene defect, the centromeric boundary of the critical interval is situated 
between D17S1353 and D17S786 based on recombination events observed in the healthy 
individuals IV-2 and IV-5.  
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AIPL1 and PRPC8 mutation analysis  
At the onset of this study, two retinal disease genes were localised in the D17S926-
D17S786 region. The AIPL1 gene is located in the proximal part of the critical region. This 
gene previously was implicated in autosomal recessive Leber congenital amaurosis 
(LCA4)30 and ad juvenile RP and cone-rod dystrophy.31 Sequence analysis of the 6 exons 
did not reveal a disease causing mutation in patients from the Dutch family. The retinal 
guanylate cyclase (GUCY2D or RETGC) gene, implicated in LCA type 1 (LCA1) and ad 
cone-dystrophy (CORD6), is positioned just inside the critical region but was not analysed 
in this family. 32,33  
A pre-mRNA splicing factor gene PRPC8 was identified in the 17p13 region and found to 
be mutated in exon 42 of five adRP families (chapter 2.2).34 In this study a base change at 
nucleotide position 6970G>A was found in our family, resulting in an amino acid change 
R2310K. We analysed the segregation of this mutation in the RP13 family (figure 2.4). 
Healthy individuals invariably show co-migrating HaeIII fragments of 127 and 112 bp 
whereas the 239 bp fragment is refractory to HaeIII digestion in all affected individuals. 
Clearly, all affected individuals, including III-5 who showed a relatively mild disease 
course, carry the R2310K missense mutation. 
Figure 2.3 Genetic and morbid map of 17p13. The
linkage intervals for families with adRP, cone dystrophy
(CORD5) and central areolar choroidal dystrophy (CACD)
are depicted. The localization of the markers and the map
distances (cM) are derived from Généthon. The PEDF
gene encodes the pigment epithelium derived factor. The
RCV1 gene encodes recoverin. References are given in
brackets. 
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Figure 2.4 Segregation analysis of the PRPC8 6970G>A in the Dutch RP13 family. HaeIII restriction 
digestion products of a 264-bp PCR fragment containing exon 42 are shown. Digestion of a wild-type PCR 
product results in co-migrating DNA fragments at 127 and 112 bp, as well as an invisible 25-bp fragment. 
The 6970G>A mutation ablates one of two HaeIII sites in the 264-bp fragment yielding a heterozygous band 
pattern consisting of both cut (127/112 bp) and uncut (239 bp) fragments next to the 25 bp fragment. 
Individual III-4 shows a weak band due to insufficient PCR product. Although mutation-carriers and non-
carriers can be clearly distinguished, an unspecific or partial restriction fragment migrating at ~240 bp 
remains weakly visible in all lanes.  
 
 
DISCUSSION 
 
RP exhibits a high degree of clinical, genetic and allelic heterogeneity. A classification 
based on a genotype-phenotype correlation would provide a valuable diagnostic 
improvement. The adRP families that were instrumental in the identification of genetic 
loci have been described with type 1 (early onset and diffuse retinal involvement), type 2 
(late onset and regional retinal involvement) or a variable intrafamilial expression. 
Mutations in the rhodopsin gene and the as yet not identified RP10 gene have been 
associated with both types 1 and 2. 12,35-40 Mutations at the RP18 locus display a type 1 
phenotype.11 A mutation in the peripherin/RDS gene has been associated with adRP type 
2.41 Digenic inheritance of heterozygous mutations in the peripherin/RDS and ROM genes 
were found in RP families with variable intrafamilial expression.42 Families with 
mutations at the RP1 locus, the RP9 locus or the RP17 locus are reported with adRP type 2 
or with variable intrafamilial expression. 9,12,15,43,44 
Previously, genetic defects segregating in a South African family from British stock, 
one British family with adRP, and a multigeneration American adRP family of British 
descent were linked to the RP13 region.14,45-47 The Dutch adRP family described in this 
study is the fourth family mapping to the RP13 locus. The phenotypes observed in the 
previously reported families linked to the RP13 locus, are indicative of type 1 adRP. The 
phenotype seen in the Dutch RP13 family comprises diffuse pigmentary changes without 
regional preponderance. All visual fields show concentric depression and most fields are 
constricted to 10°. The EOG values are abnormal in all patients. The cone and rod 
responses are non-recordable in most patients. The ERG in individual IV-7 is abnormal at 
young age, but most probably his ERG would be non-recordable at his current age, 
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comparable to the ERG of his sister. Individual III-5 is notable, since he still has some 
detectable cone response. He also has relatively good visual fields in comparison to his 
family members of the same age. His dark adaptation curve is only 0.5 log elevated, much 
less than other family members. He has a mild red-green defect, while family members 
with the same age have a blue-yellow defect, as expected in the late stage of the disease. In 
summary, this family is characterized by the more severe diffuse type I adRP 
corresponding to the phenotype of other previously reported RP13 families, with a mild 
progression of the disease in one male patient.  
The RP13 locus initially was mapped to the chromosomal region between markers 
D17S926 and D17S804.14 In a follow-up study of the same family, the RP13 locus could be 
refined to a 3.3-cM region between markers D17S1529 and D17S831 (Fig. 2.3).45 
Subsequently, a second adRP family was ascertained in which the genetic defect was 
positioned in a 7.2-cM interval harbouring the D17S1529-D17S831 region.46 In a third 
family with adRP, multipoint-analysis pointed to a location of the gene defect distal to 
D17S926, near the telomere of 17p.47 However, in two-point linkage analyses, DNA 
markers located proximal to D17S926, i.e. D17S695 and D17S34, showed the highest lod 
scores at a genetic distance of 5 cM, suggesting a more proximal location of the gene defect 
(Fig. 2.3). Since no haplotype analysis was performed in the study by Kojis et al., the 
location of the gene defect in that family cannot be determined with certainty.47 The adRP 
gene defect in this Dutch family clearly is located proximal to D17S926, which suggested 
that the same gene is involved in at least three and possibly four families. The 16.7-cM 
critical interval of the Dutch adRP family harbors two retinal disease genes, the AIPL1 
gene, and the GUCY2D/RETGC1 gene, both of which have been implicated in several 
forms of early onset ar retinal degeneration and ad cone(-rod) dystrophy.30,31,32,33 Sequence 
analysis of the AIPL1 gene ruled out the presence of a small mutation in its open reading 
frame in the Dutch RP13 family. The GUCY2D/RETGC1 gene was not analysed in this 
study. 
Using a positional cloning and candidate gene strategy, McKie and coworkers in 
the mean time identified the PRPC8 gene as the causative gene for RP13. Seven different 
missense mutations (P2301T, F2304L, H2309P, H2309R, R2310G, R2310K, and F2314L) 
affecting 5 different amino acid residues were found in the South African, UK, and this 
Dutch family, as well as in four unrelated adRP families.34 All five amino acid residues 
were conserved in at least 6 of 7 PRPC8 orthologues from various species, including 
human, Drosophila and C. elegans. No sequence variants were found for exon 42 among 572 
control chromosomes. An intriguing and difficult to answer question is why mutations in 
the ubiquitously expressed PRPC8 gene can result in a specific retinal degeneration. 
Possibly, PRPC8 as well other ubiquitously expressed retinal disease genes, might be 
involved in rate-limiting steps in this extremely high metabolizing tissue.48 Alternatively, 
PRPC8 might play an important role in the splicing of U12-dependent introns.                
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U12-snRNPs excise AT-AC introns instead of introns flanked by the canonical GT-
AG nucleotides.49 Possibly, in patients with PRPC8 mutations, mRNAs transcribed from 
some retina specific genes carrying AT-AC class introns are improperly spliced leading to 
retinal degeneration. Detailed functional studies of human PRPC8 are needed to elucidate 
this fascinating mechanism of retinal degeneration. 
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ABSTRACT 
 
Retinitis pigmentosa is a genetically heterogeneous disorder characterised by progressive 
degeneration of the peripheral retina leading to night blindness and loss of visual fields. 
With an incidence of approximately 1 in 4000, RP can be inherited in X-linked, autosomal 
dominant or autosomal recessive modes. The RP13 locus for autosomal dominant RP was 
placed on chromosome 17p13.3 by linkage mapping in a large South African adRP family. 
Using a positional cloning and candidate gene strategy, we have identified seven different 
missense mutations in the splicing factor gene PRPC8 in adRP families. Three of the 
mutations cosegregate within three RP13 linked families including the original large South 
African pedigree and four additional mutations have been identified in other unrelated 
adRP families. The seven mutations are clustered within a 14 codon stretch within the last 
exon of this large 7kb transcript. The altered amino acid residues at the carboxy-terminus 
exhibit a high degree of conservation across species as diverse as human, Arabidopsis and 
trypanosome, suggesting some functional significance is associated with this part of the 
protein. These mutations in this ubiquitous and highly conserved splicing factor offer 
compelling evidence for a novel pathway to retinal degeneration.  
 
INTRODUCTION 
 
The term Retinitis pigmentosa was first used by Donders (1857) to describe the pattern of 
pigmentation seen in the peripheral retina of a proportion of blind people. Patients with 
RP report narrowing of visual fields (tunnel vision) and night blindness, often progressing 
to complete blindness in later life. This condition affects approximately 1 in 4000 
individuals and exhibits considerable genetic heterogeneity with 30 reported genes or loci 
at which mutations give rise to an RP phenotype. Eleven known autosomal dominant loci 
include five identified genes and a further six loci for which the genes remain to be found. 
This locus was first identified by linkage mapping in a large South African family of 
British ancestry.1 It was later confirmed with the identification of two further RP13 linked 
families, one from the USA and the other from the UK.2,3 The phenotype in the UK family 
is one of classical RP with relatively early onset and a severe prognosis in comparison with 
other dominant forms of RP. Affected individuals consistently report night blindness and 
visual field loss by 5 years of age and are usually registered blind or partially sighted by 
30 years. Haplotype analysis in the South African family placed RP13 within a 3cM 
interval between the markers D17S1529 and D17S831, which distinguished the locus 
genetically from a number of other eye disease loci in the region (Fig. 2.5). 4 Two further 
RP13 linked families have recently been identified, one from the UK (JCM, EET & CFI 
unpublished data) and the other from The Netherlands bringing the total to five.5 
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MATERIALS AND METHODS 
 
Patients’ sample collection 
Patients and first degree relatives were recruited, with informed consent and local ethics 
committee approval, through ophthalmic clinics in London, The Netherlands, South Africa 
and Australia. Genomic DNA was prepared from peripheral blood leucocytes by standard 
protocols. Samples from each of the families described herein were subjected to linkage 
analysis and were shown to link to the RP13 locus for dominant RP on chromosome 
17p13.3.1,3,5  
 
Identification of 17p13.3 ESTs and sequence-tagged sites (STSs) 
EST and gene sequences were identified as mapping in or near the RP13 interval from our 
own physical mapping data and from the GeneMap (www.ncbi.nlm.nih.gov/genemap/), 
UniGene (www.ncbi.nlm.nih/UniGene/), Whitehead Institute (www.genome.wi.mit.edu/) 
and Weizmann Institute (www.bioinformatics.weizmann.ac.il/) databases. Genespecific 
STSs and primers for individual exons were purchased from Life Technologies.6 
 
P1-derived artificial chromosome (PAC) analysis and sequence sampling 
PAC clone DNA was isolated using alkaline lysis method.7 PAC-end sequence derivation 
was accomplished with standard T7- and Sp6-specific primers using the [33P]-dideoxy 
terminator kit (Amersham-Pharmacia Biotech.). In addition, further sequence of 
YAC/PAC clones was determined by vectorette PCR.8 Finally, in an attempt to identify 
new genetic markers in the RP13 region, PAC 222-B19 DNA was digested with HindIII, 
size-fractionated by agarose gel electrophoresis and Southern blotted. A d(GT)10 oligomer 
was then used to probe the filter, identifying a 4kb fragment containing the d(GT)15 repeat, 
referred to as 4kbGT. This was used to refine the distal crossover boundary in the UK and 
South African families. 
  
Mutation screening 
Coding exons were amplified from patient DNA using primers in flanking intron and 
untranslated region sequences (for exon 42; forward primer, 5’-
CCAGCATCTTGCTGTGAACCGC-3’ and reverse primer, 5’-
TGCATGAGGCAGGAGCCCTGTT-3’). PCR amplification was carried out in 20µl reaction 
volumes containing 10mM Tris-HCL, pH 8.9, 50mM KCL, 1.5-2.5 mM MgCl2, 0.1% Triton 
X-100, 10 pmol of each primer, 200 µM each dNTP, 50-100 ng of patient genomic DNA and 
0.25 U of either BiotaqTM thermostable DNA polymerase (Bioline) or Red-HOT DNA 
Polymerase (ABgene). Cycling parameters were 3 min at 94 ˚C, followed by 35 cycles of 20 
s at 94 ˚C, 20 s at 58 ˚C and 30-90 s at 72 ˚C, with a final 10 min extension at 72 ˚C. The PCR 
products were purified using a pre-sequencing exonuclease and phosphatase digestion kit 
(Amersham-Pharmacia Biotech). Alternatively, PCR products were purified by 
ultracentrifugation through Qiaquick columns (Qiagen). Sequences were size-fractionated 
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on standard 6% acrylamide denaturing gels using ready-made sequegel-6 mix (national 
Diagnostics) and Sequi-Gen II apparatus (Bio-Rad). Sequences were aligned using the 
Autoassembler software from Applied Biosystems. SSCP analysis was carried out by 
incorporating [33P]dCTP (~0.02 µCi per sample) and size fractionating the samples on 6% 
non-denaturing polyacrylamide gels (acrylamide monomer: Bis acrylamide ratio of 49:1) 
for 20 h at room temperature in 0.5x TBE supplemented with 5% glycerol. Gels were then 
dried and exposed to autoradiography for 24-72 h. 
 
Segregation anlysis by ApaL1 restriction digestion 
Segregation of mutations in the UK and South African RP13 linked families was tested by 
digestion of the exon 42 PCR fragment generated by primers detailed above with the 
restriction enzyme ApaL1. In each case, 6ml of a 30 ml PCR reaction was incubated with 10 
U of ApaL1 in a 30 ml reaction volume at 37ºC for 3 h. The products were then analysed by 
electrophoresis on a 3.0% NuSieve gel (FMC) at 10 V/cm. 
 
RT-PCR 
Human kidney, heart, lung, liver, placenta, adult brain, fetal brain, spinal cord and 
cerebellum total RNA were purchased from either Clontech or Ambion. Retinal RNA was 
isolated from human retinal obtained from the Eye Bank in Bristol, UK. Random priming 
and reverse transcription was carried out using Superscript AMV reverse transcriptase 
from Life Technologies, according to the manufacturer’s recommendations. Primer pairs 
were designed to amplify a fragment containing exons 41 and 42 of the PRPC8 gene, 
spanning intron 41 [exon 42 (RT) forward, 5’-AGTTGAGGAAGTGAGAGGCCTGT-3’ and 
exon 41 (RT) reverse, 5’-CCAGTCCTCGTGGAACTACAACTTC-3’]. The PCR products 
were then separated by agarose gel electrophoresis on 3.0% Nu Sieve (FMC) agarose gels. 
 
Northern blot analysis 
Total RNA (5 µg) from kidney, lung, heart, liver, brain and retina were analysed by 
electrophoresis on a 1% formaldehyde gel and blotted to Hybond N+ positively charged 
nylon membrane (Amersham-Pharmacia Biotech). The filter was hybridized in Perfecthyb 
plus (Sigma) following the product information supplied, with a probe covering exons 41 
and 42 of PRPC8 which had been labelled by the rediprime II random labelling kit 
(Amersham-Pharmacia Biotech). 
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Figure 2.5 Ideogram and genetic map of the short arm of chromosome 17 illustrating the order of markers on 
band 17p13 and the intervals of known ophthalmic disease loci. The genetic intervals for RP13, anterior 
polar cataract (CTAA2), autosomal dominant progressive cone degeneration loci (CORD5 and CORD6), 
central areolar choroidal dystrophy (CACD) and two loci for Leber’s congenital amaurosis (LCA1 and LCA4) 
are shown. The gene AIPL1 is mutated in LCA4 and the GUCY2D gene is mutated in LCA1 and CORD6 
cases. The RP13 interval between D17S1529 and D17S831 was further refined with the marker 4kbGT 
which reduced the interval from the distal boundary. This marker lies on BACs RP11-433M14 and RP11-
145P4 which also contain the PRPC8 gene. A simple line figure to illustrate the complex gene structure of 
PRPC8 is also included in Figure 2.5, with filled boxes representing the exons of this large transcript. The 
spacing of the exons is approximately to scale, indicating a large intron of 11kb between exons 23 and 24. 
Also highlighted is the sequence of exon 42, with the positions of all seven missense mutations identified 
thus far indicated.  
 
 
RESULTS 
 
We carried out further haplotype analysis on the South African, Dutch and the two UK 
families. This revealed that the two UK families are clearly related and are therefore in 
effect one extended pedigree, but that this larger UK pedigree, the South African and 
Dutch families are unrelated (Fig. 2.6). To further characterize the RP13 interval, a physical 
contig of the region was used to create an expression map of uniquely ordered expressed 
sequence tags (ESTs) and known genes.6 Sequence data from the Whitehead Institute 
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chromosome 17 project (www.genome.wi.mit.edu/) was integrated with this data and 
used to orientate genetic markers. A new microsatellite marker designated 4kbGT was 
identified in the interval, and this further refined the distal boundary by detecting 
crossovers in the UK and South African families (Figs. 2.5 and 2.6). The proximal 
boundary remained defined by the marker D17S831 which detected a crossover in the 
South African family.4 Within the D17S831-4kbGT interval, we identified the known genes 
PEDF, RPA1, PLI, PITPn-a, SKIP, KIAA00149, MYO1-ß, IMPC23B, a retinal EST AA0016967 
and several putative genes predicted by the nucleotide identification package NIX 
(www.hgmp.mrc.ac.uk). We obtained the IMAGE cDNA clone from which EST AA016967 
was derived and sequenced this in its entirety. This revealed a small region of unique 
sequence at one end of the clone, but the remainder consisted of Alu repeat and it 
therefore seems likely that this clone represents a cloning artefact. Nevertheless, this 
stretch of repeat-free sequence and each of the other candidate genes listed above were 
excluded from involvement in RP13 by mutation screening in affected members of the UK 
and South African families by single strand conformation polymorphism (SSCP) and 
genomic sequencing of all exons including splice donor/acceptor boundaries.  
.  
Figure 2.6 Haplotype analysis revealing the key crossover events in subsections of the UK (A) and South 
African (B) RP13 pedigrees. From top to bottom, markers are shown in the order: TEL, D17S1529, 4kbGT, 
cCI17-571, D17S831, D17S1528, CEN. The UK family was ascertained as two separate pedigrees. The 
closed diamond symbol to the right of this pedigree (A) denotes the affected haplotype in the previously 
published pedigree 5, while the subpedigree to the left is part of the new UK pedigree shown in Figure 2.7B. 
These families came from adjacent towns in Cumbria and share a haplotype for these and other markers in 
the RP13 interval, so they are almost certainly related. Similarly, the closed diamond symbol to the right of 
pedigree (B) represents the affected haplotype in the published South African family 3. Crossovers in both 
families place the locus proximal to 4kbGT, while a single crossover in the South African pedigree puts the 
RP13 gene distal to D17S831. No further refinement was obtained from analysis of the Dutch family and the 
linked haplotype shared no alleles with those of the UK and South African pedigrees. 
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Spectrum of mutations in the PRPC8 gene 
We then examined the gene encoding the 220 kDa U5 snRNP factor denoted PRP8. The 
genomic structure of the human PRPC8 gene was ascertained on the basis of comparisons 
between the cDNA (GenBank accession number AB007510),9 and genomic bacterial 
artificial chromosome (BAC) sequences from the chromosome 17 sequencing project (BAC 
RP11-145P4, GenBank accession number AC002093; and BAC RP11-433M14, accession 
numer AC068936). This showed that this large 2335 amino acid protein was encoded by 42 
exons spanning approximately 36 kb of genomic sequence (Fig. 2.5). All of the exons were 
screened by SSCP and genomic sequencing in DNA samples from affected members of the 
three RP13 linked families. Three different missense mutations were found within two 
adjacent codons in the last exon of the PRPC8 gene, one in each family (Fig. 2.7a) and in 
each case they segregated perfectly with the disease. The UK and South African families 
have different base changes at the same nucleotide position (nucleotide 6967; Table 2.2) 
with a third missense mutation in affected individuals from the Dutch pedigree identified 
in the adjacent codon (nucleotide 6970). Segregation of the nucleotide 6967 mutations in 
the complete South African and UK pedigrees was demonstrated by virtue of loss of an 
Apa L1 restriction cleavage site on the mutated allele (Fig. 2.7b). Segregation of the Dutch 
mutation can be detected as loss of Hae III or Dra II restriction sites (data not shown).  
 
Table 2.2 Summary of mutations found to date in the PRPC8 gene 
Family/case ID Location Mutation Amino acid change 
UK family Exon 42 c. 6967A→C H2309P 
SA family Exon 42 c. 6967A→G H2309R 
NL family Exon 42 c. 6970G→A R2310K 
614 (UK) Exon 42 c. 6942C→A P2301T 
161 (UK) Exon 42   
162 (UK) Exon 42 c. 6953C→G F2304L 
622 (UK) Exon 42   
189 (UK) Exon 42 c. 6969A→G R2310G 
690 (UK) Exon 42 c. 6983C→A F2314L 
 
 
Further screening using these restriction digestion assays on a collection of 332 RP 
patient DNAs from centres in the UK and Australia revealed no further cases with these 
specific mutations. However, a preliminary mutation screen of all 42 PRPC8 exons by 
SSCP in a sample of 60 adRP cases from the UK identified four further missense mutations 
in exon 42 (Fig. 2.7C and Table 2.2). One of these exhibited a change at the preceeding base 
to the Dutch mutation (nucleotide 6969) within the same codon (2310). Another had a base 
change at nucleotide 6953 which cosegregated with RP in two affected relatives of the 
patient. The third and fourth mutations were each in single patients and altered bases at  
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Figure 2.7 (A) Sequence surrounding codons 2309 and 2310 of PRPC8 with autoradiographs depicting (1) 
wild-type sequence, (2) mutation c.6967A→C resulting is H2309P amino acid change in the UK family, (3) 
mutation 6967A→G resulting in H2309R amino acid change in the South African family, and (4) mutation 
c.6970G→A resulting in R2310K amino acid change in the Dutch family. The shaded boxes represent ApaL1 
and HaeIII restriction enzyme recognition sequences which formed the basis of a PCR-digest assay to 
examine segregation in the large families. Primers used to amplify exon 42 were (for exon 42; forward primer 
5’-CCAGCATCTTGCTGTGAACCGC-3’; and reverse primer, 5’-TGCATGAGGCAGGAGCCCTGTT-3’), 
which produced a 290 bp PCR product. The sequence above was generated using the reverse primer.  
 
 
 
 
Figure 2.7(B) Segregation analysis of c.6967A→C mutation the second UK family by ApaL1 restriction 
digestion of a PCR fragment containing exon 42. Complete digestion of the PCR product results in a wild-
type pattern of bands migrating at 300 and 360 bp. The mutation ablates the ApaL1 site in the affected 
individuals giving rise to a heterozygous band pattern with both cut and uncut bands present at 300, 360, 
and 660 bp. 
 
positions 6942 (codon 2301) and 6983 (codon 2314). All seven mutations are in a 42 bp 
sequence (14 codons) approximately 100 bp from the stop codon at the 3’ end of this large 
transcript. 
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The Apa L1 and Hae III restriction assays were also used to exclude the occurrence of the 
sequence changes seen in the RP13 linked families in 120 normal control DNA samples, 
ruling out the possibility that they are neutral sequence variations occurring with a 
significant frequency in the general population. Similarly, an SSCP screen of PRPC8 exon 
42 in 572 control chromosomes from individuals of a similar ethnic background revealed 
no sequence changes, confirming that the mutations are unlikely to be common 
polymorphisms. 
 
 
Figure 2.7 (C) Sequence surrounding codons 2301, 2304, 2310 and 2314, with autoradiographs depicting 
the wild-type and mutated sequence at all of these points in adRP cases from the UK. AdRP case 614 is 
heterozygous for the c6942C→A transversion which results in a P2304T amino acid change. Cases 161 and 
162 are sibs heterozygous for the c6953C→G transversion which gives rise to a F2304L amino acid change. 
Case 189 is heterozygous for the c6969A→G transition which results in an R2304G amino acid change. 
Case 690 is heterozygous for the c6983C→A transversion which results in an F2314L amino acid change. 
 
 
PRPC8 gene expression is ubiquitous 
The EST database (www.ncbi.nlm.nih.gov/UniGene/) reveals that PRPC8 is expressed in 
a wide range of tissues. However of approximately 450 EST entries, over 70 are derived 
from neural tissue, of which 18 are from the eye. Northern blot analysis using a probe 
from the 3’ end of the PRPC8 gene which included exon 42 gave a single band of 
approximately 7 kb in total RNA from six tissues. Reverse transcriptase-PCR (RT-PCR) 
was carried out on total RNA from a variety of normal tissue sources including retina and 
other neuronal tissues. Multiplexed RT-PCR was carried out with primers within exons 41 
and 42 of PRPC8 as a single amplicon to ensure that exon 42 is present in retinal 
transcripts (Fig. 2.8). The PRPC8 amplicon is clearly expressed in all the tissues as a single 
MUTATIONS IN THE PRPC8 GENE IN ADRP (RP13) 
 
    79
band of 124 bp. Control primers for the GAPDH gene amplified a 220bp fragment in each 
lane. 
 
 
 
Figure 2.8 Multiplex RT-PCR was carried out with primers from PRPC8 and GAPDH. PRPC8 primers from 
exon 41 and 42 crossing intron 41 and including codons 2309 and 2310 [exon 42 (RT) forward, 5’-
AGTTGAGGAAGTGAGAGGCCTGT-3’ and exon 41 (RT) reverse, 5’-
CCAGTCCTCGTGGAACTACAACTTC-3’] were multiplexed with the GAPDH control primers. This was 
carried out on total RNA from tissue extracts from 1, kidney; 2, lung; 3, placenta; 4, heart; 5, liver; 6, adult 
brain; 7, fetal brain; 8, cerebellum; 9, spinal cord; 10 and 11, two separate retinal RNA preparations; 12, 
genomic control; and 13, water control. The RT-PCR-specific band for PRPC8 can be observed as a 124 bp 
fragment, with the same primers amplifying a 290 bp product on genomic control DNA. The GAPDH product 
was 220 bp. 
 
Sequence conservation 
Protein alignment at exon 42 between human PRP8 and its orthologues in other species 
was carried out using the programme Clustal and the shaded boxes were created using the 
programme Mac-Boxshade (Fig. 2.9). The parameters employed by the shading process are 
not confined only to amino acid sequence but also take account of conservation of the 
amino acid physiochemical properties.  
 
 
 
Figure 2.9 The amino acid sequence of human PRP8 exon 42 is aligned with that of Drosophila 
melanogaster (Dros), Caenorhabditis elegans (c.eleg), Arabidopsis thaliana (Arab), Schizosaccharomyces 
pombe (S.pombe), Leishmania major (Liesh) and Trypanosoma bruceii (Tryp) using the programme Clustal. 
The shaded boxes were created using the programme Mac-Boxshade with the default parameters set. The 
intensity of shading represents the relative degree of conservation and physio-chemical similarities. Hence 
the black boxes indicate amino acid identity or only highly conservative variation, while lesser shaded boxes 
show conservation but with more variation and with less conservative amino acid substitutions. The five 
amino acid residues mutated in the adRP cases are highlighted above with the codon number. 
 
This analysis illustrates conservation of the two amino acids changed in the three RP13-
linked families and one non-related adRP case (codons 2309 and 2310) in Drosophila 
melanogaster, Arabidopsis thaliana, Caenorhabditis elegans, Schizosaccharomyces pombe and 
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Trypanosoma bruceii. Particularly striking is the level of homology around residues 2309 
and 2310 and the absolute conservation of these two residues throughout the species 
shown in the multiple alignment. Additionally, the proline residue at position 2301 has the 
same high degree of conservation and is altered in one adRP case. The remaining missense 
mutations alter the amino acid residues 2304 and 2314 which are also conserved, but to a 
lesser degree.  
 
DISCUSSION 
 
Prp8 is the most highly conserved large nuclear protein known to date, yet the amino acid 
sequence shows no evidence of homology to any recognized protein domains other than 
its orthologues in other species.10 Functional information has been derived from studies in 
the budding yeast Saccharomyces cerevisiae, which identified some of the protein 
components necessary for spliceosome formation. Over 40 prp (precursor mRNA 
processing) proteins have been identified in yeast to date, of which Prp3, Prp4, Prp5, Prp7, 
Prp8 and Prp11 have been shown to be vital for spliceosome assembly in vitro.11 Yeast 
Prp8 protein is thought to be the core component of the U5 snRNP and is required for 
formation of the U4/U6-U5 tri-snRNP, without which spliceosome assembly and pre-
mRNA processing do not take place.12 The U1 snRNP is the first particle to interact with 
the substrate mRNA precursor, followed by U2 snRNP. Concurrently, the U4/U6 and U5 
snRNPs associate to form the triple snRNP and this then joins the U1/U2-pre-mRNA 
complex to form the spliceosome.13 UV-crosslinking studies have shown that Prp8 
interacts with the pre-mRNA substrate at both the 5’ and 3’ splice sites, and may function 
as the principle anchoring factor for exons in the spliceosome.14-17 A region of the Prp8 
protein near the C-terminus has been shown to crosslink with the 5’ splice-site consensus 
sequence.18 This is approximately 400 amino acid residues away from the region 
containing the mutations described above, but the relationship between them in the 
tertiary structure is unknown. The study of a cold-sensitive yeast mutant has led to the 
proposal that Prp8 may also facilitate unwinding of the U4 and U6 snRNAs during 
activation of the spliceosome to the catalytic “complex C”.19,20 Therefore, because of its 
dynamic interactions as part of the spliceosome and the many interactions it has with 
other splicing factors, Prp8 may represent the spliceosomal protein with the most complex 
structural organization, providing important catalytic and regulatory functions for pre-
mRNA processing. 
Having such a central role in this basic housekeeping function, PRPC8 was 
therefore not an obvious candidate for involvement in retinal disease. Most of the genes 
implicated in retinal disease have retina-specific expression and, where function is known, 
encode proteins essential for photoreceptor development/structure or are components of 
either the phototransduction cascade or the visual cycle which provides and recycles 11-
cis-retinaldehyde.21 This may however represent a bias in the selection of candidate genes 
when screening in these diseases and a number of retinal disease genes identified more 
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recently have ubiquitous expression patterns. These include the RPGR and RP2 genes 
mutated in X-linked RP, the EFEMP1 gene involved in dominant drusen, the MERTK gene 
involved in recessive RP, the OPA1 gene involved in optic atrophy and the TIMP3 gene 
mutated in Sorsby’s macular dystrophy (www.sph.uth.tmc.edu/retnet). The RPGR gene 
encodes a protein with homology to the guanine-nucleotide-exchange factor RCC1, and 
alternatively spliced products specific to retina have been identified in the 3’ half of the 
gene that harbours most of the mutations in RP3 kindreds.22 RT-PCR analysis of the 3’ 
exons of the PRPC8 gene has not provided any evidence of alternatively spliced transcripts 
in retina or in any other tissue thus far examined. Exon 42 is ubiquitously expressed in the 
10 tissue types examined and we observed no discernable differences in expression levels, 
though reports of such differences in expression have been found in literature, with the 
highest expression being observed in muscle tissue.23 
Nevertheless, we have found different mutations in three RP13 linked families and 
four further mutations in patients with a family history of dominant RP. This provides 
compelling evidence that PRPC8 is indeed the gene mutated in this form of dominant RP. 
The occurrence of seven missense mutations within the last of 42 exons in this large gene 
may imply that this region of the protein is involved in some particular aspect of retinal 
maintainance or function. The fact the mutations are all missense and that the RP13 locus 
is associated with a relatively severe phenotype may imply a dominant negative 
mechanism for disease causation. Nonsense mutations in genes such as Rds/peripherin 
and RP1 generally correspond to a milder phenotype, which may represent a 
haploinsufficiency defect.24,25  
Most of the current knowledge about Prp8 function derives from studies in yeast, 
whereas Prp8 function in higher eukaryotes is less well researched. It is therefore possible 
that this discovery will shed light on some other unknown function attributable to Prp8, 
which is specific to the retina. Prp8 and some of the other protein factors known to interact 
in spliceosome assembly are also thought to be involved in cell cycle control, carbon 
catabolism, cytoplasmic mRNP export and processing, protein secretion and Golgi 
trafficking as well as possibly DNA repair.7,26-30 Alternatively, it may be that Prp8 and 
other ubiquitously expressed genes mutated in retinal disease represent a series of rate-
limiting steps in what is one of the fastest metabolising tissues in the human body.31 Thus 
a defect in splicing or mitochondrial metabolism which is sub-pathological in other tissues 
might only manifest as a disease in the retina.  
On the other hand, the involvement of factors specifically associated with splicing 
in neuronal degeneration is not unprecedented. SMN1, the gene mutated in Spinal 
Muscular Atrophy (SMA) types 1, 2 and 3, is thought to play a role in both snRNP 
assembly in the cytoplasm and regeneration in the nucleus by binding to and aggregating 
the U1, U2, U4 and U5 snRNP-specific Sm proteins.32 The basis for the absolute specificity 
of motor neuron death in SMA remains unclear, since this protein, like Prp8 is expressed 
in a number of tissues including other regions of the brain not affected in SMA. 
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Aetiological parallels can therefore be drawn between SMA and RP13, which both involve 
mutations in ubiquitously expressed splicing factors leading to neuronal degeneration. 
In mammals, the vast majority of introns are removed by the major U2-dependant 
spliceosome complex (composed of four snRNPs U1, U2, U4/U6 and U5). A second type 
of spliceosome was recently discovered - the U12-dependant spliceosome complex that 
removes so-called U12-dependant introns.33 The U12-dependant introns comprise less 
than 1% of all introns. Interestingly, the splicing mechanism of this class of introns not 
only recognizes different splice donor and acceptor consensus sequences, but employs a 
different set of snRNPs. The exception to this is the U5 complex which appears to have a 
pivotal role in both these systems. One family of genes which maintain U12-dependant 
introns is the voltage-gated sodium and calcium channel alpha subunits.34 Mutations in 
these genes cause numerous neuromuscular and neurological diseases.35 One could 
therefore postulate that the exon 42 mutations in PRPC8 mediate their effect through a 
failure of the U12-dependant spliceosome complex. Significantly, the U12-dependant 
splicing mechanism is absent from budding yeast which has been the main experimental 
organism furnishing most of the current knowledge of Prp8 function. 
In conclusion, we have shown that mutations in PRPC8, the human orthologue of 
the yeast splicing factor Prp8, are implicated in the RP13 form of RP. As the function of 
this protein in humans is less well studied than in yeast, it is possible that this observation 
will highlight some as yet unknown function for Prp8 outside its core role in mediating 
spliceosome assembly and catalysis.  
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ABSTRACT 
 
The aim of this study was to describe the clinical findings and to identify the genetic locus 
in a Dutch family with autosomal dominant benign concentric annular macular dystrophy 
(BCAMD). All family members underwent ophthalmic examination. The BCAMD 
phenotype is initially characterized by parafoveal hypopigmentation and a good visual 
acuity, but progresses to a retinitis pigmentosa-like phenotype. We performed linkage 
analysis of candidate retinal dystrophy loci and a whole genome scan. Five candidate 
genes from the linked locus were analyzed for mutations by direct sequencing. Linkage 
analysis established complete segregation of the BCAMD phenotype (maximum 
multipoint LOD score 3.8) with DNA markers at chromosome 6p12.3-q16. Recombination 
events defined a critical interval spanning 30.7 cM at chromosome 6q between markers 
D6S269 and D6S300. This interval encompasses several retinal dystrophy loci, including 
the ELOVL4 gene, mutated in autosomal dominant Stargardt disease and the RIM1 gene, 
mutated in autosomal dominant cone-rod dystrophy, as well as the retinally expressed 
GABRR1 & 2 genes. Mutation screening of these four genes revealed no mutations. 
Sequence analysis of the interphotoreceptor matrix proteoglycan 1 gene, IMPG1, also 
residing in the BCAMD locus, revealed a single base pair change (T>C) of nucleotide 1866 
in exon 13, resulting in a Leu579Pro amino acid substitution. This mutation was absent in 
190 control individuals. So in conclusion significant linkage for the BCAMD defect with 
chromosomal region 6p12.3-q16 was found and a Leu579Pro mutation in the IMPG1 gene 
might play a causal role. 
 
INTRODUCTION 
 
Benign concentric annular macular dystrophy (BCAMD) (OMIM #153870) is initially 
characterized by parafoveal hypopigmentation together with a relatively good visual 
acuity.1 Patients do not have a history of chloroquine ingestion nor do they show 
symptoms typical for cone dystrophy, like photophobia and severely defective colour 
vision.2,3 Several other patients have been reported with clinical features similar to this 
initial stage of BCAMD including a three generation family,4 and six isolated patients.5-7 A 
10 year follow-up of the Dutch family reveals a more pronounced involvement of the 
peripheral retina together with increased photoreceptor cell dysfunction, as found in RP.8 
Currently, 12 genetic loci are associated with non-syndromic autosomal dominant RP and 
18 loci are associated with autosomal dominant dystrophies of the retina and choroid with 
primary involvement of the macular area.9 In this study we describe the progression of the 
BCAMD clinical features during the last 15 years and we report on the results of a 
genome-wide search undertaken to find the gene responsible for BCAMD in this family. 
We detected linkage with chromosomal region 6p12.3-q16, and subsequently analyzed 
five candidate genes residing in this chromosomal region. 
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METHODS 
  
Clinical studies 
The study protocol adhered to the tenets of the Declaration of Helsinki. Fifteen relatives 
from the original Dutch BCAMD family were included in this study. Informed consent 
was obtained from all participants. The medical histories were obtained from 5 unaffected 
and 10 affected individuals and subsequent ophthalmic examinations included best 
corrected Snellen visual acuity determination, fundus examination and fluorescein 
angiography. An ERG and an EOG were obtained according to the International Society 
for Clinical Electrophysiology of Vision protocol (http://www.iscev.org). Visual field 
examination was performed monocularly with a Goldmann perimeter. In addition several 
patients underwent colour vision testing and dark adaptation testing. 
 
 
Molecular Genetic studies 
Linkage analysis 
Blood samples of 19 individuals from three generations were collected and DNA was 
isolated as described elsewhere.10 Microsatellite markers were chosen from the Généthon 
database11 to investigate the candidate loci for autosomal dominant RP and autosomal 
dominant macular dystrophy. Simultaneously, a whole genome scan was performed with 
highly polymorphic DNA markers, spaced between 10-15 cM, which were derived from 
Généthon (available on request by the authors).11 DNA samples were subjected to PCR 
amplification with a standard cycling profile of 30 cycles at 94°C, 55°C and 72°C with 30 
seconds at each step. DNA markers were labeled by the incorporation of α[32P]-dCTP and 
the products were separated by electrophoresis on a 6.6% denaturing polyacrylamide gel. 
We calculated two-point LOD scores using the subroutine MLINK of the LINKAGE 
program (version 5.1).12-14 Multipoint analysis was performed by means of four-point 
linkage analysis (FASTLINK version 2.30).15,16 A gene frequency of 0.0001 and a 
penetrance of 95% were assumed for the disorder.  
 
 
Mutation Screening 
For sequence analysis of the IMPG1 gene, exons 1-17 were amplified using 
oligonucleotides as described.9 Twenty-five ng of genomic DNA was denaturated for 5 
min at 95°C and subjected to 35 cycles of PCR, with the following conditions: denaturation 
for 30 sec at 94°C, annealing for 30 sec at temperatures varying from 49°C to 58°C and 
extension for 30 sec at 72°C. Finally, an extension was performed for 5 min at 72°C. To 
screen for the presence of the mutation in control individuals and to analyze the 
segregation of the mutation in the pedigree, an amplification refractory mutation system 
(ARMS) PCR for IMPG1 1866T>C was developed.17 PCRs were performed using the same 
reverse primer of exon 13 of the IMPG1 gene9 and in one PCR the wild-type specific 
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forward primer 5’-TGGTAGTGTTCTTCAGTCT-3’ and in the other PCR the mutant-
specific forward primer 5’-TGGTAGTGTTCTTCAGTCC-3’. The PCR conditions were the 
same as mentioned above with annealing temperatures of 56°C and 59°C respectively. The 
PCR products were analyzed on a 1.5% agarose gel. Sequence analysis of the ELOVL4 and 
RIM1 genes was performed using primers and conditions as described before.18,19 The 
GABRR-1 and GABRR-2 genes were screened for mutations by direct sequencing of exons 
and exon/intron boundaries with PCR primers and conditions available from the authors 
upon request.  
 
RESULTS  
 
Clinical Findings 
The clinical features are shown in table 3.1. The genetic defect is inherited in an autosomal 
dominant manner (Fig. 3.1). Visual acuity was normal at the age of onset, but decreased 
gradually after the fourth to fifth decade to 20/40, except for individual III-2.  Her visual 
acuity was 20/60 in the right eye, due to amblyopia. She also underwent retinal 
detachment surgery in both eyes at the age of fifteen. Six patients complained of night 
blindness. In the affected individuals, fundus disorders ranged from macular pigment 
alterations to bull's eye maculopathy and from minimal peripheral pigment disturbance to 
a pigmentary dystrophy with bone corpuscles. In late stages of the disease waxy optic 
atrophy and attenuated arterioles were found (Fig. 3.2). Electroretinographic testing 
revealed photoreceptor dysfunction even at young age (individuals III-2, III-6, IV-1, IV-3 at 
the age of 28, 33, 17 and 22 respectively) with a slight predominance of rod dysfunction 
above cone dysfunction. EOG was almost invariably subnormal (1.5-1.8) or abnormal 
(<1.5) and deteriorated with age. Only in individuals III-3 at the age of 16 and 26 and II-2 
at the age of 44, EOG was normal (>1.8) or subnormal. The dark-adaptation curves 
decreased to a normal or moderately elevated level, except for patient III-2, whose curve 
was elevated due to previous retinal detachments. Visual fields varied from normal to a 
ring-like zone of decreased sensitivity surrounding a small central island of mildly 
decreased sensitivity, to constricted visual fields in a later stage. The colour vision 
examination revealed a congenital deuteranomaly in the 3 male patients and an acquired 
blue yellow defect in all affected individuals, except III-5 and IV-1. Individual IV-3 was 
not tested. 
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Table 3.1 Clinical details of the BCAMD family 
Pt. exam. 
year 
age VOD VOS ERG 
sotopic 
ERG 
fotopic 
EOG  DAE 
     OD OS OD OS OD OS  
            
II-2 1974  
1984   
44 
54 
20/25 
20/40 
20/25 
20/25 
SN 
NR 
SN 
NR 
SN 
SN 
SN 
SN 
 
1.87 
1.11 
1.91 
0.97 
1.0 
1.0 
II-4 1984    
1999    
50 
65 
20/25 
20/30 
20/20 
20/25 
SN 
NR 
SN 
NR 
SN 
NR 
 
SN 
NR 
1.12 
0.98 
1.00 
0.96 
0.5 
1.5 
II-7 1984  
1999  
45 
60 
20/25 
20/25 
20/25 
20/25 
SN 
NR 
SN 
NR 
SN 
SN 
SN 
SN 
1.50 
1.40 
1.70 
1.30 
0.5 
1.0 
 
II-9 1999  47 20/25 20/25 NR NR N 
 
N 0.98 1.04 0.5 
III-2 1974   
1984   
1999   
 
18 
28 
43 
20/60 
20/60 
20/60 
20/25 
20/40 
20/40 
SN 
NR 
NR 
SN 
NR 
NR 
SN 
NR 
NR 
SN 
NR 
NR 
1.00 
1.00 
1.09 
1.00 
1.00 
0.97 
NP 
1.5 
3.0 
III-3 1974   
1984   
1999   
16 
26 
41 
20/20 
20/15 
20/15 
20/20 
20/15 
20/40 
N 
SN 
NR 
N 
SN 
NR 
SN 
SN 
N 
SN 
SN 
N 
2.14 
2.00 
1.65 
2.36 
1.75 
1.38 
N 
N 
NP 
 
III-5 1984  
1999 
 
24 
40 
20/25 
20/20 
20/25 
20/15 
SN 
NR 
SN 
NR 
SN 
NR 
SN 
NR 
1.22 
0.89 
1.27 
0.77 
0.5 
N 
III-6 1999 33 20/20 20/20 NR NR SN SN 1.00 1.00 1.0 
 
IV-1 1999  17 20/15 20/15 SN SN N N 1.64 1.75 N 
 
IV-3 2002   22 20/25 20/25 SN-
NR 
SN-
NR 
SN SN 1.00 1.00 NP 
EOG: electro-oculography (Arden ration p95: >1.65) 
DAE: dark adaptation elevation(10log) 
N: normal, SN: subnormal, NR: non recordable, NP: not performed 
 
 
Molecular genetic findings 
Linkage analysis 
Using linkage analysis the following candidate loci for X-linked and autosomal dominant 
RP were analyzed: Xp21.1 (RP3), 1q21.1 (RP18), 3q21-q24 (RP4), 6p21.2-cen (RP7), 7p15.1-
p13 (RP9), 7q31.3 (RP10), 17p13.1 (RP13), 17q22 (RP17), 19q13.3 (CRX) and 19q13.4 (RP11). 
Not tested were the loci 8q11-q13 (RP1), 14q11.2 (RP27) and 17q25 (FSCN2). Likewise, the 
following loci for X-linked and autosomal dominant macular dystrophy were tested: 
Xp21.1 (COD1), Xq27 (COD2), 1q25-q31 (ARMD1), 2p16-p21 (DHRD), 4p (STGD4), 6p21.1 
(COD3), 6p21.2-cen (RDS), 6q13-q14 (CORD7), 6q14 (STGD3), 6q14-q16.2 (PBCRA, 
MCDR1), 6q25-q26 (RCD1), 7p21-p15 (CYMD), 11q13 (VMD2), 17p13 (CACD), 17p13.1 
(CORD6), 17p13-p12 (CORD5), 17q (CORD4), 17q11.2 (UNC119), 19q13.3 (CORD2) and 
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22q12.1-q13.2 (SFD). All loci except 6q14 (STGD3) and 6q13-q14 (CORD7) were excluded. 
The genetic defect cosegregated with markers from chromosome 6p12.3-q16. In the 
genome scan, except for the 6p12.3-q16 region, multiple recombinations were found in 
affected family members with all markers analysed. 
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Figure 3.1 Pedigree and linkage analysis results of the BCAMD family. The 6p (between D6S269 and 
D6S257) and 6q (between D6S1570 and D6S300) boundaries of the critical interval at 6p12.3-6q16 are 
determined by recombination events observed in individuals II-7 and III-6. Note that marker D6S1570 is non-
informative based on the deduced haplotypes in individuals I-1 and I-2. The order of the markers is derived 
from the human genome project working draft (freeze Nov 2002) (at http://genome.cse.ucsc.edu/) and 
Généthon11. Marker alleles between brackets are deduced. At risk haplotypes are boxed. Stippled boxes 
designate non-informative markers in one of the parental haplotypes. 
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Figure 3.2 A: Fundus photo of patient II-9, age 47 years: Typical bull’s eye maculopathy and slightly 
attenuated arterioles; B: Fluorescein angiogram of patient II-9, age 47 years: Ring-like macular 
hyperfluorescence, surrounded by mid-peripheral diffuse granular hyperfluorescence. 
C: Fundus photo of patient II-4, age 65 years : Bull’s eye maculopathy, attenuated arterioles, bone corpuscle 
pigmentations, peripheral chorioretinal atrophy. D: Fluorescein angiogram of  patient II-4, age 65 years: 
Irregular macular fluorescence, areas of choriocapillaris atrophy. In the mid-periphery diffuse granular 
hyperfluorescence and bone corpuscle pigmentations. 
 
 
Two-point LOD scores between the relevant markers from 6q12.3–q16 and the disease 
phenotype are given in Table 3.2. A maximum LOD score of 3.81 at θ= 0.0 was obtained 
with markers D6S1609 and D6S1613. Multipoint analysis with the markers D6S257, 
D6S1609 and D6S1570 resulted in a maximum LOD score of 3.81 in the whole region 
between D6S257 and D6S1570. The analysis of the recombination events in individuals II-7 
and III-6 revealed a critical region on chromosome 6 between markers D6S269 and 
D6S300, which flank a 30.7-cM interval (Fig. 3.1). In this region the loci for autosomal 
dominant Stargardt  
disease (STGD3), dominant drusen (DD), and autosomal dominant cone rod dystrophy 
(CORD7) have been positioned, as well as two loci for autosomal recessive disorders, i.e. 
RP25 and Leber congenital amaurosis (LCA5)19-23 (Fig. 3.3). 
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Table 3.2 Two-point LOD score data of the BCAMD family for chromosome 6p 
microsatellite markers 
 
Recombination fraction 
Marker 0.00 0.01 0.05 0.1 0.2 0.3 0.4 Zmax θmax
D6S269 -3.99 0.31 0.96 1.13 1.04 0.71 0.32 1.13 0.1 
D6S257 3.51 3.44 3.18 2.83 2.09 1.27 0.45 3.51 0.0 
D6S1609 3.81 3.74 3.48 3.13 2.38 1.54 0.63 3.81 0.0 
D6S1613 3.81 3.74 3.48 3.13 2.38 1.54 0.63 3.81 0.0 
D6S1570 1.05 1.02 0.93 0.81 0.60 0.40 0.19 1.05 0.0 
D6S300 -4.66 0.90 1.40 1.45 1.20 0.77 0.29 1.45 0.1 
 
 
 
 
 
 
 
Figure 3.3 A genetic and morbid map of 6p12.3-6q16. The linkage intervals for families with Leber 
congenital amaurosis (LCA5), RP25, progressive bifocal chorioretinal atrophy (PBCRA)45, north carolina 
macular dystrophy (MCDR1)46, CORD7, STGD3, dominant drusen (DD) and the BCAMD family are depicted, 
as well as the localizations of the RIM1, ELOVL4, GABBR1 & 2, and IMPG1 genes. The localization of the 
markers and the genetic distances (cM) are derived from the human genome project working draft (freeze 
Nov 2002) (at http://genome.cse.ucsc.edu/) and Généthon11.  
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Mutation analysis 
Candidate genes located in the BCAMD locus at chromosome 6 include ELOVL4, GABRR-
1, GABRR-2, RIM1 and IMPG1 (Fig. 3.3). ELOVL4 is involved in the biosynthesis of very 
long chain fatty acids and mutated in patients with autosomal dominant STGD3.19,24 The 
GABRR-1 and GABRR-2 genes encode the gamma-aminobutyric acid (GABA) rho-1 and 
rho-2 subunits of the of GABA-C receptor, which is the effector of lateral inhibition in the 
retina.25,26 The Rab3A-interacting molecule (RIM1) gene, which is expressed in brain and 
photoreceptors, is involved in photorecepor synaptic vesicle priming and exocytosis and 
mutated in a family with autosomal dominant CORD.18 We analyzed the 6 protein coding 
exons of ELOVL4, the 9 protein coding exons of GABRR1, the 9 protein coding exons of 
GABRR2, and the 35 protein coding exons of RIM1 in two BCAMD patients. No sequence 
alterations were detected in the open reading frames of these four genes in the BCAMD 
family. IMPG1 encodes the interphotoreceptor matrix proteoglycan-1 protein, a major 
retina-specific glycoprotein of the interphotoreceptor matrix (IPM).27,28 Sequence analysis 
of the 17 exons of IMPG1 in the BCAMD family revealed a T to C change at nt. 1866 in 
exon 13 resulting in a Leu579Pro substitution (Fig. 3.4). ARMS analysis showed that this 
mutation segregated with the BCAMD phenotype (Fig. 3.5) and was not found in 190 
control individuals (data not shown). Furthermore, a previously described H518D 
polymorphism in exon 139 and a 2162G>A alteration in exon 15, resulting in an R711H 
substitution, were found. The latter DNA variant was also found in 6/20 DNAs of control 
individuals (data not shown) rendering it a frequent polymorphism.  
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CT A TC AG CG AAC C C GA AA GAAAA G
CT A TC AG CG AAC C C GA AA GAAAA G
Patient III-6
Control
nt 1877
nt 1877
Pro
LeuArg Ser
T TC GG GA CT
LeuArg Ser
T TC GG GA CT
C
G
nt 1854
nt 1854
579
 
Figure 3.4 DNA sequence analysis of part of exon 13 of IMPG1. Top: Antisense sequence of patient III-6, 
carrying a heterozygous T to C transition at nt 1866, resulting in an amino acid change Leu579Pro. Bottom: 
Antisense sequence of a control individual is shown for comparison. Above these sequences part of the 
complementary sense sequence is depicted in the reverse orientation.  
 
 
 
Figure 3.5 Amplification refractory mutation system assay showing the inheritance of the Leu579Pro 
mutation in a large part of the family (III-4, III-7, IV-3 and IV-4 were not tested and therefore not depicted in 
the figure). Top: PCR product of the mutant primer pair. Bottom: PCR product of the wild-type primer pair. 
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DISCUSSION 
 
We have performed a 15-year follow up of a BCAMD family. Affected members present 
with a ringlike depigmentation around the fovea, associated with relatively good visual 
acuity in the third decade, which slowly decreases in the fourth to fifth decade. The 
progression of the phenotype is indicative of RP with a bull’s eye configuration, because of 
the more pronounced involvement of the peripheral retina and the increased 
photoreceptor dysfunction, with slight predominance of rod dysfunction even at an early 
stage. It is hard to differentiate BCAMD from cone-rod dystrophy, but progressive central 
acuity loss and photo-aversion are not typical findings at any stage of disease, while night 
blindness is found already at young age in some patients. Only one three-generation 
family and six sporadic patients with a clinical entity similar to BCAMD have been 
described earlier.4-6 However a follow-up of these patients is unknown, which complicates 
comparison of these cases with patients from our family. 
By performing extensive linkage analysis, we observed full co-segregation of the 
BCAMD phenotype with DNA markers of 6p12.3-q16 with maximum two-point (3.8) and 
multipoint LOD scores (3.8). Mutation analysis of the ELOVL4, GABRR1 & 2, RIM1, and 
IMPG1 genes on chromosome 6 revealed a Leu579Pro mutation in IMPG1. IMPG1 and its 
homologue IMPG2 encode the chondroitin sulfate proteoglycan core proteins, 
interphotoreceptor matrix (IPM) 150/SPACR and IPM 200/SPACRCAN, respectively. 
IMPG1 is expressed in the retina.29 IMPG2 has been detected around rod and cone 
photoreceptors and in pinealocytes.29,30 Chondroitin-6-sulfate rich glycosaminoglycans 
have been identified around cone photoreceptor cells and have been named "cone matrix 
sheets".31,32 These molecules appear to play a crucial role in the physical attachment of the 
neural retina to the RPE.33-39 The human IMPG1 and IMPG2 proteins consist of 771 and 
1160 amino acids respectively. Both contain a predicted signal peptide at the amino-
terminus and they show two regions with high sequence homology (domain C1: Arg67 – 
Trp126 and domain C2: Leu573 – Val 654).40,41 They contain one (IMPG1) or two (IMPG2) 
putative EGF-like domains thought to be involved in protein-protein interaction. Both 
contain a putative hyaluronan-binding motif and IMPG2 contains three putative 
glycosaminoglycan binding motifs.29,42 It is thought that IMPG1 and IMPG2, through their 
binding with hyaluronan may serve to organize the basic macromolecular scaffold for the 
IPM.29 The mutated leucine residue at position 579 resides in the second conserved region 
(domain C2 Leu573 – Val654), and is present in human IMPG1, human IMPG2, mouse 
Impg1 and rat Impg1.29,42-44 According to a secondary structure prediction programme 
(http://www.embl-heidelberg.de/predictprotein) the Leu579Pro mutation has no major 
effect. The IMPG1 amino acid residues 568 - 571 are predicted to form a coiled coil; the 
residues 572 - 582 form a beta-sheet, which is followed by a coiled coil (residues 583 - 586). 
The Pro for Leu exchange at 579 merely predicts a stronger beta-sheet for residues 578-582. 
An LCA5 family has been tested for mutations in IMPG1, but no alterations have been 
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found.23 In patients from 6q linked multigeneration families diagnosed with PBCRA and 
MCDR1, as well as a single patient from an autosomal dominant STGD pedigree unlinked 
to either of the two known STGD2 and STGD3 loci on chromosomes 13q and 6q, 
respectively, no disease associated mutations were identified in the IMPG1 gene.9 The 
IMPG2 gene could not be implicated in 40 patients with LCA, 92 patients with RP, and 92 
patients with age-related macular degeneration.41   
In summary, the BCAMD phenotype, which progresses from a parafoveal 
hypopigmentation with good visual acuity into a RP-like entity, apparently is caused by a 
gene defect residing at chromosome 6. IMPG1 represents an excellent functional candidate 
gene for BCAMD at chromosome 6 and the Leu579Pro mutation may play a causal role. 
However, additional patients with BCAMD and RP need to be analyzed to establish 
causality for the IMPG1 gene.  
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ABSTRACT 
 
The objective of this study is to describe the clinical and genetic findings in a family with a 
peculiar autosomal dominant macular dystrophy with peripheral deposits. All family 
members had an ophthalmic examination and their genomic DNA was screened for 
mutations in the peripherin/RDS and rhodopsin genes. In selected cases fluorescein 
angiography and electrophysiologic testing was performed. The age of onset of the disease 
was between the third and fourth decade, starting with mild visual acuity loss and periods 
of metamorphopsia. Clinical signs included subretinal yellowish macular deposits 
evolving into geographic atrophy and retinal hypo- and hyperpigmentations. 
Electroretinography demonstrated rod dysfunction and electrooculograms were mildly to 
severely disturbed. All affected members were found to carry a 3-base pair deletion 
affecting codon 169 of the peripherin/RDS gene. This mutation resulted in an asparagine 
(Asn) deletion in the peripherin/RDS protein and was not found in 155 control 
individuals. We conclude that a deletion of Asn169 in the peripherin/RDS protein causes a 
peculiar form of autosomal dominant macular dystrophy in a large family from The 
Netherlands. 
 
INTRODUCTION 
 
Autosomal dominant hereditary macular dystrophies can be categorized into many types, 
often clinically subdivided by descriptive fundus signs and electrophysiologic findings. In 
general, age of onset, bilateral appearance, slow progression, gradual loss of visual acuity 
and central visual field loss characterize these dystrophies.1 No entirely satisfactory 
categorization of the hereditary retinal dystrophies has yet been established. Identification 
of molecular causes reveals a high degree of genetic and allelic heterogeneity.2 One of the 
best examples of allelic heterogeneity is the human retinal degeneration slow 
(peripherin/RDS) gene.3 To date 70 different mutations in the peripherin/RDS gene have 
been associated with a spectrum of retinal phenotypes. They can be grouped into four 
broad categories: adRP, digenic RP, progressive macular dystrophy and pattern 
dystrophy.4 The mutations account for approximately 3-8% of all adRP cases, 7-10% of 
central retinal dystrophies and 18% of adult-onset vitelliform macular dystrophy cases.5-8 
Most mutations are restricted to single families and show a broad phenotypic spectrum in 
patients7; some mutations even cause intrafamilial variability in clinical expression.9 In this 
study we describe the ocular features of several members of a family from The 
Netherlands, which invariably carry a novel 3-base pair (bp) deletion in the peripherin/RDS 
gene. 
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METHODS 
 
Clinical studies 
This family originates from the northeastern part of The Netherlands and some members 
are known to us for over 25 years. We examined 20 family members from two generations. 
Their medical histories were obtained and subsequent ophthalmic examination included 
best corrected Snellen visual acuity, fundus examination and fluorescein angiography. 
Five patients underwent electroretinography, among which three patients (III-2, III-4, IV-
2) were tested according to the International Society for Clinical Electrophysiology of 
Vision protocol (ISCEV) (http://www.iscev.org). In eleven family members with the 
deletion in the peripherin/RDS gene, electrooculography was performed. Six of them were 
tested according to the ISCEV protocol (http://www.iscev.org). The ERG (individuals III-
1, III-10) and EOG tests, which were not done according to the ISCEV protocol, were 
performed in the past in different laboratories. Informed consent was obtained from all 
subjects involved in the study. 
 
Molecular genetic studies 
Blood samples were obtained from 19 family members and their genomic DNA was 
isolated as described elsewhere.10 For mutation analysis of the peripherin/RDS gene, 25 ng 
of genomic DNA was amplified using the polymerase chain reaction, under the following 
conditions: initial denaturation 5 min at 95 OC, denaturation for 30 sec at 94 OC, annealing 
for 30 sec at 55 OC, extension for 1 min at 72 OC, and a final extension for 5 min at 72 OC. 
For peripherin/RDS exon 1, part a (cDNA nucleotides 209 – 484)3, we used the forward 
primer 5’-GTGGGAAGCAACCCGGAC-3’, and the reverse primer 5’- 
AGATCTTCCCAGCCAGCG-3’. For exon 1, part b (cDNA nucleotides 431 – 673)3, we 
employed the forward primer 5’-TGATAGGGATGGGGGTGC-3’, and the reverse primer 
5’CTGTGTCCCGGTAGTACTTC-3. For exon 1, part c (starting at cDNA nucleotide 611)3, 
we used the forward primer 5’-GCTCGCTGGAGAACACCCT-3’ and the reverse (intron 1) 
primer 5’-TCTGACCCCAGGACTGGAAG-3’.3 The primers used to amplify exon 2 and 
the forward primer to amplify exon 3 have been described elsewhere.5 For exon 3, the 
reverse primer 5’-TGCACTATTTCTCAGTGTTCG-3’ located at cDNA nucleotides 1305 to 
1325 of the 3’ untranslated region was used. The amplified fragments were subjected to 
sequence analysis. To screen for the presence of the deletion in control individuals and to 
analyze the segregation of the deletion in the pedigree, we used the same primers for part 
c of exon 1 as mentioned above. PCR products were labeled with the incorporation of 
α[32P]-dCTP and size separated by electrophoresis in a 6.6% denaturing polyacrylamide 
gel. After drying of the gels, bands were visualized by overnight exposure to Kodak X-
OMAT S films. In total 155 Dutch individuals, who had been randomly chosen at the 
blood bank, were tested. The primers and conditions used to perform sequence analysis of 
the rhodopsin gene have been described elsewhere.11 
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RESULTS 
 
Clinical Findings 
The pattern of inheritance in the family is consistent with autosomal dominant inheritance. 
Dominant X-linked inheritance can be excluded since there are seven father-to-son 
transmissions of the genetic defect (Fig. 4.1).  
 
 
Figure 4.1 Pedigree and segregation analysis of the 3-bp deletion of the peripherin/RDS gene. 
Heterozygous carriers can be distinguished from non-carriers, since they carry a 3-bp shortened fragment. 
Four carriers (IV-4, IV-5, IV-6, IV-10) have not developed clinical symptoms yet. Individual IV-3 was not 
tested. 
 
We examined all known clinically affected family members except individual II-1 and II-2 
(Table 4.1). Complaints of metamorphopsia started in the fourth decade for all affected 
persons, but macular changes were already seen in the third decade in individual IV-1. 
Visual acuity varied from 20/100 to 20/16. Seven cases had periods of metamorphopsia 
and/or paracentral scotomas. Six cases complained of night blindness, of which two 
individuals since the age of 19 and 20 years (III-8 and III-10). Two other individuals 
without any fundus changes (IV-4, IV-10) had very mild complaints of nightblindness, but 
no other visual symptoms. We classified the retinal findings into three stages, varying 
from small subretinal macular deposits in stage I (individuals IV-1, IV-2, IV-3, IV-9) and 
butterfly shaped macular lesions or lesions with a scrambled-egg appearance 
accompanied by 0.1 disk diameter large mid-peripheral non-elevated deposits in stage II 
(individuals III-4, III-6, III-7, III-8, III-10), to large atrophic scarring in stage III (individuals 
III-1, III-2) (Fig. 4.2). Fluorescein angiography showed a small area of central 
hypofluorescence surrounded by a hyperfluorescent rim in stage I. In stage II this 
developed into a more pattern dystrophy-like hypo/hyperfluorescent central lesion. The 
peripheral deposits seemed hyperfluorescent and did not always correspond to the 
deposits visible by ophthalmoscopy. In stage III the central choroidal vessels became 
visible within the lesion due to chorioretinal atrophy and the central atrophic area was 
surrounded by a mottled hyperfluorescence (Fig. 4.2). In individuals III-3, III-5, III-9, IV-4, 
IV-5, IV-6, IV-7, IV-8 and IV-10, fundus examination demonstrated no abnormalities. 
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Table 4.1 Clinical characteristics of the affected family members and four clinically 
unaffected family members, which harbor the 3bp deletion 
 
Pedigree 
Number 
Clinically
affected 
Age (y) of    
onset and exam.
VA 
OD 
VA 
OS 
Symptoms Fundus  
I,II,III 
ERG EOG 
(Arden)
III-1 yes 38  68 20/25 20/25 metamorphopsia, 
nightblindness 
III sco:AN 
pho:N 
ODS: 1.0
III-2 yes 30-40 65 20/100 20/50 metamorphopsia, 
paracentral scotomas 
III sco:AN 
pho:AN 
ODS: 1.0
III-4 yes 36 64 20/30 20/20 metamorphopsia, 
nightblindness, 
paracentral scotoma 
II sco: AN
pho:N 
ODS: 1.4
III-6 yes 35 49 20/20 20/16 metamorphopsia, 
nightblindness 
II - - 
III-7 yes 30-40 48 20/20 20/20 metamorphopsia II - - 
III-8 yes 20 44 20/40 20/40 nightblindness II - ODS: 1.0
III-10 yes 19 60 20/20 20/20 nightblindness, 
metamorphopsia 
from 39y 
II sco:N 
pho:N 
- 
IV-1 yes - 24 20/16 20/16 no complaints I - OD: 1.4 
OS: 1.3 
IV-2 yes 35-40 40 20/20 20/20 metamorphopsia, 
nightblindness 
I sco:N 
pho:N 
OD: 4.0 
OS: 2.9 
IV-3 yes ? 38 20/20 20/20 unknown I - ODS: 1.3
IV-4 no 30-35 35 20/20 20/20 mild nightblindness N - ODS: 1.7
IV-5 no - 20 20/16 20/16 no complaints N - OD: 2.0 
OS: 2.2 
IV-6 no - 16 20/20 20/20 no complaints N - ODS: 2.2
IV-9 yes ? 39 20/20 20/20 unknown I - OD: 1.7 
OS: 1.5 
IV-10 no 30 30 20/20 20/20 mild nightblindness N - - 
Y = year, VA = visual acuity, ERG = electroretinogram, EOG = electrooculogram (Arden ratio), sco = 
scotopic, pho = photopic, AN = abnormal, N = normal 
 
 
In cases III-1, III-2 and III-4, ERG testing demonstrated pathologic b-wave amplitudes for 
dark-adapted rods (Table 4.2). The b-wave amplitudes for cones and the maximal dark 
adapted combined responses were diminished in III-2 (Table 4.2). Individuals III-10 and 
IV-2 showed normal scotopic and photopic ERG values (data not shown). EOG testing was 
normal in three cases (IV-2, IV-5, IV-6). The Arden ratio was between 1.5 and 2.0 in two 
(IV-4, IV-9) and below 1.5 in six (III-1, III-2, III-4, III-8, IV-1, IV-3). Individuals III-6, III-7, 
III-10 and IV-10 were not tested. 
 
 
 
 
 
 
          MACULAR DYSTROPHY CAUSED BY AN ASN 169 DELETION IN THE RDS GENE 
 
  105
                      
 
                      
 
                      
 
 
Figure 4.2 A: Fundus photograph of patient IV-2 at age 37 years (stage I). B: Fluorescein angiogram of 
patient IV-2 at age 37 years (stage I). C: Fundus photograph of patient III-4 at age 52 years (stage II). D: 
Fluorescein angiogram of patient III-4 at age 52 years (stage II). E: Fundus photograph of patient III-2 at age 
65 (stage III). F: Fluorescein angiogram of patient III-2 at age 65 (stage III).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
     106
Table 4.2 Electroretinographic Findings 
 
 
 
 
 
Scotopic b-wave 
amplitudes 
(p99:>70µV,         
M: 223µV) 
Photopic b-wave 
amplitudes 
(p99:>69µV,        
M: 156µV) 
Max. dark adapted 
combined responses 
(p99:>195µV, M: 424µV) 
 OD OS OD OS OD OS  
III-2 28.9µV 
 
18.0µV 
 
36µV 49µV 125µV 144µV 
III-4 68.9µV 
 
62.5µV 
 
92.1µV 85.7µV 288.2µV 261.8µV 
III-1 28.0µV 
  
40µV 144µV 149µV - - 
 
 
 
Molecular Genetic Findings 
Direct sequencing of the PCR products from cases III-4 and III-10 revealed a 3-bp deletion 
in exon 1 of the peripherin/RDS gene affecting either codon 168 or 169, both coding for 
asparagine (Fig. 4.3). According to the nomenclature for the description of human 
sequence variations, the most 3' copy is arbitrarily assigned to have been changed in case 
of deletions in amino acid stretches, so we state the deletion involves codon 169.12 This 
novel deletion was found in all affected individuals and in four non-symptomatic 
individuals of this family (Fig. 4.1), but not in 155 control individuals (data not shown). 
Individual IV-3 was not tested. In addition the sequence variant 558C→T (Val106Val) was 
found representing a previously reported synonymous mutation.13 The rhodopsin gene 
showed no disease causing mutations. 
 
 
 
Patient
III-4
Control
Asn
169
Nt 737 Asn
168
 
 
 
Figure 4.3 Sequence analysis of
the aberrant allele of patient III-4
(top) and of a control individual
(bottom). A 3-bp deletion results in
the deletion of an asparagine (Asn)
          MACULAR DYSTROPHY CAUSED BY AN ASN 169 DELETION IN THE RDS GENE 
 
  107
DISCUSSION 
 
This family demonstrated a retinal dystrophy characterized by an age of onset in the third 
to fourth decade, with a typical history of periods of metamorphopsia and paracentral 
scotomas, mild visual acuity loss, subretinal macular deposits, which slowly evolved into 
lesions resembling geographic atrophy in age related macular degeneration and posterior 
pole deposits. Upon ophthalmoscopy, these deposits did not always correspond to the 
angiographic appearance. Possibly, lesions showed blocked hypofluorescence due to 
accumulation of lipofuscin, with adjacent small areas of atrophy causing 
hyperfluorescence. EOG values were normal or subnormal in the beginning (stage I) but 
gradually became abnormal in later stages (stages II, III). The scotopic ERG was abnormal 
in stages II and III.  
Currently 21 loci (12 cloned genes) are associated with non-syndromic autosomal 
dominant dystrophies of the retina and choroid with primary involvement of the macular 
area (http://www.sph.uth.tmc.edu/Retnet/disease.htm). The phenotype of the family 
presented here differs from all of them. The first stage of our dystrophy resembles 
AVMD.14 In AVMD the age of onset is in the middle age group, the progression of visual 
loss is slow, patients complain of metamorphopsia, the EOG is often reduced and fundus 
features consist of bilateral symmetrical and slightly raised small yellow subretinal 
lesions.14 Families with AVMD may display an autosomal dominant pattern of 
inheritance.15,16 All these features are compatible with the dystrophy in the family 
described here, but incompatible features are also seen. In our family the EOG became 
non-recordable in later stages, while in AVMD the EOG findings stay normal or 
subnormal.15 Abnormal scotopic ERGs as observed in several individuals of our family are 
not found in patients with AVMD. AVMD is known to be associated with mutations in the 
peripherin/RDS gene and in the vitelliform macular dystrophy (VMD2) gene. 8,17,18  
Similarities with Best disease are the progression of the foveal lesions to scrambled-egg 
appearing lesions and the diminished EOG values.19,20 Nevertheless, the characteristic 
configuration of the early lesions in Best disease, often already seen in children between 
the ages of five and fifteen, including the intact egg-yolk and pseudohypopyon cyst and 
the “fluid-level” appearance of the fluorescein staining within the lesion are not seen in 
any of our family members. Furthermore, the ERG in Best disease is normal, while in some 
of our family members the ERG was disturbed.20 Best disease is associated with mutations 
in the VMD2 gene.17,18 Another entity from which this family needs to be differentiated is 
dominant slowly progressive macular dystrophy.21 In these patients the age of onset is in 
the fifth decade, but the visual acuity remains good until the seventh decade. Several 
patients have visual acuity fluctuations and metamorphopsia. Obvious retinal changes 
include perifoveal pigment epithelial atrophy, posterior pole flecks, and lesions 
resembling an atrophic form of age related macular degeneration. The ERG is normal or 
has slightly reduced photopic as well as scotopic responses. Nevertheless, the EOG is 
normal in these patients and this entity has recently been found to be associated with 
CHAPTER 4 
 
     108
mutations in the elongation of very long fatty acids 4 (ELOVL4) gene.22 For other dystrophies 
with subretinal deposits, distinguishing features involving the clinical history, 
electrophysiologic findings and form and distribution of deposits, are easily found. These 
dystrophies include autosomal dominant Stargardt disease, caused by mutations in the 
ELOVL4 gene and the prominin (mouse)-like 1 (PROML1) gene at 4p, macular drusen, 
caused by mutations in the epidermal growth factor-containing fibrillin-like extracellular matrix 
1 (EFEMP1) gene, and butterfly shaped dystrophy, caused by mutations in the 
peripherin/RDS gene.22-26 Half of the mutations found in the peripherin/RDS gene are 
identified in families with diseases of the central retina but in a few of these families 
deposits in the peripheral retina are found.9,27,28 Within two of these families clinically 
disparate phenotypes are observed. These vary from retinitis pigmentosa, pattern 
dystrophy, fundus flavimaculatus in a family with a 3-bp deletion of codon 153 or 154 of 
the peripherin/RDS gene9 to Stargardt disease, dominant drusen, adult vitelliform 
dystrophy and retinitis pigmentosa in a family with a P210R mutation of the 
peripherin/RDS gene.27 In three families with point mutations at codon 172 of the 
peripherin/RDS gene and macular dystrophy with peripheral deposits, normal rod 
electrograms are found, while our family demonstrates rod dysfunction.28     
It is likely that the novel peripherin/RDS deletion of codon 169, resulting in a 
deletion of asparagine, is associated with the clinical presentation in this family. Four 
individuals, IV-4, IV-5, IV-6 and IV-10, varying in age from 16 to 35 years, with normal 
results of fundus examinations have been found to harbor the 3-bp deletion in the 
RDS/peripherin gene. Two of these (IV-4 and IV-10) had mild complaints of nightblindness. 
Most likely these individuals will develop more symptoms in the future, although we 
cannot rule out non-penetrance in some cases.  
Peripherin/RDS, an integral membrane glycoprotein, is exclusively expressed in 
the outer segments of both rod and cone photoreceptor cells and is thought to play a role 
in morphogenesis and maintenance of the disk structure of the photoreceptor outer 
segments.29,30 The majority of mutations is located in the large second intradiscal loop. 
Some of the adRP associated mutations affect protein folding and subunit assembly, which 
might lead to the inability of the peripherin/RDS mutant protein to form intermolecular 
disulfide bonds which are required for oligomerization.31 Oligomerization and 
dimerization of the peripherin/RDS protein are necessary for the maintenance of a 
flattened photoreceptor disc morphology.32 This is critical for the visual process, since disc 
flattening maximizes the area available for photoreception and allows efficient renewal of 
the rod outer segments. The in-frame deletion found in the present family is located in the 
large second intradiscal loop and might affect the disc flattening through the mechanism 
described above, precipitating the retinopathy in this family. It has been described that 
peripherin/RDS molecules carrying the P216L and C165Y mutation are unable to flatten 
membrane vesicles, implicating such mutations as the primary cause of RP.32 On the 
contrary, the R172W peripherin/RDS mutation, associated with macular dystrophy and 
also located in the second intradiscal loop, has no effect on the expression, dimerization, 
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glycosylation, and subunit assembly of the peripherin/RDS molecule.31 This could mean 
that R172W peripherin/RDS-ROM1 complexes can form in vivo and that a relatively 
subtle change in their structure undermines their function in cone, but not rod 
photoreceptors. These findings are consistent with the fact that only a subset of the retinal 
photoreceptors (cones), appears to be affected.31 Further analysis of the asparagine 
deletion in peripherin/RDS should allow elucidation of the structural defect in the 
protein.  
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ABSTRACT 
 
Butterfly-shaped macular dystrophy (BSMD) has so far only been associated with 
mutations in the peripherin/RDS gene. The initial aim of our study was to investigate the 
peripherin/RDS gene as the causative gene in a family with BSMD. Subsequently the 
putative involvement of the ROM-1 gene, 4 genes expressed in cone photoreceptors, all 
known non-syndromic macular, retinal pigment epithelium and choroidal dystrophy loci, 
all known Leber congenital amaurosis loci and all known non-syndromic congenital and 
stationary retinal disease loci was examined  
Thirteen members from the original family with autosomal dominant BSMD were 
examined. The protein coding exons of the peripherin/RDS gene were screened for 
mutations by sequence analysis. Linkage analysis was performed using markers flanking 
the peripherin/RDS gene to rule out the presence of a heterozygous deletion. Likewise, 
involvement of the ROM-1 gene, four cone genes, 41 non-syndromic retinal disease loci 
and one syndromic retinal disease locus was investigated.  
Sequence analysis of the peripherin/RDS gene revealed no mutations. In addition, the 
BSMD phenotype could not be genetically linked to the peripherin/RDS gene, the ROM-1 
gene and the four cone genes nor to any of the 42 retinal disease loci.  
So this study reveals genetic heterogeneity for BSMD by the identification of a BSMD 
family, which is not associated with a mutation in the peripherin/RDS gene nor with any 
other known non-syndromic retinal disease gene. 
 
INTRODUCTION 
 
Butterfly-shaped pigment dystrophy of the fovea, also named butterfly-shaped macular 
dystrophy, was described for the first time by Deutman and coworkers1 and is 
characterized by bilateral accumulation of pigmented or yellowish material at the level of 
the retinal pigment epithelium. Lesions consist of 3 to 5 “wings”, resembling the wings of 
a butterfly. Fundamental for the diagnosis are a subnormal EOG, a normal or only slightly 
diminished visual acuity and an autosomal dominant inheritance pattern. Older patients 
can suffer from markedly reduced visual acuity due to large retinal atrophic lesions in the 
macular area.2 Several entities including BSMD, reticular dystrophy, macroreticular 
dystrophy, fundus pulverulentus, and adult-onset foveomacular vitelliform dystrophy 
belong to a group of autosomal dominant dystrophies of the RPE, known as pattern 
dystrophies.3-7 Variability of expression of pattern dystrophy has been described within 
families and in a single patient during various stages of the disease.8-11 So far BSMD has 
only been associated with mutations in the peripherin/RDS gene.12-19 The purpose of this 
study is to screen the original BSMD family for mutations in the peripherin/RDS gene and 
to examine putative involvement of the ROM-1 gene, four cone expressed genes, all 
known non-syndromic autosomal dominant and recessive macular, RPE and choroidal 
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dystrophy loci, all known Leber congenital amaurosis (LCA) loci and all known non-
syndromic congenital and stationary retinal disease loci.  
 
METHODS 
 
Thirteen individuals from the original Dutch BSMD family were included in this study. 
An informed consent was obtained from all participating individuals. The medical 
histories were obtained from two unaffected and 8 affected individuals. Subsequent 
ophthalmic examination included best corrected Snellen visual acuity, slit-lamp 
biomicroscopy, fundus examination and fluorescein angiography. Five patients (II-1, II-3, 
II-4, II-8, III-1) underwent electroretinography and eight affected individuals EOG. ERG 
and EOG were recorded and interpreted as previously described.1,20,21 In three patients 
EOG was performed according to ISCEV protocol (http://www.iscev.org/). In addition 
five patients (II-1, II-3, II-4, II-8, III-1) underwent colour vision and dark adaptation 
testing.  
For molecular analysis, blood samples of all participating individuals were 
collected and DNA was isolated as described elsewhere.22 For mutation analysis of the 
peripherin/RDS gene, 25 ng of genomic DNA was amplified using the polymerase chain 
reaction (PCR), under the following conditions: initial denaturation 5 min at 95 °C, 
denaturation for 30 sec at 94 °C, annealing for 30 sec at 55 °C, extension for 1 min at 72 °C, 
and a final extension for 5 min at 72 °C. For peripherin/RDS exon 1, part I (cDNA 
nucleotides 209 – 484), we used the forward primer 5’-GTGGGAAGCAACCCGGAC-3’, 
and the reverse primer 5’-AGATCTTCCCAGCCAGCG-3’.23 For exon 1, part II (cDNA 
nucleotides 431 – 673), we employed the forward primer 5’-TGATAGGGATGGGGGTGC-
3’, and the reverse primer 5’-CTGTGTCCCGGTAGTACTTC-3’.23 For exon 1, part III 
(starting at cDNA nucleotide 611), we used the forward primer 5’-
GCTCGCTGGAGAACACCCT-3’ and the reverse (intron 1) primer 5’-
TCTGACCCCAGGACTGGAAG-3’.23 For exon 2, we used forward primer (derived from 
3' end of the first intron) 5'-AAGCCCATCTCCAGCTGTCT-3' and reverse primer (derived 
from 5' end of the second intron) 5'-CTTACCCTCTACCCCCAGCTG-3'. For exon 3 we 
used forward primer (derived from 3' end of the second intron) 5'-
AGATTGCCTCTAAATCTCCTC-3' and reverse primer 5'-
TGCACTATTTCTCAGTGTTCG-3', located at cDNA nucleotides 1305 to 1325 of the 3' 
untranslated region.24 Mutation analysis of the peripherin/RDS gene was performed by 
direct sequencing using a BigDye Terminator chemistry on an ABI Prism 377 (PE Applied 
Biosystems). Flanking microsatellite markers were chosen from the Généthon database25 to 
investigate the peripherin/RDS locus, the ROM-1 locus, 19 autosomal dominant macular, 
RPE and choroidal dystrophy loci, 9 autosomal recessive macular, RPE and choroidal 
dystrophy loci and 8 LCA loci (Tables 5.1 and 5.2). 
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Table 5.1 Autosomal dominant macular, RPE and choroidal dystrophy loci, listed by 
chromosomal location and the microsatellite markers used for linkage analysis. 
 
Chrom. 
Location 
Locus Gene Phenotype Markers  
1q25-q31 ARMD1 - Age-related macular 
degeneration 
D1S238, F13B, D1S2683 
2p16-p21 DHRD EFEMP1 Dominant drusen /  
Doyne honeycomb retinal 
dystrophy  
D2S1771, D2S123 
4p                STGD4 - Stargardt disease D4S2957, D4S431, D4S394 
D4S3048, D4S419, D4S230 
6p21.1 COD3 GUCA1A Cone dystrophy D6S1680, D6S1582 
6p21.2-cen - RDS Adult vitelliform macular 
dystrophy 
Central areolar choroidal 
dystrophy 
Cone-rod dystrophy 
Pattern dystrophy 
D6S1680, D6S1582, 
D6S1651 
6q CORD7 - Cone-rod dystrophy D6S1681 
6q14 STGD3 ELOVL4 Stargardt disease D6S1681, D6S1609, 
D6S1613 
6q14-q16.2 MCDR1 
PBCRA 
- North Carolina macular 
dystrophy 
Progressive bifocal 
chorioretinal atrophy 
D6S1613, D6S300, 
D6S302  
6q25-q26 RCD1 - Cone dystrophy D6S290, D6S305 
7p21-p15 CYMD - Cystoid macula dystrophy D7S2493, D7S673 
11p15 
 
AA - Atrophia areata / 
chorioretinal degeneration 
D11S1318, D11S4149 
11q13 VMD2 VMD2 Best disease D11S1883, PYGM, 
D11S987 
17p13 CACD - Central areolar choroidal 
dystrophy 
D17S1528, D17S1876 
17p13.1 CORD6 GUCY2D Cone-rod dystrophy D17S1876, D17S786 
17p13.1 - AIPL1 Cone-rod dystrophy D17S1876, D17S786 
17p13-p12 CORD5 - Cone-rod dystrophy D17S786, D17S945 
17q11.2 - UNC119 Cone-rod dystrophy D17S798, D17S250 
19q13.3 CORD2 CRX Cone-rod dystrophy D19S867, D19S572 
22q12.1-
q13.2 
SFD TIMP3 Sorsby's fundus dystrophy D22S281, D22S421 
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Table 5.2 Autosomal recessive macular, RPE and choroidal dystrophy loci and Leber 
congenital amaurosis loci, listed by chromosomal location and the microsatellite markers 
used for linkage analysis. 
 
Chrom. 
Location 
Locus Gene Disease Markers  
1p31 LCA2 RPE65 Leber congenital amaurosis D1S246, D1S430 
1p21-22 STGD1 ABCA4 Stargardt disease, cone-
rod dystrophy 
D1S424, D1S497 
1q12-24 CORD8 - Cone-rod dystrophy D1S506, APOA2, 
D1S194 
1q31-q32.1 - CRB1 Leber congenital amaurosis F13B, D1S238, D1S2683
4p16.2 - PROML1 Retinal degeneration D4S3048, D4S419 
6q11-q16 LCA5 - Leber congenital amaurosis D6S1681, D6S1609, 
D6S1613, D6S300 
8p11 CORD9 - Cone-rod dystrophy D8S1771, D8S1810, 
D8S87, D8S1737 
10q24 - RBP4 RPE degeneration D10S583, D10S603 
10q26 - OAT Gyrate atrophy D10S534, D10S187 
12q13-q14 - RDH5 Cone dystrophy D12S1618, D12S1691 
14q11 - RPGRIP1 Leber congenital amaurosis D14S50, D14S1032, 
D14S80 
14q24 LCA3 - Leber congenital amaurosis D14S999, D14S287, 
D14S48, D14S81 
15q26 - RLBP1 Bothnia dystrophy D15S115, D15S202 
17p13-p12 RCD2 - Cone-rod dystrophy D17S786, D17S945 
17p13.1 LCA4 AIPL1 Leber congenital amaurosis D17S1876, D17S786 
17p13.1 LCA1 GUCY2D Leber congenital amaurosis D17S1876, D17S786 
19q13.3 - CRX Leber congenital amaurosis D19S867, D19S572 
 
 
Furthermore 8 autosomal dominant and recessive congenital and stationary retinal disease 
loci and four chromosomal regions harboring cone photoreceptor expressed genes were 
examined (Tables 5.3 and 5.4). Finally, one syndromic autosomal recessive retinal 
degeneration locus at 4q24 (MTP) was tested using microsatellite markers D4S414 and 
D4S411. Samples were subjected to PCR amplification, with a standard cycling profile of 
30 cycles at 94°C, 55°C and 72°C with 30 seconds at each step. DNA markers were labeled 
by the incorporation of α[32P]-dCTP and the products were separated by electrophoresis 
on a 6.6% denaturing polyacrylamide gel. Haplotype analysis was performed and two-
point LOD scores were calculated using the subroutine Mlink of the Linkage package.26-28 
Multipoint analysis was performed using FASTLINK version 2.30.29,30 A gene frequency of 
0.0001 and a penetrance of 95% were assumed for the disorder.  
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Table 5.3 Autosomal dominant (AD) and recessive (AR) congenital and stationary retinal 
disease loci, listed by chromosomal location and the microsatellite markers used for 
linkage analysis. 
 
Chrom. 
Location 
AD/
AR 
Locus Gene Disease Markers 
3p22 AD - GNAT1 Congenital stationary night 
blindness 
D3S1298, D3S1289
3q21-q24 AD - RHO Congenital stationary night 
blindness 
D3S3607, D3S1292
4p16.3 AD CSNB3 PDE6B Congenital stationary night 
blindness 
D4S1614, D4S2957
7q31.3-q32 AD - OPN1SW Tritanopia D7S480, D7S635 
1p13.1 AR - GNAT2 Achromatopsia D1S248, D1S250 
2q11 AR ACHM2 CNGA3 Achromatopsia D2S113 
8q21-q22 AR ACHM3 CNGB3 Achromatopsia D8S275, D8S167 
15q23 AR ESCS NR2E3 Enhanced S-cone syndrome D15S131, D15S115
 
 
Table 5.4 ROM1 and cone specific genes, listed by chromosomal location and the 
microsatellite markers used for linkage analysis 
 
Chrom. 
Location 
Gene Markers 
11q13 ROM1 D11S1883, PYGM 
7q21 GNB2 COL1A2, D7S479, D7S646, D7S662, 
D7S2504 
10q24 PDE6C D10S583 
12p13 PDE6H D12S169, D12S364 
17q21 GNGT2 D17S1827, D17S1820, D17S1606 
 
 
 
RESULTS 
 
The clinical features are summarized in Table 5.5. Visual acuity was normal or nearly 
normal in all affected individuals except individual II-8, who had a visual acuity of 20/50 
in his right eye and 20/200 in his left eye, but he also suffered from a optic neuropathy, 
due to multiple sclerosis. Ophthalmoscopy revealed pigmented butterfly-shaped 
structures in both eyes in 6 affected individuals (II-1, II-3, II-4, II-8, III-1, III-4) (Figs. 5.1A, 
C). Individuals III-2 and III-5 had butterfly-shaped pigmentations in one eye, and small 
pigment alterations without any pattern in the other. The butterfly-shaped pigmentations 
seemed to be localized in the deeper layers of the retina in or near the RPE. The retinal 
vessels continued their course across the pigmentations. Individuals II-1, II-4 and II-8, 
which were 70, 71 and 65 years old respectively at examination, showed parafoveal 
chorioretinal atrophy, accompanied by peripheral bone spicule-like structures in II-1 and 
II-4 (Fig. 5.1D). Individual II-8 had developed some peripapillary atrophy. In individual II-
3 many peripheral reticular pigmentations were seen (Fig. 5.1E). Five patients had drusen-
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like alterations surrounding the butterfly-shaped pigmentations. Fluorescein angiograms 
demonstrated clearly outlined hypofluorescent butterfly-shaped structures in the macular 
area in all patients (Fig. 5.1B). 
 
Table 5.5 Clinical details of the BSMD family 
 
Pt.   Exam.
year 
Age 
 
Visual acuity Scotopic Photopic EOG DAE
     OD   OS  OD  OS  OD  OS  OD  OS  
II-1    ’68     
’95 
43 
70 
20/20 
20/25 
20/20 
20/20 
285 
-  
305 
- 
125 
- 
120 
- 
1.6 
- 
1.5 
- 
N 
- 
II-3    ’68     
’94 
42 
68 
20/20 
20/20 
20/20 
20/25 
205 
- 
285 
- 
135 
- 
110 
- 
1.0 
- 
1.0 
- 
N 
- 
II-4    ’68     
’01 
38 
71 
20/20 
20/20 
20/20 
20/20 
325 
- 
345 
- 
135 
- 
135 
- 
1.3 
- 
1.3 
- 
N 
- 
II-8    ’68     
’01 
32 
65 
20/25 
20/50 
20/20 
20/200 
320 
- 
260 
- 
130 
- 
120 
- 
1.85 
- 
1.95 
- 
N 
- 
III-1   ’68 14 20/25 20/25 435 355 145 120 1.4 1.45 N 
III-2   ’01 40 20/40 20/16 - - - - 1.35 1.41 - 
III-4  ’01 35 20/20 20/40 - - - - 1.44 1.46 - 
III-5  ’01 26 20/25 20/25 - - - - 1.78 1.65 - 
Scotopic: ERG scotopic b-wave amplitudes in µV (Normal: >200 µV) 
Photopic: ERG photopic b-wave amplitudes in µV (Normal: >80 µV) 
EOG: electro-oculography (Arden ration p95: >1.65) 
DAE: dark adaptation elevation 
 
The EOG was pathological (Arden ration p95: >1.65) in all patients over age 35 years, 
except for individual III-1, who already had a disturbed EOG from age 14. ERG, colour 
vision and dark adaptation were normal in all 5 patients tested. The normal ERG values of 
the scotopic and photopic b-wave amplitudes are stated in Table 5.5.1  
Direct sequencing of the PCR products of the three exons of the peripherin/RDS gene 
from cases II-8 and III-1 revealed no mutations. Using haplotype analysis, the 
peripherin/RDS gene could be excluded (Fig. 5.2). No haplotype could be deduced around 
the peripherin/RDS gene, that co-inherited with the BSMD phenotype. Notably, individual 
I-2 had not inherited the D6S426 / D6S1582 haplotype, that was shared by the other  
affected individuals. 
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Figure 5.1 A: Fundus photograph of patient III-5 at age 16 years showing a black butterfly-shaped structure. 
B: Fluorescence angiography of individual III-5, showing a striking pigmented structure in front of a brightly 
fluorescent choroid. C: Fundus photograph of patient II-4 at age 52 years showing a more or less butterfly-
shaped, slightly pigmented structure. D: Peripheral bone spicule-like structures and some parafoveal 
chorioretinal atrophy in patient II-4. E: Peripheral reticular pigmentations in patient II-3. 
 
 
 
 
The LOD score obtained by multipont linkage analysis was less than –2 in the entire 
D6S426 / D6S282 interval. Subsequently, the ROM-1 gene, the 4 cone genes, all 41 non-
syndromic retinal disease loci and the syndromic MTP gene at 4q24 could also be excluded 
by haplotype analysis and multipoint linkage analysis. A LOD score of –2 or less in the 
entire critical interval of the locus or surrounding the gene was taken as proof that the loci 
were not linked to the phenotype. Two loci (STGD4 and the GNB2 gene) could not be 
excluded by multipoint linkage analysis. The locus for STGD4 at chromosome 4p was 
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situated between markers D4S1582 and D4S2397. Using markers D4S2957, D4S431, 
D4S394, D4S3048, D4S419 and D4S230, multipoint LOD scores varying from –0.25 to –4.1 
were obtained. Haplotype analysis revealed three affected individuals that did not show 
the at risk chromosome 4 haplotype (data not shown). Markers D7S646 and D7S662, 
flanking the GNB2 gene demonstrated multipoint LOD scores varying from –0.5 to –1.6 
between these markers. Haplotype analysis however, revealed one affected and one 
unaffected individual who did not carry the same haplotype of the chromosome 7 interval 
containing the GNB2 gene (data not shown).   
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Figure 5.2 Pedigree and linkage analysis results of the BSMD family. The order of the markers is derived 
from the Généthon database.25 Markers D6S426, D6S1582, and D6S271 flank the peripherin/RDS gene at 
4.5 cM, 0 cM, and 1.2 cM, respectively. None of the haplotypes around the peripherin/RDS gene 
cosegregates with the BSMD phenotype. Haplotypes with brackets in generation I were deduced. Individual 
I-2 is either homozygous for the (1,4,4,5)-haplotype or by chance only transmitted this haplotype to her five 
children 
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DISCUSSION 
 
In this family with BSMD, the main clinical features were the butterfly shaped macular 
lesions, the relatively good visual acuity and the disturbed EOG, while the ERG, colour 
vision and dark adaptation were normal. Only in individual II-8 a diminished visual 
acuity was found but he also suffered from an optic neuropathy. BSMD shares important 
similarities with age-related macular degeneration, since in both an abnormal deposition 
of lipofuscin-like material at the level of the RPE is found, which results in the loss of the 
overlying photoreceptors.  
In several families with pattern dystrophy (among which BSMD), mutations have 
been found in the peripherin/RDS gene. These include the missense mutations Gly167Asp, 
Pro210Arg, Pro216Ser and Cys213Tyr, as well as the protein truncating mutations 
Gln331stop, a 4-base pair (bp) deletion at codon 140, a 2-bp frameshift deletion at codon 
290, a 2-bp frameshift deletion at codons 299/300, and a large deletion that removes exons 
2 and 3 of the peripherin/RDS gene.12-19 The BSMD family described in this study has no 
mutations in the peripherin/RDS gene. Sequence analysis would not be able to identify a 
heterozygous deletion of the peripherin/RDS gene. We therefore performed linkage 
analysis with markers flanking the peripherin/RDS gene, but found no fully cosegregating 
haplotypes. A Swiss family with pattern dystrophy has been reported in which the genetic 
defect shows no linkage to the peripherin/RDS gene nor to the rhodopsin gene, but the 
phenotype of this family has not been described.31  
Because peripherin-2, the protein product of the peripherin/RDS gene form a 
heterotetramer with ROM-1, the ROM-1 gene was considered a candidate gene for BSMD. 
The heterotetrameric peripherin-2/ ROM-1 complex is important for rod photoreceptor 
disk morphogenesis and mutations in both components result in a defective subunit 
assembly of the heterotetrameric peripherin-2/ROM-1 complex.32 Non-allelic 
heterozygous peripherin/RDS and ROM-1 mutations cause digenic RP.33 Linkage analysis 
however, excluded the involvement of ROM-1 in this BSMD family.  
The VMD2 gene, associated with Best disease, was considered another good 
candidate gene, because BSMD and Best disease have been found within the same patient 
and within the same family.8-10 Moreover Best disease and BSMD both share the presence 
of hyperpigmented material in the RPE, a subnormal EOG, a normal ERG and an 
autosomal dominant pattern of inheritance.34,35 The VMD2 gene is located on chromosome 
11q13.36,37 Nevertheless, this family showed no linkage to markers flanking the VMD2 
gene.  
Subsequent linkage analysis excluded all other macular, RPE and choroidal 
dystrophy loci, the LCA loci, the congenital and stationary retinal disease loci and 4 genes 
expressed in cones including the ß-subunit of guanine nucleotide binding protein (GNB2), 
the ß-subunit of guanine nucleotide binding protein (GNGT2) and the α and γ subunits of 
cone cGMP phosphodiesterase 6H (PDE6C and PDE6H).38-42   
CHAPTER 5                                                                                                                 
 
 122
In this study we present clear evidence of genetic heterogeneity for BSMD. We 
could exclude not only the peripherin/RDS gene, but all other known macular, RPE and 
choroidal dystrophy loci, all known LCA loci and all known congenital and stationary 
retinal disease loci. In the future we will expand the BSMD family, which will enable us to 
perform a whole genome linkage scan.  
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ABSTRACT 
 
The purpose of this study was to describe a clinical classification for autosomal dominant 
cystoid macular edema (CYMD), to refine the genetic localisation of the CYMD locus and 
to perform candidate gene analysis. Seventy-one members of a large Dutch CYMD family 
were examined. In addition, fluorescein angiography and electrophysiology was 
performed in selected cases. The CYMD locus has been positioned in a 20-cM interval at 
7p15-p21. Using an extended DNA marker set, we performed haplotype analysis, 
employing DNA of 135 family members. We performed sequence analysis of the exons 
and flanking intron sequences of five genes. 
The clinical classification for CYMD, that we propose in this study, is based on 
ophthalmoscopic and fluorescein angiographic findings, and correlates well with both age 
and visual acuity of the CYMD patients, as well as with the outcome of colour vision tests, 
perimetry and electro-oculography. Three clinical stages could be identified in CYMD. The 
genetic analysis enabled us to establish a shared haplotype refining the critical region to a 
3.8 cM/2.0 Mb interval between the markers D7S493 and D7S673 at 7p15.3. This interval 
contains 17 genes with a known or inferred function and 17 predicted genes. We could not 
identify mutations in the open reading frame of five genes: interleukin-6 (IL6), nucleoporin-
like protein 1 (NLP-1), glycoprotein neuromedin B (GPNMB), LOC115416 and LOC90693. 
 
INTRODUCTION 
 
In previous reports dominant cystoid macular dystrophy (CYMD, MIM 153880, Online 
Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim)   
previously referred to as DCMD or MDDC, has been established as a distinct chorioretinal 
dystrophy.1,2 CYMD is characterized by cystoid macular edema (CME) occurring in the 
first or second decade of life, a moderate to high axial hyperopia and a moderate to severe 
decrease in visual acuity.3-5 The visual acuity varies and can be influenced by intervening 
illness (e.g. fever) or feminine hormonal changes.6 Extensive genealogical studies revealed 
a common Dutch ancestor, that lived in the early 18th century.3 In addition, one unrelated 
Greek family and a Spanish woman with CYMD have been described.7,8  
 Retinal dystrophies often develop through a continuum of fundus alterations. In 
this study we propose a clinical classification for CYMD, which has not been described in 
prior publications, based on the findings in 71 affected family members. In addition we 
have refined the previously determined 20-cM critical region for CYMD on chromosome 
7p15-p21, and investigated five genes residing in the 2.0 Mb critical interval for 
mutations.9 
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MATERIALS AND METHODS 
 
Clinical examination 
We reviewed the records of 71 affected individuals. Informed consent was obtained from 
the participating family members. Clinical examination included ophthalmoscopy, 
fluorescein angiography, ERG, EOG, colour vision tests and visual fields examination. 
ERG and EOG were performed in 52 and 67 patients respectively, according to the 
International Society for Clinical Electrophysiology of Vision protocol 
(http://www.iscev.org/) or as previously described.10,11 Colour vision was tested in 53 
patients under standardized conditions (AO-H-R-R test, Ishihara edition 1970, Panel D-15, 
or Lanthony New Colour Test box 4, Farnsworth F2 plate, FM 100 Hue test and 
anomaloscope Nagel model II).3 The Goldmann perimeter was applied for kinetic 
perimetry in 27 patients (two stage I patients, 19 stage II patients and 6 stage III patients).  
 
Genotyping 
Genomic DNA of 52 family members, 28 of whom affected, was available through a 
previous study.9 Peripheral blood was collected from another 46 affected and 37 
unaffected individuals and DNA was extracted by standard procedures.12 In addition to 
the markers which were used before (D7S513, D7S507, D7S493, D7S529, D7S516, D7S435, 
D7S526),9 we employed the following markers for genetic fine mapping (from pter to qter): 
D7S2535, D7S2510, D7S629, D7S682, D7S673, D7S2444 and D7S2493. An amplification 
reaction was performed with 100 ng genomic DNA, 2.5 pmol of each primer, 200 µM of 
each dATP, dTTP, dGTP, and dCTP, 1×SuperTaq buffer (10 mM Tris-HCl pH 9.0, 50 mM 
KCl, 1.5 mM MgCl2, 0.1% (w/v) Triton X-100, 0.01% (w/v) gelatine) and 0.06 U SuperTaq 
(HT Biotechnology Limited, England). Cycling parameters consisted of 94°C for 4 min, 
followed by 30 cycles of 94°C for 1 min, 55°C for 2 min, 72°C for 1 min, and a final 
extension of 6 min at 72°C. The reactions were performed in a 96 wells thermal cycler (M.J. 
Research Inc.). Prior to amplification, one primer was end-labelled with γ32P-ATP and T4 
DNA polynucleotide kinase (Life Technologies). Samples were analysed after 
amplification on a 6.6% denaturing polyacrylamide gel (acrylamide: N,N’-methylene-
bisacrylamide 19:1), containing 100 mM Tris-borate, 2 mM EDTA pH 8.3 and 8.3 M Urea. 
The dried gels were exposed to Kodak X-OMAT X-ray film overnight at room 
temperature. 
 
Sequence analysis of positional candidate genes 
Exon flanking intronic primers were designed, using the sequences as deposited in 
Genbank or EMBL for the genes IL6 (NM000600), NLP-1 (NM007342), GPNMB 
(NM002510), LOC115416 (NM138446) and LOC90693 (NM138771) (Table 6.1). Nucleotide 
sequence analysis was performed with the dye terminator sequencing kit on an Applied 
Biosystems automated sequencer as described, both using DNA of patients (numbers 25 or 
75) and a control individual.13 
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Table 6.1 Primers (5’→3’) used to analyse the open reading frame of the genes IL6, NLP-
1, GPNMB, LOC90693 and LOC15416 
Interleukin 6 (IL6)                                                 
1F* GGGAACGAAAGAGAAGCTCTATC 1R† ACTGACAGCACAGCTGGGAG 
2F TCCCAGCTGTGCTGTCAGTCAC 2R ACCTCCTTATGCAGGCAGC 
3F ACTTAGGTGATAACAATTCTGG 3R TATACAGGACTGCATGCAAG 
4F CAAATTGATTCTATCTCCTGG 4R GGAAGTGGCATTGCATCCC 
5F CATCCCTCCACTGCAAAAGG 5R ATAGTGTCCTAACGCTCATAC 
 
Nucleoporin-like protein 1 (NLP-1) 
1F ACCTCCAGCCTTCCTGTAG 1R ACCAGCAGCGGGAAACAC 
2F CCAAGATCATGCCACTGTAC 2R GAAACAACAAAGATTGTAGGTG 
3F TCACACTTCTATAAACTTGTGC 3R CTCCTAGTTGTAGCTAAGTTG 
4F AAGTTTCTTCCTCATGGTTATG 4R AAAGATCATAGACCTCATCGG 
5F ACAAATAGGCCAAGTCAATGC 5R CCCTGACTCTTAAGTGATGC 
6F CCAAAGTGCTAGGATTACAGG 6R CAAATGTCTAATGAGTCAAATGC 
7F CGTCCGTCCAGTAAGCTTC 7R GTTCCAGTTCTTCTACTGTTAG 
8F CCTTTGGAGGTGGCAGTTC 8R ATCCTGAACATGAAGTCATGC 
 
Neuromedin B (GPNMB) 
1F TCCAACCTCTAGTTCAGAGG 1R CTTAATACCATCACATGATCC 
2F TTACCATCTACAAGACTTACTG 2R AACCACTGTGAGGTGATTAC 
3F AAGCACCTGTGATCATTAAGG 3R CATATGGGTCCTCTGGTCC 
4F GAAAGTTAGCAGGGTGACTG 4R TTCTGAGCCTAGATAACACTC 
5F TGGGCCAGATGCATTGTAAC 5R AGCTAGTCTTTAAGGAACAGC 
6F AATCACCGCAGAGTCCTTAC 6R CTAAAAGCATCGTCGAAGCC 
7F CCCTAGGTGGAGTCTAGC 7R ATTTCATAGTATAGTGTTCCTG 
8F AGACTTGAGGTCCTCAGTTG 8R CATTCAATCTATACCAGAGTG 
9F GCTTTAGTATGGGATACACAC 9R GTTTGAGTAACAATGAGGTGG 
10F CTATTTACACAGAGATATATTCAC 10R CCTCTAGGTGGAAGACATAAC 
11F GAAACAACTGTAAGTGAAATTG 11R GTCTTGCAAACTGTCAATCATG 
    
Alpha-1,3(6)-mannosylglycoprotein (LOC90693)    
1F GCTTCCTCATTCTGGGACTACATCC 1R TCCGCAGCAGCGGCCCTAG 
2F CGGAGCTGCGGGATGTAGATC 2R TGAGCCATTCTCATTACCGTCACAG 
3F GTCGTCTGTTCTGTTACTGATACAG 3R CCATCTTTAAACAGGGATTGGAGG 
4F TCCCTCAGATGACCCAGTAGTTGTT
C 
4R AGAGTTCCATGAATCCAGCATACTCC 
    
Hypothetical protein BC012331(LOC115416)   
1F TCTTCACGGGCTCCAGACTCC 1R TGGGACCTGACTCCAGACTGC 
2F TGCATACACGTCTATCTGCTTGGC 2R CACTGTCACTATTCCACTCAGTTAATGG 
3F GACCTTCAGCAAGAACAGGCTTC 3R CAATTCAAGATTAGCGTAGTACCAACAG
4F CTAGAGTTAGCCAGTGTGTGTTGTA
AGG 
4R CAAGGAGACGGACTTTAGGAGCTG 
*: forward, †: reverse 
 
 
RESULTS 
 
Clinical findings 
All 71 patients showed some degree of hyperopia, with a mean hyperopic refractive state 
of 4 to 5 diopters (range: +1 sph / +12 sph). Based on the ophthalmoscopic findings in 
combination with fluorescein angiography, we were able to distinguish three stages. Stage 
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I: fine folding of the foveal inner limiting membrane. In addition, capillary dilatation and 
angiografically proven CME had to be present. Stage II: ophthalmoscopically detectable 
CME without visible abnormalities at the level of the RPE. Stage III: atrophy of the RPE, 
within the region of overlying CME. In this stage peripheral pigmentary disturbances in a 
granular or reticular pattern, peripheral bone spicule-like pigmentations and attenuated 
arterioles are often present. In the second and third stage, a variable degree of whitish 
punctate deposits can be observed in the vitreous. 
Twenty patients (28%) fulfilled the criteria as mentioned for stage I. Thirty-four 
patients (48%) were classified as having CYMD stage II and the remaining 17 patients 
(24%) displayed CYMD stage III. The age distribution of these patients was 4-20 years for 
stage I, 21-50 years for stage II and 51 years or older for stage III. Three patients below the 
age of 51 (31, 45 and 48) were classified as stage III and one patient older than 20 (37) was 
classified as stage I. The visual acuity, the electrophysiological findings and perimetry 
with respect to the various stages of CYMD, are listed in table 6.2. Visual acuity was 
highly variable ranging from 20/20 to 20/100 in stage I, from 20/25 to counting fingers in 
stage II and from 20/50 to hand movements in stage III. The EOG Arden ratios were 
recorded in 67 patients. In stage I, the Arden ratios were normal (>1.8) in 16 patients 
(80%), subnormal (1.8-1.5) in one patient (5%) and clearly pathological (<1.5) in 3 patients 
(15%). In stage II, the Arden ratios were normal in 9 patients (27%), subnormal in 14 
patients (41%) and abnormal in 11 patients (32%). In stage III, the Arden ratios were 
subnormal in 3 patients (18%) and pathological in 10 patients (59%). The remaining 4 
patients (23.5%) were not tested. The ERG, recorded in 52 patients, was normal in 45 
patients. A subnormal ERG, without selective cone or rod impairment, was recorded in 
three stage II patients (8.8%) and in four stage III patients (23.5%). Visual fields were 
recorded in 27 patients. In the group of patients with stage I retinal dystrophy, one patient 
demonstrated a central sensitivity loss, while the other patient did not show any 
abnormalities. In the stage II group, 13 patients showed small central scotomas and six 
patients demonstrated central sensitivity loss. In stage III, perimetry revealed four patients 
with central scotomas and two patients with central sensitivity loss. 
The results of colour vision testing, recorded in 53 patients, depended on the site of the 
lesion in relation to the central fixation. Stage I patients demonstrated an anomaloscopic 
diminished red-sensitivity in 10 persons, corresponding with retinal damage at the central 
fovea. Patients in stage II (25 patients) demonstrated an acquired blue-yellow defect as 
long as fixation remained central. When visual acuity drops and eccentric fixation 
develops, as happens with stage II and III CYMD patients, a red-green defect in addition 
to the blue-yellow defect becomes apparent (18 patients).  
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Table 6.2 Classification of CYMD clinical features 
Stage Age (y)  VA Fundus/FAG EOG Visual fields CV 
I  4-20 20/20- 
20/100 
fine folding of the foveal 
inner limiting membrane and 
granular pigment dispersion. 
FAG: capillary dilatation and 
leakage in the macular area 
with CME. 
(sub)normal normal or 
central sensi-
tivity loss 
diminished 
red-
sensitivity 
       
II 21-50 20/25-
CF 
CME normal/ 
subnormal/ 
abnormal 
(mean: 1.5) 
central sensi- 
tivity loss, or 
small central 
scotoma 
BYD 
       
III >50 20/50- 
HM 
atrophy of the RPE within the 
region of prior CME. 
Peripheral pigmentary 
disturbances 
subnormal/ 
abnormal 
central sensi- 
tivity loss or   
central 
scotoma  
RGD/BYD   
y: years, VA: visual acuity, FAG: fluorescein angiogram, CME: cystoid macular edema, EOG: electro-
oculogram, CV: colour vision, BYD: blue-yellow defect, RGD: red-green defect 
 
 
We will now describe two representative cases for each stage of CYMD.  
Case 1, 5 year old boy, stage I. His visual acuity was 20/25 in the right eye with +4.0 sph = -
1.25 cyl x 145° and 20/25 in the left eye with +6.50 sph = -1.25 cyl x 60°. Ophthalmoscopy 
revealed fine folding of the foveal inner limiting membrane (Fig. 6.1A). The EOG and 
colour vision tests were normal; ERG and Goldmann perimetry were not performed.  
Case 2, 12 year old girl, stage I. Her visual acuity was 20/25 in the right eye with +10.0 sph = 
-2.0 cyl x 10° and 20/80 in the left eye with +10.0 sph = -1.25 cyl x 165°. Shortly after 
rubella vaccination, she had a fever and her visual acuity in the left eye temporarily 
dropped from 20/80 to 20/200. Fundus examination showed foveal reflex irregularities. 
Fluorescein angiography revealed capillary dilatation and leakage in the macular area 
resulting in CME (Figs. 6.1B,C). ERG and EOG were both normal and colour vision tests 
demonstrated a minor decrease in red sensitivity. Goldmann perimetry was not 
performed. 
Case 3, 24 year old male, stage II. His visual acuity was 20/100 in the right eye with +7.5 sph 
= -2.25 cyl x 10° and 20/60 in the left eye with +9.0 sph = -2.5 cyl x 175°. He experienced a 
loss in visual acuity since the age of 19. On ophthalmoscopy, irregularities of the foveal 
reflex could be observed. (Fig. 6.1D). Fluorescein angiography showed the presence of 
CME (Fig. 6.1E). The EOG Lp/Dt ratios were 1.6 in the right eye and 1.48 in the  
left eye. Colour vision analysis showed a blue-yellow defect and Goldmann visual fields 
revealed central sensitivity loss. ERG was not performed. 
Case 4, 31 year old female, stage II. Her visual acuity was 20/25 in the right eye with +1.25 
sph and 20/60 in the left eye with +3.0 sph = -1.0  cyl x 160°. She experienced visual loss 
since the age of 13. Both maculae showed characteristic abnormalities associated with 
CME. Fluorescein angiography confirmed hyperfluorescent microcystoid changes in the 
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right eye and a typical pattern of CME in the left eye (Figs. 6.1F,G). The EOG was 
subnormal (Lp/Dt ratios R.E.: 1.52, L.E.: 1.67). The ERG was normal and colour vision 
tests revealed a red-green defect in the left eye and a blue yellow defect in the right eye. 
Goldmann perimetry was not performed.  
Case 5, 51 year old female, stage III. Her visual acuity was 20/600 in the right eye with +3.0 
sph = -1.5 cyl x 60° and 20/1200 in the left eye with +5.0 sph = -2.5 cyl x 20°. The decrease 
in visual acuity was present for more than ten years. Punctate opacities in the vitreous of 
the right eye were seen. There was chorioretinal atrophy of both maculae and the retinal 
arterioles were slightly attenuated (Fig. 6.1H). Fluorescein angiography demonstrated a 
central hyperfluorescent area, surrounded by patchy hyperfluorescence (Fig. 6.1I). The 
scotopic and photopic ERG recordings were both subnormal and the EOG recording was 
also pathologic (Lp/Dt ratios R.E.: 1.0, L.E.: 0.8). Colour vision analysis revealed a severe 
mixed red-green and blue-yellow defect. Kinetic perimetry showed central scotomas with 
a maximum of 30˚ in both eyes with I-4-e target and superior peripheral limitations due to 
blepharoptosis  
Case 6, 69 year old female, stage III. Her visual acuity was 20/400 in both eyes with +3.5 sph. 
She experienced visual loss for more than 20 years. In both eyes, opacities were present in 
the vitreous. Ophthalmoscopy revealed large zones of chorioretinal atrophy, pericentral 
bone spicule formation and attenuated arterioles (Fig. 6.1J). On fluorescein angiography a 
central hyperfluorescent area, surrounded by patchy hyperfluorescence was seen (Fig. 
6.1K). The ERG was normal but the EOG was pathologic (Lp/Dt ratios in both eyes: 1.0). 
Colour vision testing demonstrated a severe red-green and blue-yellow dyschromatopsia. 
In both eyes, large central scotomas of approximately 20˚ were demonstrated with the I-4-e 
target. 
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Figure 6.1 Stage I: A-C, Stage II: D-G, Stage III: H-K. 
A: Fundus photograph of a 5 year old patient showing fine folding of the foveal inner limiting membrane. B: A 
12 year old patient with foveal reflex irregularities. C: Fluorescein angiography of the same 12 year old 
patient showing capillary dilatation and leakage in the macular area with CME. D: Central reflex irregularities 
in a 24 year old patient. E: Fluorescein angiography of the same 24 year old patient demonstrating CME. F: 
Cystic-appearing spaces which may well be fluid filled in a 31 year old patient. G: Fluorescein angiography of 
the same 31 year old patient showing CME. H: A 49 year old patient with atrophic appearances of both 
maculae and slightly attenuated retinal arterioles. I: Fluorescein angiography of the same 49 year old patient 
demonstrating a central area of atrophy of the RPE and choroid, surrounded by patchy hyperfluorescence 
due to atrophy of the RPE. J:  Zones of atrophy of the RPE, pericentral bone corpuscles formation and 
attenuated arterioles in a 69 year old patient. K: Fluorescein angiography in this 69 year old patient revealing 
a hyperfluorescent central area surrounded by patchy hyperfluorescence due to atrophy of the RPE. 
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Molecular genetic analysis 
 
Haplotype analysis 
The CYMD pedigree consists of 9 generations and was, for practical reasons, divided into 
9 branches (Fig. 6.2). Hundred and thirty-five individuals were genotyped using 
microsatellite markers from the 7p21-p15 region.  
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Figure 6.2 Simplified CYMD pedigree and haplotype sharing and recombination events determining the 
CYMD critical disease interval. Haplotypes of individuals from different pedigree branches (A-I). Individuals 
26, 37, 150, 238 and 250 show recombinations. The grey box indicates the shared alleles between different 
branches of the pedigree, suggesting the occurrence of recombinations in earlier generations. The critical 
disease interval is determined by a recombination event in individual 238 and the region of haplotype sharing 
(grey box), between the markers D7S493 and D7S673. 
 
 
At the telomeric side, recombinations were observed between D7S507 and D7S2535 in 
individuals 250 and 253, positioning the gene defect centromeric to D7S507 (Fig. 6.3A). 
This interpretation of the marker analysis was based on the assumption that individuals 
239 and 240 carried non-recombined chromosomes and that 250 and 253 carried 
recombined chromosomes. The alternative interpretation, non-recombined chromosomes 
in 250 and 253 and recombined chromosomes in 239 and 240, was equally probable, 
because it also required two recombinations. At the centromeric side, recombinations were 
observed in affected individuals 26 (Fig. 6.3B) and 150 (data not shown) and in unaffected 
individuals 37 (Fig. 6.3B) and 238 (Fig. 6.3A), positioning the CYMD gene defect telomeric 
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to D7S673. In a previous linkage study, Kremer and co-workers observed non-penetrance 
in two individuals.9 We identified the at-risk affected haplotype in one other healthy 
individual (data not shown). Fluorescein angiography confirmed his unaffected status. 
Based on the extended pedigree, penetrance was estimated to be 96%. 
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Figure 6.3 Haplotype analysis in two families of the CYMD pedigree. The haplotypes of the deceased 
individuals were deduced. A. Recombinations between D7S507 and D7S2535 can be seen in the affected 
individuals 250 and 253, defining the telomeric boundary, and between D7S682 and D7S673, in the 
unaffected individual 238, defining the centromeric boundary of the CYMD critical region. B. Recombinations 
between markers D7S516 and D7S435 in the affected individual 26 and between markers D7S673 and 
D7S2444 in the unaffected individual 37 define the centromeric boundary of the critical region. 
 
 
Haplotype sharing 
Kremer and co-workers described ‘historical’ recombinations within the family, which 
placed the CYMD gene defect centromeric to D7S493.9 Analysis of all affected individuals 
from the 9 branches of the CYMD family revealed haplotype sharing for markers D7S2510, 
D7S629, D7S682, and D7S673 (Fig. 6.2; shaded area). The extent of the shared haplotype 
confirmed our previous delineation of the critical region at the centromeric side based on 
recombinations in the unaffected individuals 37 and 238. These results yield a genetic 
interval for the CYMD gene defect of 3.8 cM, corresponding to a physical size of 2.0 Mb, 
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according to the human genome sequence draft (freeze November 2002) between markers 
D7S493 and D7S673. 
 
Sequence analysis of five positional candidate genes 
Based on the human genome sequence draft (http://genome.ucsc.edu: freeze November 
2002), the 2.0 Mb CYMD critical region between D7S493 and D7S673 contains 17 known 
genes, (in SWISS-PROT, TreMBL, mRNA and RefSeq) (Fig. 6.4), as well as 17 predicted 
genes based on exon prediction (data not shown). At the telomeric side, D7S493 resides in 
the DNAH11 gene, encoding the dynein, axonemal, heavy polypeptide 11. At the 
centromeric side, D7S673 is situated in the STK31 gene, encoding a serine/threonine 
kinase 31 isoform a. In order to identify the CYMD gene defect, we have initiated the 
sequence analysis of the 17 known genes based on SWISS-PROT, TreMBL, mRNA and 
RefSeq and in this study we selected five of these genes. IL6 was considered an attractive 
candidate gene because the involvement of a cytokine might also explain the occurrence of 
macular edema in other disorders, such as intermediate uveitis. The gene LOC90693, 
encoding alpha-1,3(6)-mannosylglycoprotein, was found to be photoreceptor enriched.14 
GPNMB is thought to be important for melanin biosynthesis and the development of the 
RPE and iris.15 The NLP-1 and LOC115416 genes were the first two of the 15 remaining 
genes with a known, unknown or inferred function, residing in the CYMD critical region. 
We designed exon-flanking primers for IL6, NLP-1, GPNMB, LOC115416 and LOC90693 
and sequenced the protein coding exons (table 6.1) of one of two patients (numbers 25 or 
75) and a healthy individual. Compared to the Genbank sequence and the sequence of a 
healthy control individual, we found one homozygous alteration (IVS1+42T>C) in the 
NLP-1 gene and three homozygous variants (IVS2-42A>G, c.481G>A (P130P) and IVS5-
26A>C) in the GPNMB gene. Three heterozygous variants (IVS2-16C>G, c.514C>T 
(D143D) and IVS7-30T>C) in the GPNMB gene did not segregate with the CYMD 
phenotype in the pedigree (data not shown) 
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DISCUSSION 
 
In this study, we propose a clinical classification into three stages for CYMD. This 
classification is based on ophthalmoscopic findings in combination with fluorescein 
angiography and correlates with both the age and visual acuity of the CYMD patients as 
well as with the outcome of colour vision tests, Goldmann perimetry and electro-
oculography (Table 6.2). In stage I the CME can only be detected with fluorescein 
angiography. The EOG is usually normal or slightly subnormal in this stage. In stage II the 
CME is visible on ophthalmoscopy. The EOG is moderately to severely disturbed, small 
central scotomas can be present and colour vision tests reveal a blue-yellow defect. Stage 
III is characterized by atrophy of the RPE limited to the region of CME and peripheral 
pigmentary disturbances in a granular or reticular pattern, peripheral bone spicule-like 
pigmentations and attenuated arterioles might be present. The EOG becomes pathologic 
(<1.5) in most cases, central scotomas might be present and, when eccentric fixation 
develops, a red-green defect appears in addition to the blue-yellow defect. In a minority of 
patients in stage II and III, a decrease in both scotopic and photopic ERG recordings is 
Figure 6.4 Genetic and physical map of the CYMD
critical region. Known genes based on SWISS-PROT,
TreMBL, mRNA and RefSeq are indicated by arrows.
These genes encode the following proteins:  DNAH11:
dynein, axonemal, heavy polypeptide 11;
DKFZp762L0311: hypothetical protein
DKFZp762L0311; GFR: guanine nucleotide factor for
Rap1; AF267861: EF1a-like protein; BC027978: similar
to LOC168778, IL-6: interleukin 6; TOM-7: probably
encoding a mitochondrial import receptor subunit TOM7
homolog; DRCTNNB1A: down-regulated by Ctnnb1 a;
SBBI26: hypothetical protein FLJ31828; NLP-1:
nucleoporin-like protein 1; GPNMB: glycoprotein
(transmembrane) neuromedin B; LOC115416:
hypothetical protein BC012331; KOC1: insulin-like
growth factor-II mRNA binding protein 3; BC026177:
hypothetical protein; HSU53209: transformer-1 alpha
(htra-2 alpha); LOC90693: alpha-1,3(6)-
mannosylglycoprotein; STK31: serine/ threonine kinase
31 isoform a. An additional 17 predicted genes are not
depicted. 
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found. These ERG findings suggest, together with the early deterioration of the EOG, a 
primary defect in the RPE, rather than in the neuroretina. However, studies of CYMD 
treatment with acetazolamide, which increases fluid resorption through the RPE, failed to 
show a beneficial effect. This might indicate that the RPE is not involved early in the 
disease process.16 Histopathological studies suggest primary pathologic processes at the 
Müller cells, but this also is not in accordance with the normal ERG in the early stages.17 
The gene defect in CYMD might interfere with capillary permeability resulting in a 
disturbance of the blood-retina barrier. Identification of the causative gene will give 
insight into the pathogenesis of CYMD, and perhaps shed light on the mechanisms 
causing CME in diseases such as uveitis, diabetes or following ophthalmic surgery.  
Currently there is no therapy with a long-term beneficial effect available for CYMD. 
In one study a patient with idiopathic CME was treated with octreotide, a synthetic 
analogue of the naturally occurring hormone somastatin, which resulted in a regression of 
the macular edema. However, two to four weeks after discontinuation of this therapy the 
CME reappeared with a gradual worsening of visual acuity.18 We are involved in an 
ongoing trial to evaluate the effects of this drug in these patients. The mechanism 
underlying the regression of the CME by octreotide is currently unknown, but it is 
suggested that there might be a direct effect on the endothelial cells of the macular 
capillaries. On the other hand, inhibition of growth hormone in association with an 
increase in production of insuline-like growth factor might also explain the beneficial 
effect of this somatostatin analogue.19 Although no definitive therapy exists to date, it is 
nevertheless important to detect CYMD in an early stage. An early diagnosis may have 
considerable impact on the life of a patient, for instance when certain career choices are 
considered. Early detection of this retinal disorder is possible with ophthalmoscopy and 
fluorescein angiography, but at this stage, only genetic analysis can make the definitive 
diagnosis. 
The genetic analysis of the expanded Dutch CYMD pedigree resulted in a refined 
critical region of 3.8 cM/2.0 Mb, flanked by the markers D7S493 and D7S673. We selected  
five out of 17 known genes, based on SWISS-PROT, TreMBL, mRNA and RefSeq (IL6, 
NLP-1, GPNMB, LOC115416 and LOC90693), all residing within the critical interval, for 
mutation analysis. CME is encountered in a variety of retinal disorders such as retinal vein 
occlusion, intermediate uveitis, diabetic retinopathy, as well as a late sequela of cataract 
surgery. Since inflammation is a constant factor when CME is concerned, a cytokine, such 
as IL6, was considered a good candidate gene. The LOC90693 gene product was found to 
be photoreceptor enriched,14 and GPNMB is thought to be important for melanin 
biosynthesis and the development of the RPE and iris.15 The NLP-1 and LOC115416 genes 
were the first two of 15 other genes with a known or inferred function that were analysed 
for mutations. All five genes revealed no putative CYMD-mutations, but we cannot 
exclude the presence of heterozygous deletions, nor the presence of promotor or intronic 
mutations.  
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 In conclusion, we identified three clinical stages in CYMD using ophthalmoscopical 
and fluorescein angiographical criteria. Furthermore, we refined the region of the CYMD 
gene defect to a 3.8 cM/2.0 Mb interval at 7p15.3 and excluded five positional candidate 
genes. In the future we will determine the nucleotide sequence of all exons of the genes 
located in the critical region. The elucidation of this gene defect will shed light on the 
development of CME in CYMD patients, and may be of value in unravelling the 
mechanisms underlying CME in general. 
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7.1 Elucidation of the molecular causes of autosomal dominant retinal dystrophies  
In the last decade linkage and candidate gene analysis resulted in the identification of 133 
loci and 87 genes involved in syndromic and non-syndromic retinal dystrophies 
(http://www.sph.uth.tmc.edu/Retnet). Eleven genes for adRP and 13 genes for various 
clinical subtypes of adMD were identified. The causative genes have not yet been 
identified in one adRP locus and 8 adMD loci. It is estimated that the cause of 50-75% of 
adRP and adMD resides in known disease genes. In order to elucidate the molecular 
causes of adRP and adMD in three and four families respectively, we employed several 
strategies depending on the size of the families and the distinction of the phenotype. Table 
7.1 summarizes the results. 
 
Table.7.1 Linkage analysis and candidate gene analysis in 8 families with ad retinal 
dystrophy 
 
Family  # 
 
Described 
in chapter 
Phenotype Linkage known loci 
 
 
Candidate 
gene analysis 
Pathologic 
mutation  
W99-123 2 and 7.2 AdRP 17p13.1-p13.3 (RP13) PRPC8 R2310K 
W00-234 8 AdRP absent - - 
W00-259 8 AdRP 14q11.2 (RP27) 
 
NRL 
RPGRIP1 
absent 
absent 
W00-314 4 and 7.3 MD 6p21.2-cen  RDS 
Rhodopsin 
N169 del 
absent 
W95-049 5 and 7.3 BSMD absent RDS absent 
W95-222 2 and 7.4 BCAMD 6p12.3-q16  
(STGD3, CORD7) 
 
ELOVL4 
GABRR1 & 2 
IMPG1 
RIM1 
absent 
absent 
L579P (?) 
absent 
W99-210 8 NCMD 6q14-q16.2  (MCDR1)
 
- - 
 
 
Thus, the chromosomal locus was found in five of eight families and the underlying 
defect was found in at least two of these families (W99-123 and W00-314), and possibly a 
third family (W95-222). 
RP and several adMD’s are genetically highly heterogeneous, and in many families a 
“unique” mutation segregates with the phenotype. Therefore the search for the molecular 
defect is time-consuming and costly. Genetic testing for adRP and several types of adMD 
is currently mainly carried out in research settings (positive results may confirm the 
diagnosis). However, when it concerns small families, in which a statistically significant 
LOD score of 3 cannot be reached, cosegregation of markers of a known locus with the 
phenotype is suggestive for linkage, but not conclusive (e.g. family W00-259). In small 
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families that show no cosegregation of the phenotype with a known locus (e.g. W00-234) 
the identification of new adRP genes needs to be awaited, because these families are not 
large enough to perform a genome linkage scan.  
 
7.2 Retinal degeneration caused by mutations in ubiquitously expressed genes 
(PRPC8, HPRP3 and PRPF31)  
In chapter 2, we described an adRP family, which demonstrated linkage with the RP13 
locus, and the PRPC8 gene was found to be mutated in this family and several other RP13 
families. The PRPC8 gene has an ubiquitous expression pattern. Most (30/49) of the genes 
implicated in retinal degenerations show retina-specific expression.1 However, several 
genes which are ubiquitously expressed have been associated with autosomal dominant 
retinal dystrophies, including EFEMP1, involved in dominant drusen, TIMP3, involved in 
SFD, and HPRP3, PRPF31, PIM1K and IMPDH1, all involved in adRP.2-9  Several other 
ubiquitously expressed genes are involved in X-linked or recessive retinal dystrophies.1 
An intriguing question is why mutations in the broadly expressed genes can result in 
specific retinal degenerations. In this chapter we will discuss three precursor RNA 
processing (PRP) genes: PRPC8, HPRP3 and PRPF31, associated with RP13, RP18 and 
RP11 respectively.4-6 These three genes encode spliceosomal proteins, providing important 
catalytic and regulatory functions for pre-mRNA processing. A defect in the splicing 
process, leading to photoreceptor degeneration, represents a novel mechanism of retinal 
degeneration. 
The process of intron-removal or pre-mRNA splicing occurs on the spliceosome, a 
dynamic RNA protein complex, consisting of small nuclear (sn) RNA-protein complexes 
(snRNPs) together with non-snRNP protein splicing factors. The snRNPs are composed of 
snRNA molecules attached to specific proteins like PRPC8, HPRP3 and PRPF31. They 
recognize and bind specific sequences (splice junctions or branch sites) and/or sequences 
in other snRNPs. The major spliceosomal snRNPs UI, U2, U5 and U4/U6 are responsible 
for splicing the majority of pre-mRNA introns (Fig. 7.1).10 The U1 snRNP recognizes and 
binds the splice donor site by base pairing. The U2 snRNP brings the two splice junctions 
close together and the U4/U6 and U5 snRNPs associate with this complex as a single tri-
snRNP particle to form the spliceosome. Subsequently, the intronic sequences are removed 
and their flanking exonic sequences are spliced together. Although the majority of introns 
are removed by the snRNPs U1, U2, U5 and U4/U6, a second type of spliceosome has 
been discovered: the U12-dependent spliceosome. U12-snRNPs excise AT-AC introns 
instead of introns flanked by the canonical GT-AG nucleotidesand comprise less than 1% 
of all introns.5,11 
 
                                        GENERAL DISCUSSION 
 
  145
Exon 2Exon 1 GU AGA5’ 3’
Pre-mRNA
Exon 2Exon 15’ 3’
U1
Exon 2
Exon 1 5’
3’A
U2
U1
Exon 2
Exon 1 5’
3’A
U1
U5U2
U4 U6
3’5’ Spliced mRNA
U5
U4 U6
PRPC8
HPRP3
PRPF31
Exon 1 Exon 2
GU AGA
 
 
Figure 7.1 The process of pre-mRNA splicing. U1 snRNP recognizes the splice donor site (GU), U2snRNP 
recognizes the branch site (A) and interaction between U1 snRNP and U2 snRNP, brings the two splice 
junctions close together. Thereafter U4, U5 and U6 snRNPs associate with the U1-U2 snRNP complex and 
finally the intronic sequences are removed 
 
 
Most of the proteins associated with snRNP particles have initially been 
characterized in yeast, among these are Prp8, Hprp3 and Prp31p, the yeast orthologs for 
the human proteins PRP8, HPRP3 and PRPF31. Yeast Prp8 protein is thought to be the 
core component of the U5 snRNP and required for the formation of the U4/U6-U5 tri-
snRNP.12 UV-crosslinking studies have shown that Prp8 may function as the principle 
anchoring factor for exons in the splicesome.13-16 Hprp3p is one of the proteins tightly 
associated with U4/U6 snRNP and mutations in its orthologue in yeast have been 
reported to cause U6 snRNA instability and prevent the splicing proces.17,18 Yeast Prp31p 
is involved in recruiting the U4/U6-U5 tri-snRNP to the pre-spliceosome complex and/or 
stabilizing these interactions to form the mature spliceosome complex.19,20 Interestingly, 
Hprp3p and Prp31p are the core components of the U4/U6 snRNP particle and Prp8 is the 
core component of the U5 snRNP particle, suggesting an important role for the U4/U6-U5 
tri-snRNP in the splicing of retinal transcripts. An early interaction between the U4/U6-U5 
tri-snRNP, the U1 snRNP and the 5’splice site has been observed and this could represent 
an important initial recruitment of the tri-snRNP to the pre-mRNA, which might be the 
rate limiting step in splicing.10,21,22 Western blot analysis and immunofluorescence 
microscopy of mammalian cells transfected with mutant PRPF31 revealed a reduced 
localisation of the protein into the nucleus, leading to a net reduction in concentration of 
functional PRPF31 protein in the nucleus.23 In highly metabolically active tissues such as 
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the retina, with a high rate of opsin turnover prior to disc shedding in the rods, efficient 
splicing may be crucial.24-26 Subnormal activity, or a low concentration of functional 
protein, can be deleterious for the rod outer segment structure and phototransduction. 
Possibly, low levels of rhodopsin cause retinal dystrophy as previously reported for mice 
with homozygous and heterozygous mutations in the rhodopsin gene, which is revealed 
only under conditions of elevated splicing demand.23 Another possibility is that the high 
rate of opsin production makes the rod photoreceptors highly susceptible for incomplete 
intron removal and the production of aberrant proteins. However, an in vivo assay of 
PRPF31 activity was designed to detect the presence of aberrant splicing or failure to splice 
by the mutant PRPF31, but neither was detected, suggesting that there is no dominant 
negative effect on the wild-type protein.23 Alternatively, there may exist yet unknown 
retina specific splice products that interact with these three proteins. Another possibility is 
that PRPC8 or PRPF31 and HPRP3 play important roles in the splicing of U12-dependent 
introns. The voltage-gated sodium and calcium channel α-subunits contain U12-
dependent introns and mutations in these genes cause numerous neuromuscular and 
neurological diseases.27,28 A number of U12-dependent introns occur within other gene 
families like the protein kinase superfamily, the matrilin family, the EF2 transcription 
factor family, the phospholipase C family, the transportin family, the diaphanous family 
and the cAMP-binding guanine nucleotide exchange factor family.29-31 Antibodies raised 
against PRPC8 immunoprecipitate both the major U2-dependent, and minor U12-
dependent spliceosomes. Other than the core Sm proteins, PRPC8 is the first splicing 
factor shown to be common to both spliceosomes.32 Detailed functional studies of human 
PRPC8 and the other pre-mRNA splicing genes are needed to elucidate this fascinating 
mechanism of retinal degeneration. 
 
7.3 Variable expression of mutations in the peripherin/RDS gene 
In Chapter 4 we have described the association of a peculiar macular dystrophy in a large 
family with a 3-basepair deletion in the peripherin/RDS gene. The peripherin/RDS protein 
is present in all vertebrate rod and cone photoreceptors examined to date and has an 
essential role in disc morphogenesis and maintenance.33-35 Various retinal dystrophies, as 
summarized in Table 7.2, are associated with mutations in the peripherin/RDS gene.36-48 A 
total of 76 different peripherin/RDS mutations has been reported (The Human Gene 
Mutation Database Cardiff at http://uwcmml1s.uwcm.ac.uk/uwcm/mg/  (Table 7.2). 
The same mutation can give rise to different phenotypes both within families and in 
separate families. The P216S mutation is associated with both RP and pattern dystrophy.49 
Likewise the K154 deletion is associated with RP, pattern dystrophy and fundus 
flavimaculatus in the same family.47 The W246R mutation causes RP and AVMD in the 
same family.50 The P210R mutation is associated with macular dystrophy (with peripheral 
involvement) and AVMD in patients from different families.51,52 The R46X mutation causes 
RP and fundus flavimaculatus in separate families.53,54 Clearly either the genetic 
background, environmental factors or both determine the phenotypic expression of 
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peripherin/RDS mutations. The macular dystrophies are associated with 19 protein 
truncating mutations, 32 missense mutations, or small in-frame deletions. On the contrary, 
RP is associated with only two protein truncating mutations and 25 missense mutations or 
small in-frame deletions. Protein truncating peripherin/RDS mutations might have a milder 
phenotypic effect through haploinsufficiency, while missense mutations might have a 
stronger phenotypic effect through loss of protein activity/function as a consequence of 
the mutant protein interfering with the function of the normal gene product of the 
corresponding allele (dominant negative mutations). For example, the P216L mutation 
causes adRP through a dominant negative effect on outer segments, possibly arising 
through the introduction of a new N-linked oligosaccharide chain, that may destabilize 
disk structure.55 However, the missense mutation C214S, a tetramerization deficient 
mutant, results in adRP primarily through a deficiency in the level of wildtype 
peripherin.56   
Although peripherin/RDS mutations are distributed throughout the protein, a 
weak clustering of 52 mutations (68%) can be seen in the second intradiscal loop D2 
(codons 123-264), which contains 40% of the protein. The D2 region appears to be 
particularly important for protein structure and it is suggested that discrete regions within 
the D2 region contain determinants for normal subunit assembly, which is essential for 
normal disc morphogenesis.58;59  The D2 loop also contains 7 conserved cysteine residues 
(Fig. 7.2). In the remaining part of the protein 6 nonconserved cysteins are present, but 
these have no apparent effect on dimer formation, folding or subunit assembly.60;61 In 
contrast, 6 of the conserved residues (C165, associated with adRP, C166, C213, both 
associated with pattern dystrophy, C214, associated with adRP and adMD, C222 and 
C250) are crucial for proper folding and subunit assembly, possibly through formation of 
intramolecular disulfide bonding. The conserved C150 residue is required for 
intermolecular disulfide bonding but not subunit assembly.60;62 For example the C150S 
mutant is incapable of forming intermolecular disulfide bonds, but does associate with 
ROM-1 into a heteroteramer, while the C214S mutant, as describe earlier, is unable to fold 
normally, interact with ROM-1 or self-assemble into tetramers, but instead forms a 
mixture of large aggregates and smaller components, which may be retained and 
degraded by the endoplasmatic reticulum and lead to retinal disease through 
haploinsufficiency. 
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 Table7.2 Mutation spectrum of the peripherin/RDS gene 
 
Phenotype Missense 
mutations 
In frame 
deletions 
Protein truncating  
AVMD M1p.?, P210R#, 
S212T, W246R***, 
V268I, G305D 
  
 Q224fsX299, Y258X, 
W316X 
Cone 
dystrophy 
 
S27F, S289L  K193fsX323 
Cone-rod 
dystrophy 
 
G170S, Y184S, 
K197E, V200E, 
N244H 
 R123fsX138, R203fsX255
Fundus 
flavimaculatus 
 
 K154del** R46X#,# 
Macular 
dystrophy 
(also CACD) 
 
I32V, Y141H, 
R142W, R172G, 
R172W, R172Q, 
P210R#, C214Y, 
P219R 
N169del P147fsX152, F275fsX276 
associated with 
IVS2+22ins7 
Pattern 
dystrophy, 
(non BSMD)  
D157N, C213R, 
P216S* R220Q, 
R220W 
M67del, 
K154del** 
D87fsX175, Y140fsX175,  
G208fsX217, 
Y234fsX299, Q239X, 
Y285X, IVS2+3A>T  
BSMD G167D, P210R  Ex2_3del, E300fsX   
 
Retinitis 
pigmentosa 
G68R, L126R, 
K153R, C165Y, 
N173V, W179R, 
G208D, P210S, 
F211L, S212G, 
C214S, P216L, 
P216S*  Q226D, 
N244K, W246R***, 
G266D 
C119del, 
K154del** 
V206-V209del, 
P219del,  
G305-L308del 
R46X#,#, L307fsX323,  
Digenic RP R13W, L45F, L185P   
RP/CRD64  M67_V69delins
 
I32fsX44 
RPA   W25fsX43 
AVMD; adult vitelliform macular dystrophy; CACD; central areolar choroidal dystrophy; BSMD; butterfly-
shaped dystrophy; RP; retinitis pigmentosa; CRD; cone rod dystrophy; RPA; retinitis punctata albescens; * 
**,***; mutations associated with different phenotypes in the same family; #,## ; mutations associated with 
different phenotypes in different families 
 
 
. 
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Figure 7.2 Topological model for peripherin/RDS in disc membranes. Nonconserved cysteines (open circles) 
are at positions 72, 81, 105, 118, 119, and 301; conserved cysteines (shaded circles) are present within the 
second intradiscal loop at positions 150, 165, 166, 213, 214, 222, and 250 
 
The deletion of N169 in the peripherin/RDS, associated with macular dystrophy 
(Chapter 4), is also located in the D2 loop. In the absence of a 3-dimensional structure of 
peripherin/RDS, no phenotype-genotype correlation can be made for the N169 codon, 
because several distinct mutations, which are located in this region, are associated with 
different phenotypes like RP, BSMD, CRD and macular dystrophy.  
Although the majority of mutations associated with retinal disease are located in 
the D2 region, the cytoplasmically oriented peripherin/RDS C terminus has been 
proposed to be critical for catalyzing membrane fusion processes in the outer segments.64 
The retinal phenotype of the rds mouse provides evidence for the role of peripherin/RDS 
in membrane effusion. In adult heterozygotes the rod outer segments are reduced in 
length and appear morphologically abnormal.60,65 Besides the C-terminus, the N-terminus 
may also contribute to the fusion process.64,66-68 Because the total number of tetramers in a 
single disc is comparable to the number of interdiscal filaments, it has been proposed that 
tetramers may serve as constituents of the bridging filaments for connecting adjacent 
discs.69-71   
Besides these retinal dystrophies resulting from a single defect in the peripherin/RDS 
gene (monogenic), mutations in this gene have also been linked to digenic RP. Digenic RP 
occurs when a heterozygous peripherin/RDS gene mutation (R13W, L45F, L185P) is 
inherited together with a heterozygous ROM-1 null mutation.57,72 Peripherin/RDS and 
ROM-1 both are tetraspanning membrane proteins, which assemble into noncovalent 
tetramers and higher order disulfide-linked oligomers (Fig. 7.3). The L185P mutant 
peripherin/RDS protein is incapable of forming homotetramers and corresponding higher 
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order disulfide-linked oligomers.57 Individuals who inherit this mutation along with a null 
allele in ROM-1 will have a level of peripherin/RDS containing oligomers below the 
critical threshold level required for the formation of stable outer segments. In individuals 
carrying the peripherin/RDS L185P mutation and no mutations in the ROM-1 gene, a 
significant amount of the mutant protein will assemble with the wildtype ROM-1 as well 
as the wildtype peripherin/RDS to form functional oligomers. These individuals 
apparently experience little if any photoreceptor degeneration. Individuals who inherit 
only the ROM-1 null allele, will only have half the amount of ROM-1, which will have no 
appreciable effect.73 In conclusion, it seems as if the level of functional oligomers is critical 
for stable photoreceptor disc formation.  
It has also been suggested that peripherin/RDS may serve as a component of 
anchoring filaments that link disc rims to the adjacent plasma membrane through a direct 
association between peripherin/RDS and the β-subunit of the cGMP-gated cation channel 
(Fig. 7.3).74  
 
Channel
Plasma membrane
Disc lumen
Peripherin/RDS-
ROM-1 oligomers
Exchanger
Peripherin/RDS-
disulfide complex
 
Figure 7.3 Diagram depicting protein/protein interactions involving the rod outer segment disc rim 
(peripherin/RDS-ROM-1 oligomers & disulfide linked peripherin/RDS complex) and plasma membrane 
proteins (cGMP-gated channel). The heterotetrameric cGMP-gated channel interacts with the Na/Ca-K 
exchanger. 
 
The cGMP-gated channel consists of two homologous subunits (CNGA and CNGB) that 
assemble in a heterotetrameric complex. The β-subunit contains a large cytoplasmic 
glutamic-acid rich region called GARP at its N-terminus which is not present in the α-
subunit.75-79 The cGMP-gated channel of photoreceptors plays a central role in 
phototransduction by controlling the flow of cations into the outer segment in response to 
light-mediated changes in intracellular cGMP. The GARP domain is also expressed in rod 
photoreceptors as two spliced soluble variants (GARP-1 and GARP-2), which also interact 
with peripherin/RDS oligomers, but their role remains to be established.74 In Chapter 5, 
genetic linkage studies in a family with butterfly shaped macular dystrophy (BSMD) are 
described. Although, until now, all BSMD families were found to be caused by mutations 
in the peripherin/RDS gene, we were unable to establish linkage between the underlying 
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gene defect and polymorphic markers flanking the peripherin/RDS gene.52,80-82 We also 
could not link the defect with the ROM-1 gene, nor with several genes expressed in cone 
photoreceptors. All known non-syndromic macular, retinal pigment epithelium and 
choroidal dystrophy loci, all known Leber congenital amaurosis loci and all known non-
syndromic congenital and stationary retinal disease loci were excluded as well. In view of 
the interaction of peripherin/RDS with the cGMP-gated channel, the genes encoding 
CNGA and CNGB subunits and the genes encoding the retinal cone and rod-specific 
Na/Ca-K exchangers can be considered candidate genes for BSMD. Mutations in the 
CNGA1 gene at chromosome 4p12 and the CNGB1 gene at chromosome 6q13 have been 
identified in families with autosomal recessive RP.83,84 Variant alleles of the rod and cone 
Na/Ca-K exchanger genes, SLC24A1 at chromosome 15q22.31 and SLC24A2 at 
chromosome 9p22.1 respectively, were found, but none could be definitively associated 
with a specific retinal disease.62 It is possible that a dominantly acting mutation in one of 
these genes, is associated with BSMD. This can be tested with linkage analysis of family 
W95-049. Other candidate genes for BSMD might be identified by using the yeast two-
hybrid system in order to identify other proteins that bind to peripherin/RDS. 
 
7.4 The role of the interphotoreceptor matrix 
In chapter 3, we described a family with benign concentric annular macular dystrophy 
(BCAMD). Linkage analysis showed that the gene defect is located at chromosome 6p. 
Several candidate genes were tested and a base pair change, resulting in the amino acid 
change Leu579Pro, in the IMPG1 gene was identified, which cosegregated with the 
BCAMD phenotype and which was absent in 155 controls. Sequence analysis of 50040 kb 
in 82 unrelated individuals of different ethnic origin revealed that on average, one very 
rare sequence variant occurs every 57.6 kb, which is comparable to approximately 25 
genes (average size of a gene 2.3 kb).85 Whether the Leu579Pro amino acid substitution is 
pathologic remains uncertain in the absence of functional studies. 
IMPG1 is expressed as a glycoprotein in the human interphotoreceptor matrix (IPM), 
which is localized between the outer limiting membrane and the RPE. The IPM is 
composed of large proteins, glycoproteins, and proteoglycans.86,87 The IPM is thought to 
mediate interactions between the photoreceptors, the RPE and Müller cells. It is a major 
route by which nutrients and metabolites pass between photoreceptor cells and the 
choroid. For example, the interphotoreceptor retinol binding protein is a glycoprotein, that 
mediates the transport of the vitamin A derivative retinol between the RPE and the 
photoreceptors.88-91 In addition, IPM proteoglycans are thought to participate in the 
maintenance of normal retina-RPE adhesion and the integrity of photoreceptor cell outer 
segments.92,93 If human or primate retina is peeled off from the RPE, the matrix material 
will stretch markedly before breaking, suggesting a strong connection between the outer 
segments and the RPE.94 Photoreceptor-specific domains in the IPM have been identified, 
that contain different glycoconjugates surrounding cones versus rods. The cones are 
surrounded by a specialized sheath of matrix, that can be recognized histochemically by 
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the binding of peanut agglutin, which has a high affinity for galactose residues.95-97 Cone 
matrix sheaths remain attached to both RPE and photoreceptor cells when the neural 
retina is peeled off from the RPE.95,98 The rod matrix domains bind wheat germ agglutin, a 
lectin with high affinity for glucosamine and sialic acid residues.99-101 Possibly, the cone 
sheath insulates the cones from physical and or chemical interaction with the surrounding 
rods and vice versa. Their function may also involve the physical support for outer 
segments, facilitating the proper orientation of outer segment discs. Two major 
components of these matrix domains are expressed as chondroitin sulfate proteoglycans 
with 150 and 230 kDa core proteins, which are referred to as IMPG1 (IMP150) and IMPG2 
(IPM 200) respectively.102-105 Since IMPG1 is expressed as a glycoprotein in human IPM, 
but bares no chondroitin sulfate side chains, it is also called ‘sialoprotein associated with 
cones and rods’ (SPACR).106,107 Because of the sequence homology to SPACR and the 
presence of covalently linked chondroitin sulfate, IPM200 is also called SPARCAN.108 
SPACR and SPARCAN have functional hyaluronan-binding motifs. Hyaluronan is also 
distributed in the IPM, indicating an interaction of SPACR and SPARCAN with 
hyaluronan in the IPM.107,108 These proteoglycans may be anchored to hyaluronan for 
stabilization of the basic scaffold of hyaluronan within the IPM. There are also other 
hyaluronan-binding proteins in the IPM, Müller cells, RPE cells and in the cell membranes 
of the photoreceptor cells.109,110 Attachment of the hyaluronan scaffold to cells on both 
sides of the IPM may allow the IPM to form the structural link between the neural retina 
and the RPE. An antibody (MY-174) directed against SPACR in the photoreceptor layer 
showed that SPACR first appears by embryonic days 15-16 and expression is increased 
with developmental age, parallelling the adhesion between the neural retina and the RPE, 
suggesting that SPACR may be a functional adhesive between the neural retina and the 
RPE.111 It is also suggested that chondoitin sulfate proteoglycans may be involved in the 
maintenance of photoreceptor cells, because several studies of retinal degeneration in 
animal models have addressed the possibility of disturbed cell-IPM interactions in 
photoreceptor degeneration.112-114 For example, loss of IPM chondoitin 6-sulfate 
proteoglycan precedes detectable photoreceptor degeneration in the RCS rat and the MPS 
VII mouse.112,115,116 In addition, disruption of proteoglycan synthesis in vivo leads to the 
loss of cone matrix sheath-associated chondroitin 6-sulfate proteoglycans, IPM disruption, 
localized detachments and photoreceptor outer segment degeneration.92  
An alternative protein, important for cell-cell adhesion is cadherin.117 Recently a 
photoreceptor-specific cadherin (prCAD) was identified and an interaction between 
prCAD and matrix molecules, involved in the organization of the matrix sheaths and 
contributing to the photoreceptor-RPE adhesion, was suggested.118 In prCAD-/- mice, 
outer segments are disorganized and fragmented and there is a progressive photoreceptor 
death, suggesting that localized adhesion activity is essential for outer segment integrity. 
The data described here support the potential functional significance of the IPM. However 
complete knowledge of the IPM molecules that elicit retinal adhesion and photoreceptor 
survival will be of paramount importance for understanding the biology of the IPM in 
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pathologic processes such as photoreceptor degeneration. Genes encoding the IPM 
molecules present as good candidate genes for retinal dystrophies. 
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Results of linkage analysis and candidate gene screening in two small adRP families and a 
family with north Carolina macular dystrophy are described. 
 
Autosomal dominant retinitis pigmentosa 
Two small adRP families (W00-234 and W00-259) from Belgium (Figs. 8.1 and 8.2) were 
analysed for linkage, using markers from the known adRP loci, the BCAMD locus and the 
ROM-1 locus. The clinical examination was performed in Belgium.  
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Figure 8.1 AdRP family (W00-234) 
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Figure 8.2 AdRP family (W00-259): Cosegregation of two markers at chromosome 14q11.2 with the 
phenotype 
 
 
DNA samples of the family members were subjected to polymerase chain reaction 
amplification, using microsatellite markers as reported by Gyapay et al1, with a standard 
cycling profile of 30 cycles at 94ºC, 55ºC and 72ºC with 30 seconds at each step. The 
markers are described in Table 8.1. PCR products were labeled with the incorporation of 
α-[32P]-dCTP and size separated by electrophoresis in a 6.6% denaturing polyacrylamide 
gel. Haplotype analysis was performed and two-point LOD scores were calculated using 
the subroutine Mlink of the Linkage package.2-4 Multipoint analysis was performed using 
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FASTLINK version 2.30.5,6 A gene frequency of 0.0001 and a penetrance of 95% were 
assumed for the disorder. The markers used for of the linkage analysis are depicted in 
table 8.1. 
 
Table 8.1 Autosomal dominant RP loci, listed by chromosomal location and the 
microsatellite markers used for linkage analysis in two adRP families 
 
Chrom. 
Location 
Locus Gene Markers  
1q21.1 RP18 HPRP3 D1S250, D1S305, CRP 
3q21-q24 RP4 RHO D3S1589, D3S1273, D3S1541 
6p21.1-cen RP7 RDS D6S1616, D6S271, D6S1651 
6p12.3-q16 BCAMD - D6S257, D6S1609, D6S1570 
7p15.1-p13 RP9 PIM1K D7S673, D7S526, D7S484  
7q31.1 RP10 IMPDH1 D7S480, D7S2437 
8q11-q13 RP1 RP1 D8S166, PENK, D8S279 
11q12  ROM1 PYGM, CNTF 
14q11.2 RP27 NRL D14S50, HSMYHCOI, D14S1032 
17p13.3 RP13 PRPC8   D17S926, D17S1529, D17S1528 
17q22 RP17 - D17S787, D17S1290, HGH, D17S807 
17q25 - FSCN2 D17S787, D17S1290, HGH, D17S807 
19q13.3 - CRX D19S178, D19S867 
19q13.4 RP11 PRPF31 D19S180, D19S572 
 
All loci could be excluded by LOD scores of –2.0 or more for the W00-234 family, 
except for 19.q13.3 and 19q.13.4. Using haplotype analysis 19q13.3 could be excluded. 
Only one recombinant is found using haplotype analysis at chromosome 19q13.4, so some 
extra markers should be tested around the RP11 locus. 
Only 1q21.1 and 11q12 showed LOD scores of –2 or more for the W00-259 family. 
All other loci, except the locus at chromosome 14q11.2 had negative LOD scores and 
haplotye analysis showed no segregation between the markers around these loci and the 
phenotype. The markers D14S50 and HSMYHCOI, residing on chromosome 14q11.2, 
showed cosegregation with the phenotype (Fig. 8.2). Two candidate genes, located in that 
region were NRL and RPGRIP. NRL has been shown to upregulate the activity of the RHO 
promotor.7,8 RPGRIP1 is an interactor of the RP GTPase regulator (RPGR), which is 
involved in X-linked RP3.9-11 Mutations in this gene also have been found to be associated 
with Leber congenital amaurosis.12 
 
The NRL gene was tested using oliginucleotide primers (sense/antisense, 5’-3’):  
Exon 1: cacagatgacctcagagagctggcccttta / caggtgttaaagagggggttctaggtgagc, 
Exon 2: accatccctctggctttccaaactcttgct / gatctgattgctttcaagggaccttctccc  
Exon 3: gacctggcgctgacccggtttctgcattct / gccacccccaccagcccccactacaccaca 
with the following cycling profiles: exon 1 and 2: 94ºC for 3 min, 30 cycles of 94ºC for 30 
sec and 67ºC for 1 min, followed by a final cycle of 72ºC for 5 min (MgCl2 concentrations 
were 1.5 mM and 1.0 mM respectively). Exon 3: 95ºC for 1 min, 30 cycles of 94ºC for 30 sec 
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and 70ºC for 3 min, followed by a final cycle of 70ºC for 5 min (MgCl2 concentration was 
2.0 mM). No mutations were found in the coding region of NRL.  
The gene RPGRIP1, containing 25 exons, was screened for mutations, using primers 
and conditions, which can be obtained on request. No mutations were found in the coding 
regions.  
  
North Carolina macular dystrophy 
North Carolina macular dystrophy (NCMD) was first described in a large family living in 
the mountains of North Carolina as dominant macular degeneration and amino-aciduria,13 
but subsequently it was shown that the amino-aciduria segregated separately from the 
maculopathy.14 Families with “central areolar pigment epithelial dystrophy” and 
autosomal dominant central pigment epithelial and choroidal degeneration” were shown 
to be descendents of the original North Carolina family.15-19 Since then NCMD has been 
reported in unrelated families from Europe and Belize.20-24 The NCMD phenotype is a 
congenital maculopathy with a high degree of phenotypic variability which can be 
classified into three grades of severity based on fundoscopic appearance25;26. Grade 1 
NCMD patients have small non-progessive drusen-like lesions (< 50 µm) in the central 
macula and a normal to subnormal visual acuity (1.25-0.7). In grade 2 larger confluent 
lesions are seen with visual acuities ranging from 0.8 to 0.4. Some patients with grade 2 
lesions develop choroidal neovascular membranes with resulting disciform lesions of the 
macula and profound central visual loss. In grade 3 macular staphylomas or colobomas 
are seen, which are well demarcated, one to three disc diameters in size lesions, with sharp 
temporal shelved edges. In the base of the lesion the RPE seems either absent or 
depigmentated. Fluorescein angiography demonstrates the absence of the choriocapillaris 
with only the large choroidal vessels remaining. Peripheral retinal drusen are sometimes 
present. Depending on the severity of the lesion, these patients have visual acuities 
ranging from 0.5-0.1. Electroretinography, electro-oculography and colour vsion testing 
are normal.13-16 The youngest patient examined by Small et al. was a 4 months old baby 
with grade 3, which might suggest that the gene defect affects macular development.26 
Histopathology was performed in one patient with grade 2. A discrete macular lesion 
characterized by focal absence of photoreceptor cells and RPE with attenuation of Bruch’s 
membrane and focal atrophy of the choriocapillaris was seen with adjacent to the macular 
lesion some lipofuscin in the RPE.27 The gene defect was linked to chromosome 6q14-q16.2 
in the interval between markers D6S249 and D6S1671 25;26;28 and named MCDR1 (MC: 
macular, D: dystrophy, R: retinal, 1: first macular degeneration genetically mapped). The 
gene has not been identified yet. The interphotoreceptor maxtrix proteoglycan-1 gene 
(IMPG1) has been excluded as the disease causing gene.29 
We clinically examined a Dutch NCMD family (Fig. 8.3) and performed linkage 
analysis.  
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Fig. 8.3 MCDR1 family (W99-210) 
Individual I-1 showed some pigment alterations at ophthalmoscopy at the age of 70 years, 
but no other examinations were performed. Individuals II-1 and III-1 had complaints of 
vision loss. Visual acuity of individual II-1 was 0.7 in his right eye and 0.6 in his left eye at 
age 41 years. Visual acuity of individual III-1 at age 13 years was 0.7 in his right eye and 
0.5 in his left eye in. Ophthalmoscopy revealed coloboma in both patients (grade 3). ERG, 
EOG and colour vision testing were normal. Individuals III-2 and III-3 both had a visual 
acuity of 1.0 in both eyes at ages 10 years and 7 years respectively and ophthalmoscopy 
revealed confluent lesions (grade 2). Electrophysiologic examination was not performed.  
As expected, we found that the gene defect in this family co-segregated with markers 
(D6S1284, S3-201660, D6S1717, S5-336600 and D6S475) around the MCDR1 locus at 6q. 
Our family had an identical extended disease haptotype as a British NCMD family (tested 
by K. Zhang and associates). The search for the causative gene is still ongoing. 
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SUMMARY 
 
Retinal dystrophies are a heterogeneous group of diseases that lead to either partial 
or complete blindness. Clearly hereditary forms, like retinitis pigmentosa and various 
central retinal degenerations, affect approximately 1 in 3000 individuals. RP is 
characterized by photoreceptor cell degeneration, and patients present with night 
blindness and a gradual loss of peripheral visual fields, leading to tunnel vision and 
sometimes to complete blindness. Macular dystrophies consist of a range of retinal 
dystrophies that have been grouped on the basis of their primary pathology in the central 
retina. However, the primary defects are localized in different retinal cell types. Patients 
with macular dystrophies usually present with central vision loss and/or colour vision 
disturbances and/or metamorphopsia. 
The widespread application of linkage analysis and mutation detection techniques 
has revealed many genes or gene loci associated with retinal dystrophies, confirming the 
wide variety in phenotype, severity and mode of inheritance. Retinal dystrophies can be 
inherited in autosomal dominant, recessive, X-linked or digenic modes. In total, 78 distinct 
non-overlapping genes or gene loci have been implicated in non-syndromic retinal 
dystrophies. Of these, 12 are involved in adRP and 21 are involved in adMD. Cloning of 
these genes has shed light on retinal biosynthesis and structure, eye development, 
photoreceptor neurotransmission, phototransduction, pre-mRNA splicing, protein 
trafficking, the visual cycle, and the RPE. 
There are still many families (25-50%) with autosomal dominant retinal dystrophies 
that await the identification of the underlying gene defect. One Dutch family with adRP, 
and four Dutch families with adMD, have been clinically and genetically examined. The 
adRP family was found to be linked to chromosome 17p13.1-p13.3, the RP13 locus. A 
missense mutation (6970G>A; R2310K) was identified in exon 42 of the splicing factor 
gene PRPC8 in the affected members of this family (Chapter 2). The phenotype observed 
in this family was found to be similar to that described for three other RP13 families with 
mutations in PRPC8. The spliceosomal protein, encoded by PRPC8, has important catalytic 
and regulatory functions for pre-mRNA processing. A defect in such a ubiquitously 
expressed gene, affecting the splicing process and leading to photoreceptor degeneration, 
triggers a novel mechanism of retinal degeneration. 
A family with benign concentric annular macular dystrophy (BCAMD), an initial 
benign bull’s eye maculopathy which progresses to a RP-like phenotype, was found to be 
associated with chromosomal region 6p12.3-q16 (Chapter 3). Sequence analysis of the 
interphotoreceptor matrix proteoglycan 1 gene, IMPG1, residing in this region, revealed a 
single base pair change (T>C) of nucleotide 1866 in exon 13, resulting in a L579P amino 
acid substitution. This sequence variant was absent in 190 control individuals. SPACR, the 
glycoprotein encoded by IMPG1, has a functional hyaluronan-binding motif, and 
hyaluronan is also distributed in the IPM, which could indicate an interaction between 
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SPACR and hyaluronan in the IPM, possibly providing stabilization of the basic scaffold of 
hyaluronan within the IPM. 
A novel peripherin/RDS 3-base pair deletion, resulting in a N169 deletion of the 
predicted protein, was found in one large family with a peculiar macular dystrophy 
(Chapter 4). This gene is expressed in rod and cone photoreceptors, and its role most likely 
lies in stabilization of the highly curved rims, maintenance of a flattened disc structure 
through adhesive interactions, morphogenesis of disc membranes/rim regions, catalysis of 
disc shedding, and/or scaffolding of disc stacks. Interestingly, mutations in the 
peripherin/RDS gene cause variable progressive central and peripheral retinal dystrophies. 
Although specialized functional domains can be discerned in peripherin/RDS, allelic 
heterogeneity is clearly influenced by the genetic background, and possibly by 
environmental factors. 
The peripherin/RDS gene was also screened in a family with butterfly-shaped 
macular dystrophy (BSMD) (Chapter 5). Until now BSMD has only been associated with 
mutations in the peripherin/RDS gene. No mutations were detected in the peripherin/RDS 
gene of this BSMD family, and subsequently linkage analysis was performed with DNA 
markers flanking the ROM-1 gene; four genes expressed in cone photoreceptors; all known 
non-syndromic macular, retinal pigment epithelium and choroidal dystrophy loci; all 
known Leber congenital amaurosis loci; and all known non-syndromic congenital and 
stationary retinal disease loci. All these loci could be excluded. A genome-wide scan for 
the gene defect is currently being performed. 
A family with dominant cystoid macular dystrophy (CYMD), a very rare macular 
dystrophy, had previously been mapped to chromosome 7p. We refined the genetic 
interval to 3.8 cM, and excluded five candidate genes. In addition, we propose a clinical 
classification into 3 stages (Chapter 6). Although dominant CYMD is very rare, cystoid 
macular edema causes vision loss in various other eye pathologies, such as retinal vein 
occlusion, intermediate uveitis and diabetes, and as a complication following eye surgery. 
Elucidation of the CYMD gene defect might lead to a better understanding of the 
development of cystoid macular edema in these disorders. 
In addition to these findings, several small families with autosomal dominant 
retinal dystrophies, which were clinically and genetically examined, are described in the 
Addendum (Chapter 8) In one small adRP family, markers on chromosome 14q11 (RP27) 
cosegregated with the phenotype, but no mutations were found in the NRL and RPGRIP1 
genes. In a small family with North Carolina macular dystrophy, linkage was established 
to the known MCDR1 locus at chromosome 6p. Finally, another small adRP family was 
analysed, but no linkage to known adRP loci could be established.  
In conclusion, the identification of the entire set of genes associated with retinal 
dystrophies and genotype/phenotype correlations will facilitate clinical and molecular 
diagnosis, and aid in providing a more accurate prognosis of the disease progression. 
Genetic mapping and mutation screening in retinal dystrophy patients will reveal novel 
pathways for the development, structure and function of the visual system, leading to 
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better understanding of both normal and abnormal eye function and hopefully offering 
avenues for therapeutic intervention. 
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Netvlies dystrofieën vertonen een grote klinische en genetische variatie, en kunnen 
leiden tot gedeeltelijke of volledige blindheid. Erfelijke vormen zoals retinitis pigmentosa, 
en verschillende centrale macula dystrofieën hebben een incidentie van 1:3000. RP wordt 
gekenmerkt door de degeneratie van fotoreceptoren en patiënten hebben last van 
nachtblindheid en een geleidelijk uitbreidend perifeer gezichtsveld verlies, hetgeen 
uiteindelijk kan leiden tot kokerzien en soms tot volledige blindheid. Bij macula 
dystrofieën is primair de macula aangedaan, maar verschillende celtypen van het netvlies 
kunnen gedegenereerd zijn. Patiënten met macula dystrofie hebben meestal last van 
centraal verlies van gezichtsscherpte en/of kleurenzien stoornissen en/of metamorfopsie.  
Het gebruik van technieken als koppelingsonderzoek en mutatie analyse heeft 
geleid tot de ontdekking van veel genen of genloci die, geassocieerd zijn met netvlies 
dystrofieën. De ontdekking van al die genen is in overeenkomst met de grote variatie in 
fenotype, ernst en overervingsvorm van netvlies dystrofieën. Netvlies dystrofieën kunnen 
autosomaal dominant, autosomaal recessief, X-gebonden of digeen overerven. Acht en 
zeventig genen zijn geassocieerd met niet-syndromale netvlies dystrofieën. Van deze zijn 
12 genen geassocieerd met adRP en 21 met adMD. Deze genen zijn betrokken bij 
verschillende processen in verschillende structuren, zoals de biosynthese en structuur van 
het buitenste segment van de fotoreceptoren, de ontwikkeling van het oog, 
neurotransmissie, fototransductie, het “splicing” proces van pre-mRNA, het eiwit 
transport, de vitamine A cyclus, en processen in het pigment epitheel. 
Bij veel families (ongeveer 25-50%) is het gemuteerde gen nog niet ontdekt. In dit 
proefschrift worden een Nederlandse familie met adRP en vier Nederlandse families met 
adMD beschreven, waarbij klinisch en genetisch onderzoek is verricht. De familie met 
adRP kon gekoppeld worden aan chromosoom 17p13.1-p13.3, het RP13 locus. Een 
aminozuur verandering (R2310K) werd gevonden in het gen PRPC8 in de aangedane 
familieleden (Hoofdstuk 2). Het fenotype van deze familie was gelijk aan het fenotype van 
drie andere RP13 families met mutaties in PRPC8. Het spliceosoom eiwit, gecodeerd door 
PRPC8, heeft belangrijke katalyserende en regulerende functies voor het “splicing” proces 
van pre-mRNA. Fotoreceptor degeneratie, veroorzaakt door mutaties in het PRPC8 gen, 
dat breed tot expressie komt, ontstaat via een nieuw mechanisme.  
Koppelingsonderzoek in een familie met benigne concentrische annulaire macula 
dystrofie (BCAMD), een "bull’s eye" maculopathie, welke zich uiteindelijk ontwikkelt tot 
een RP-achtig beeld, leidde tot de identificatie van een chromosomaal gebied (6p12.3-q16), 
dat overerft met het ziektebeeld. (Hoofdstuk 3). Bij mutatie analyse van het 
“interfotoreceptor matrix proteoglycan 1” gen, IMPG1, welke in het kritische gebied op 
chromosoom 6 ligt, werd een nucleotide verandering gevonden in exon 13, hetgeen een 
L579P aminozuur verandering tot gevolg heeft. Deze variant in de sequentie werd niet 
gevonden in 190 controles. SPACR, het glycoprotein dat door IMPG1 wordt gecodeerd, 
heeft een belangrijke functie in de interfotoreceptor matrix.  
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In een familie met een bijzondere macula dystrofie, werd bij de aangedane 
familieleden een deletie van drie basenparen (Del N169) gevonden in het peripherin/RDS 
gen (Hoofdstuk 4). Dit gen komt tot expressie in staafjes en kegeltjes en is waarschijnlijk 
verantwoordelijk voor de stabilisatie van de gebogen randen van de “discs”, het behoud 
van de vlakke structuur van de “discs” in de fotoreceptoren, de ontwikkeling van de 
membranen van de “discs”, de katalysatie van het vernieuwingsproces van de “discs” 
en/of de geordende structuur van de gestapelde “discs”. Mutaties in het peripherin/RDS 
gen kunnen leiden tot een progressieve centrale of perifere netvlies dystrofie en mogelijk 
zijn bepaalde domeinen in het peripherin/RDS gen met een gespecialiseerde functie 
verantwoordelijk voor deze klinische variatie. Daarnaast kunnen ook de genetische 
achtergrond en omgevingsfactoren verklaren waarom er bij patiënten met dezelfde 
mutatie, soms zelfs binnen één familie, klinisch sterk uiteenlopende beelden worden 
waargenomen.  
Bij een familie met een vlindervormige macula dystrofie werd het peripherin/RDS 
gen ook geanalyseerd (Hoofdstuk 5). Tot dusver was deze vlindervormige macula 
dystrofie in andere families enkel geassocieerd met mutaties in het peripherin/RDS gen. 
Geen mutaties werden gevonden in onze familie met vlindervormige macula dystrofie, en 
daaropvolgend werd koppelingsonderzoek gedaan met markers rondom het ROM-1 gen, 
4 genen die in de kegeltjes tot expressie komen, alle bekende genen geassocieerd met niet-
syndromale vormen van macula, pigment epitheel en choroida dystrofie, alle bekende 
Leber congenitale amaurosis genen en alle bekende genen geassocieerd met congenitale, 
niet progressieve retinale ziekten. Al deze genen konden echter worden uitgesloten. 
Momenteel wordt een genoom scan verricht.  
Een familie met dominant cystoid macula oedeem (CYMD), een zeldzame macula 
dystrofie, was reeds eerder gekoppeld aan chromosoom 7p. Het kritische interval kon 
worden ingeperkt tot 3.8 cM en 5 kandidaat genen werden uitgesloten. Het CYMD 
fenotype werd verdeeld in 3 stadia (Hoofdstuk 6). Hoewel CYMD een zeldzaam 
ziektebeeld is, leidt cystoid macula oedeem vaak tot visus verlies in andere aandoeningen 
van het netvlies zoals veneuze occlusie, intermediaire uveitis en diabetes en ook na 
oogoperaties. Het identificeren van het gendefect voor CYMD zal mogelijk leiden tot een 
beter begrip van het ontstaan van cystoid macula oedeem in deze aandoeningen.  
Tevens zijn een aantal kleine families met autosomaal dominante netvlies 
dystrofieën, klinisch en genetisch onderzocht en beschreven in het addendum (Hoofdstuk 
8). In een kleine adRP familie bleken de markers op chromosoom 14q11 (RP27) over te 
erven samen met het aangedane fenotype, maar er werden geen mutaties gevonden in de 
NRL en RPGRIP1 genen. In een kleine familie met north Carolina macula dystrofie werd 
koppeling gevonden met het bekende MCDR1 locus op chromosoom 6p.Tenslotte werd in 
een kleine adRP familie geen koppeling gevonden met de bekende adRP loci.  
De identificatie van genen geassocieerd met netvlies dystrofieën en het maken van 
genotype/fenotype correlaties verbetert de mogelijkheden voor diagnostiek en het 
voorspellen van het ziekteverloop. Koppelingsonderzoek en mutatie analyse in families 
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met een netvlies dystrofie zal tevens meer inzicht geven in de ontwikkeling, structuur en 
functie van het visuele systeem. Dit zal leiden tot een beter begrip van het normale en 
zieke oog en mogelijk van belang zijn bij het ontwikkelen van therapeutische 
mogelijkheden. 
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En natuurlijk al de collega’s van Antropogenetica. Met name noem ik dan Bellinda, die 
veel werk voor mij gedaan heeft en altijd heerlijk enthousiast en vol vertrouwen was. 
Aangezien ik in het begin weinig ervaring had met werken op een laboratorium, was het 
zeer prettig collega’s te hebben, waar ik terecht kon met vragen, en die altijd bereid waren 
even mee te kijken of te helpen. Zeker ook, toen ik gedurende mijn zwangerschappen, 
bepaald werk niet veilig kon doen, was het zeer prettig collega’s als Bellinda, Ellen, 
Martijn en Wendy te hebben die geheel belangeloos dat werk voor mij overnamen. En ook 
van de computer expertise van Marc, Ronald en Anja Prischmann, heb ik regelmatig 
gebruikt gemaakt, bedankt daarvoor (en tevens Marc voor jouw bijdrage aan het in 
hoofdstuk 6 beschreven onderzoek). De families, die deelnamen aan dit onderzoek, wil ik 
graag bedanken, want zonder hen, was geen onderzoek mogelijk. Hopelijk zal uw inzet 
ooit beloond worden in volgende generaties met goede therapeutische mogelijkheden. 
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Pap en mam, hoewel jullie vaak vol bezorgdheid zijn over het drukke leven van mij en 
mijn gezin, kan ik altijd rekenen op steun van jullie op alle fronten. Tijdens mijn jeugd, 
hebben jullie mij altijd enorm gestimuleerd om mijzelf te ontwikkelen, en daarvoor heb ik 
van jullie ook altijd al de mogelijkheden gehad. Jullie toonden dan ook je interesse, door 
mij in Kenya en Amerika op te zoeken. Ook nu wordt het vieren van deze mijlpaal mede 
dankzij jullie mogelijk gemaakt! Pappie en mammie van Lith, ook jullie bedankt voor de 
interesse, de steun en de bevestiging, waarom het de moeite waard is te investeren in een 
gezin en een carrière! Onmisbaar tijdens dit onderzoek is iedereen geweest, die met veel 
liefde, warmte en flexibiliteit eerst Nino en later ook Jules hebben opgevangen. Monique, 
en haar familie, jullie zijn een tweede huis geworden voor Nino en Jules. En pap en mam, 
pappie en mammie, Catherine en Natascha, ook jullie ontzettend bedankt voor jullie hulp 
in de opvang van de twee mannetjes. Zusjes, broer, schoonzussen, schoonbroers, familie, 
vrienden en vriendinnen, bedankt voor jullie interesse, maar vooral voor al de andere 
gezellige vakanties, etentjes, feestjes etc. Hoewel het sociale leven met jullie het meest lijdt 
onder de combinatie werk en gezin, weet ik dat jullie er altijd zullen zijn! In het bijzonder 
mijn twee paranimfen, Bregje en Brenda. Bregje, je was, mede ook door je studie 
diergeneeskunde altijd geïnteresseerd in mijn onderzoek en ik vind het fijn dat je (mede 
namens Elke en Maarten) me vandaag bijstaat! En Brenda (en op de achtergrond Berith en 
Famke), we zijn allemaal andere dokters geworden (huisarts, radioloog en tropenarts), 
maar het was heerlijk om tijdens de studie en nu nog (hoewel schaarser) samen te 
discussiëren over de belevenissen in het ziekenhuis en daarbuiten. Daarom is het 
vanzelfsprekend, dat één van jullie mijn paranimf is!  
Nino en Jules, hoewel ik niet altijd bij jullie kan zijn door mijn werk, hoop ik dat ik jullie 
op welke wijze dan ook kan inspireren door mijn inzet en enthousiasme voor mijn werk. 
Jullie zijn mijn liefste mannetjes! Yannick, ik heb het je al vaker gezegd, iemand te hebben 
die zo in je gelooft, is de beste drijfkracht, die een mens kan hebben! Jij hebt mij met het 
grootste gemak uit ieder dal(letje) gekregen de afgelopen jaren! Voor jouw vertrouwen, 
liefde en het zijn van mijn allerbeste vriendje, wil je echt bedanken! Hou van je! 
 
Janneke 
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Janneke (Josefina Catharina) Verhoeven werd op 30 juli 1972 geboren te Tilburg. Haar 
gymnasium bèta opleiding volgde zij aan het Theresia Lyceum te Tilburg, waar zij in 1990 
haar eindexamen behaalde. Vervolgens studeerde zij Geneeskunde, aan de Vrije 
Universiteit in Amsterdam. Haar wetenschappelijk stage betrof “The relations between 
breastfeeding and infectious diseases in a rural area in Kenya” en zij werkte daarvoor 
gedurende 5 maanden in het St. Mary’s Hospital in Mumias, Kenya. Haar doctoraal examen 
haalde zij in oktober 1995. Gedurende haar co-schappen deed zij enkele buitenlandse 
onderzoekstages. In 1995 verbleef zij gedurende 3 maanden in Will’s Eye Hospital, in 
Philadelphia, Verenigde Staten, waar zij onder leiding van Dr. L.A. Donoso deelnam aan 
een familieonderzoek naar Stargardt disease. In 1996-1997 liep zij gedurende 6 maanden 
stage bij het Department of Cellular and Molecular physiology, School of Medicine, Yale 
University in New Haven, Verenigde Staten. Zij deed hier onder leiding van Prof. Dr. 
E.L.J.B Boulpaep onderzoek naar “The Role of Occludin, a barrier protein, localized at the 
tight junction of dissociated renal proximal tubule cells that maintain epithelial polarity in 
suspension”. Dit onderzoek kreeg in 1998 een vervolg in the Department of Cell Biology, 
University of Aarhus, Denemarken onder leiding van Dr. K.P. Maunsbach. Aan het einde 
van haar co-schappen deed zij haar keuze co-schap oogheelkunde bij the Department of 
Ophthalmology, aan de University of New South Wales, in Sydney, Australie. Daar werd 
haar keuze voor oogheelkunde bevestigd, mede dankzij het veldwerk, wat zij met de Flying 
Doctors heeft kunnen doen. Haar artsexamen behaalde zij in februari 1999. In maart 1999 
begon zij als artsonderzoeker bij de afdelingen Oogheelkunde en Antropogenetica van het 
UMC St. Radboud te Nijmegen aan het in dit proefschrift beschreven onderzoek. Per 1 
januari 2003 is zij begonnen aan haar opleiding tot oogarts aan de afdeling Oogheelkunde 
van het UMC St. Radboud te Nijmegen. Janneke is sedert juni 1999 getrouwd met Yannick 
van Lith en zij hebben 2 zoontjes Nino (mei 2000) en Jules (januari 2002). 
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            Adult Vitelliform Macular Dystrophy     Age Related Macular Dystrophy 
 
 
                                                 
 
Benign Concentric Annular       Central Areolar Choroidal Dystrophy 
Macular Dystrophy  
 
                                                  
 
  Cone Dystrophy        Cone-rod Dystrophy
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  Dominant Cystoid Macular Edema        Dominant Cystoid Macular Edema  
      (FAG) 
 
                                        
 
  Dominant Drusen           North Carolina Macular Dystrophy 
 
 
                                        
  
  Macular Dystrophy (RDS mutation)         Butterfly-shaped Macular Dystrophy 
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   Autosomal Dominant Stargardt Disease   Autosomal Recessive Stargardt Disease 
 
 
                                         
 
   Vitteliform Macular Dystrophy     Vitteliform Macular Dystrophy 
    (classic egg-yolk)       (pseudohypopyon) 
 
                                                 
 
    Vitteliform Macular Dystrophy     Retinitis Pigmentosa (RP13) 
    (atrophic scar) 
